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ABSTRACT 
Charles B. Goodwin 
 
PI3K IN JUVENILE MYELOMONOCYTIC LEUKEMIA 
 
Juvenile Myelomonocytic Leukemia (JMML) is rare, fatal myeloproliferative 
disease (MPD) affecting young children, and is characterized by expansion of monocyte 
lineage cells and hypersensitivity to Granulocyte Macrophage-Colony Stimulating Factor 
(GM-CSF) stimulation.  JMML is frequently associated with gain-of-function mutations 
in the PTPN11 gene, which encodes the protein tyrosine phosphatase, Shp2.  Activating 
Shp2 mutations are known to promote hyperactivation of the Ras-Erk signaling pathway, 
but Akt is also observed to have enhanced phosphorylation, suggesting a potential role 
for Phosphatidylinositol-3-Kinase (PI3K)-Akt signaling in mutant Shp2-induced GM-
CSF hypersensitivity and leukemogenesis.   
Having demonstrated that Class IA PI3K is hyperactivated in the presence of 
mutant Shp2 and contributes to GM-CSF hypersensitivity, I hypothesized the 
hematopoietic-specific Class IA PI3K catalytic subunit p110δ is a crucial mediator of 
mutant Shp2-induced PI3K hyperactivation and GM-CSF hypersensitivity in vitro and 
MPD development in vivo.  I crossed gain-of-function mutant Shp2 D61Y inducible 
knockin mice, which develop fatal MPD, with mice expressing kinase-dead mutant p110δ 
D910A to evaluate p110δ’s role in mutant Shp2-induced GM-CSF hypersensitivity in 
vitro and MPD development in vivo.  As a comparison, I also crossed Shp2 D61Y 
inducible knockin mice with mice bearing inducible knockout of the ubiquitously 
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expressed Class IA PI3K catalytic subunit, p110α.  I found that genetic interruption of 
p110δ, but not p110α, significantly reduced GM-CSF-stimulated hyperactivation of both 
the Ras-Erk and PI3K-Akt signaling pathways, and as a consequence, resulted in reduced 
GM-CSF-stimulated hyper-proliferation in vitro.  Furthermore, I found that mice bearing 
genetic disruption of p110δ, but not p110α, in the presence of gain-of-function mutant 
Shp2 D61Y, had on average, smaller spleen sizes, suggesting that loss of p110δ activity 
reduced MPD severity in vivo. 
I also investigated the effects of three PI3K inhibitors with high specificity for 
p110δ, IC87114, GDC-0941, and GS-9820 (formerly known as CAL-120), on mutant 
Shp2-induced GM-CSF hypersensitivity.  These inhibitors with high specificity for p110δ 
significantly reduced GM-CSF-stimulated hyperactivation of PI3K-Akt and Ras-Erk 
signaling and reduced GM-CSF-stimulated hyperproliferation in cells expressing gain-of-
function Shp2 mutants.   
Collectively, these findings show that p110δ-dependent PI3K hyperactivation 
contributes to mutant Shp2-induced GM-CSF hypersensitivity and MPD development, 
and that p110δ represents a potential novel therapeutic target for JMML.   
    
Rebecca J. Chan, MD, PhD, Chair 
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CHAPTER ONE 
INTRODUCTION 
Juvenile Myelomonocytic Leuekemia 
 Juvenile Myelomonocytic Leukemia (JMML) is a rare and often fatal 
myeloproliferative disease (MPD) of early childhood, typically affecting infants and 
toddlers.  The World Health Organization (WHO) categorizes JMML as an overlap 
myeloproliferative neoplasm/myelodysplastic syndrome (MPN/MDS), accounting for 2-
3% of childhood leukemias with an incidence of 1-2 cases per million per year and 
approximately 25-50 cases per year in the United States (Loh 2011).  The typical initial 
presentation of a child with JMML is non-specific, with signs and symptoms that include 
fever, failure to thrive, lymphadenopathy, splenomegaly, and elevated white blood cell 
counts with monocytosis, which can make it difficult to distinguish from bacterial or viral 
infection, therefore potentially delaying proper diagnosis (Emanuel 2008; Loh 2011).  
WHO diagnostic criteria for JMML include absence of the BCR/ABL fusion gene, which 
characterizes Chronic Myelogenous Leukemia (CML), circulating monocyte count 
greater than 1 x 10
9
/L, and less than 20% blasts observed in a bone marrow biopsy (Chan, 
Cooper et al. 2009).  In addition, almost all patients develop splenomegaly at some point 
during the course of their disease, and for most patients it has already developed by the 
time of presentation (Loh 2011).  Other common clinical features that may assist in the 
diagnosis of JMML include elevated Hemoglobin F, the presence of a cytogenetic 
abnormality (most commonly monosomy 7), and hypersensitivity of myeloid progenitor 
cells to Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) (Emanuel, Bates 
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et al. 1991; Bergstraesser, Hasle et al. 2007; Niemeyer and Kratz 2008; Chan, Cooper et 
al. 2009). 
 At this time, the only curative therapy for JMML is allogeneic hematopoietic stem 
cell transplantation (HSCT), which under current protocols has around a 50% survival 
rate (Locatelli, Nollke et al. 2005; Bergstraesser, Hasle et al. 2007; Yoshimi, Mohamed et 
al. 2007).  HSCT is plagued with many challenges including relatively high rates of 
relapse and complications such as infection, bleeding, and graft-versus-host disease 
(GVHD); therefore better treatment modalities for JMML are badly needed (Locatelli, 
Nollke et al. 2005).  To that end, much work has been done over the past several years to 
understand the molecular mechanisms underlying JMML.  Patients with JMML 
frequently exhibit mutations in genes encoding proteins involved in RAS signaling, 
suggesting that RAS hyperactivation is common etiologic feature in JMML.  These 
mutations include gain-of-function mutations in KRAS and NRAS (together accounting 
for approximately 20% of cases) (Kalra, Paderanga et al. 1994; Miyauchi, Asada et al. 
1994), as well as loss-of-function mutations in the RAS GAP, NF1 (in 15% of cases) 
(Shannon, O'Connell et al. 1994), which negatively regulates RAS activity.  Most 
recently, loss-of-function mutations in the E3 ubiquitin ligase, CBL, have been described 
(in 10-15% of cases) (Loh, Sakai et al. 2009).  The most commonly mutated gene 
encountered in JMML patients, however, are gain-of-function mutations in PTPN11, 
which encodes the protein tyrosine phosphatase, SHP2, accounting for slightly more than 
one-third of JMML cases (Figure 1.1) (Tartaglia, Niemeyer et al. 2003).  The mechanism 
by which SHP2 regulates RAS activity is not completely understood.  Despite these 
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advances, causative mutations have not been identified in approximately 10-15% of 
JMML patients. 
 
 
 
 
Figure 1.1: Schematic diagram of RAS activation and its regulators highlighting 
mutations found in Juvenile Myelomonocytic Leukemia 
 
RAS is a GTPase molecular “switch,” which is activated when it is in its GTP-bound 
state and inactive in its GDP-bound state.  Activation of RAS is induced by the RAS 
Guanine Exchange Factor (GEF), SOS, which promotes that exchange of GDP for GTP.  
RAS is inactivated by its intrinsic, but extremely slow, GTPase activity, which promotes 
hydrolysis of the γ-phosphate group from GTP to yield GDP.  This GTPase activity is 
stimulated by the RAS GTPase Activating Protein (GAP), NF1. The E3 ubiquitin ligase 
CBL negatively regulates RAS activity and the protein tyrosine phosphatase SHP2 
positively regulates RAS activity both through mechanisms that remain incompletely 
defined.  Loss-of-function mutations in NF1 and CBL and gain-of-function mutations in 
RAS and PTPN11 (SHP2) are found in JMML.  Percentages in parentheses below 
proteins indicate the approximate frequency of JMML cases in which that protein is 
found to be mutated. 
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The Protein Tyrosine Phosphatase, SHP2, and Juvenile Myelomonocytic Leukemia 
As stated above, somatic mutations in PTPN11 (i.e., the gene encoding Shp2) 
occur in 35% of JMML cases, but are also found in childhood acute myeloid leukemia 
(AML, 4%), myelodysplastic syndrome (10%), acute lymphoid leukemia (7%) (Tartaglia, 
Niemeyer et al. 2003; Loh, Reynolds et al. 2004; Loh, Vattikuti et al. 2004; Tartaglia, 
Martinelli et al. 2004; Kratz, Niemeyer et al. 2005), and, rarely, in some solid tumors 
(Bentires-Alj, Paez et al. 2004; Loh, Martinelli et al. 2005; Martinelli, Carta et al. 2006).  
In addition, germline mutations in PTPN11 are found in about half of patients with 
Noonan Syndrome, a relatively common autosomal dominant development disorder, in 
which patients often develop a self-limiting JMML-like MPD (Roberts, Allanson et al. 
2013).  More recently, germline mutations have also been found to be associated with a 
much rarer developmental disorder, called LEOPARD syndrome, which shares many 
clinical features with Noonan Syndrome (Kontaridis, Swanson et al. 2006; Marin, Keith 
et al. 2011).  In addition to mutated forms of Shp2, recent work using murine models has 
demonstrated that wild type (WT) Shp2 participates in aberrant signaling induced by 
other oncogenes, such as Flt3-ITD-associated AML and mutant Kit in AML and 
mastocytosis (Mali, Ma et al. 2012; Nabinger and Chan 2012; Nabinger, Li et al. 2013). 
Structurally, SHP2 is a non-receptor protein tyrosine phosphatase that contains 
two Src Homology 2 domains (N-SH2 and C-SH2) and an enzymatic phosphatase 
(PTPase) domain (Figure 1.2) (Chan and Feng 2007).  In its inactive state, SHP2 is in a 
closed confirmation stabilized by intermolecular interactions between the N-SH2 and the 
PTPase domains, thereby blocking substrate access to enzymatic pocket of the PTPase 
domain.  In the course of normal activation, the SHP2 SH2 domains are recruited to 
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phosphorylated tyrosine residues on activated receptors or adapter molecules, which 
results in an interruption of the auto-inhibitory interaction between the N-SH2 and 
PTPase domains, thereby allowing SHP2 to assume an open, active confirmation with 
unobstructed access to tyrosine-phosphorylated substrates.  Leukemia-causing mutations 
typically affect amino acids in the N-SH2 or PTPase domains that participate in the 
stabilizing intermolecular interactions that contribute to the closed, inactive confirmation, 
such that the presence of such mutations results in a constitutively open and activated 
phosphatase (Chan and Feng 2007; Chan, Kalaitzidis et al. 2008).  For this reason, 
PTPN11 has been identified as a rare example of a phosphatase proto-oncogene, which 
promotes oncogenic signaling as a result of acquiring gain-of-function mutations. 
Since the cloning of murine Ptpn11 in 1992 (Freeman, Plutzky et al. 1992; Feng, 
Hui et al. 1993), numerous mechanistic studies have been conducted and published to 
clarify the role of Shp2 in Receptor Tyrosine Kinase (RTK)- and cytokine receptor-
stimulated signaling pathways.  As previously mentioned, it has been demonstrated that 
Shp2 is a positive regulator of Ras activity, though the mechanism of this regulation 
remains unclear.  Studies have shown that the phosphatase activity of Shp2 is required to 
activate Ras, though the exact tyrosine-phosphorylated substrates that participate in this 
process remain to be fully elucidated (Neel, Gu et al. 2003; Mohi and Neel 2007).  In 
addition to its enzymatic function, there is also evidence that Shp2 may promote signal 
transduction as a scaffolding protein via its two SH2 domains, and Shp2 is known to 
interact directly or in complexes with a number of proteins involved in signal 
transduction, including receptors such as the GM-CSF receptor, adapter molecules such 
as Gab2 and Grb2, and signaling molecules such as the Ras-GEF, Sos, and the p85 
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regulatory subunit of Phosphatidylinositide 3-Kinase (PI3K) (Neel, Gu et al. 2003; Mohi, 
Williams et al. 2005; Yu, Daino et al. 2006). 
As Shp2 has been shown to be a positive regulator of signal transduction 
pathways that promotes proliferation, growth, and survival downstream of various growth 
factor and cytokine receptors and adhesion molecules such as integrins, it is hypothesized 
that leukemia-associated gain-of-function mutations in Shp2 lead to hyperactivation of 
these pro-growth and pro-survival signaling pathways and enhanced responsiveness to 
stimulation with specific cytokines and growth factors.  Of particular importance to 
JMML is mitogenic signaling related to the GM-CSF receptor, since a common clinical 
diagnostic feature of JMML is hypersensitivity to GM-CSF, in which myeloid 
progenitors from JMML patients exhibit an enhanced proliferative response following 
GM-CSF stimulation (Emanuel, Bates et al. 1991).  Our laboratory and others have 
shown that expression of Shp2 bearing leukemia-associated mutations such as E76K or 
D61Y in myeloid progenitor cells is sufficient to induce the GM-CSF hypersensitivity 
phenotype in these cells  (Chan, Leedy et al. 2005; Mohi, Williams et al. 2005; 
Schubbert, Lieuw et al. 2005).  Additionally, we have shown that cells expressing gain-
of-function mutant Shp2 exhibit substantially increased signaling through both the 
Mitogen Activated Protein Kinase (MAPK) and PI3K pathways, as demonstrated by 
increased phosphorylation of Erk and Akt, respectively, compared to WT Shp2-
expressing cells in response to GM-CSF stimulation (Yang, Li et al. 2008).  This suggests 
a model in which activating Shp2 mutations result in enhanced MAPK and PI3K 
signaling that regulate down-stream effectors, which promote enhanced proliferation, 
growth, and survival following stimulation with GM-CSF and possibly other growth 
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factors and cytokines, leading to pathologic expansion of myeloid-lineage cells and the 
development of JMML.  To date, much of the work on mutant Shp2-induced aberrant 
signaling and the pathogenesis of MPD has focused on the MAPK pathway.  However, 
we have shown that Akt is hyper-phosphorylated in the presence of leukemia-associated 
Shp2 mutations, indicating a potential role for PI3K signaling, which is frequently 
hyperactivated in wide array of human malignancies, thereby contributing to their 
pathogenesis.  Thus, there is significant rationale to explore the potential contribution of 
hyperactivated PI3K to mutant Shp2-induced GM-CSF hypersensitivity and 
leukemogenesis as a potential therapeutic target. 
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Figure 1.2: Diagram showing typical mechanism of SHP2 activation and the 
consequences of common oncogenic mutations 
 
(A) In its inactive state, SHP2 forms a closed confirmation stabilized by intermolecular 
interactions between the N-SH2 and phosphatase (PTPase) domains.  When the SH2 
domains of SHP2 are engaged by phosphorylated tyrosine residues, SHP2 then assumes 
its open, active confirmation.  (B) Oncogenic mutations in SHP2 often interrupt the 
intermolecular interactions between the N-SH2 and PTPase domains, so that Shp2 
assumes an open, constitutively active confirmation (adapted from (Chan and Feng 
2007)). 
C-SH2
N
C
INACTIVE
C-SH2
N
N-SH2
pY
PTPase
C
ACTIVE
A.     PTP (SHP2)
SH3
SH2
Kinase
(N lobe)
Kinase
(C lobe)
N
C pY
C
Kinase
(C lobe)
SH3
N
pY
SH2 Kinase
(N lobe)
Y527
A.      PTK (c-Src)
INACTIVE
ACTIVE
pY
Chan and Feng, Figure 1
C-SH2
N
PTPase
CKinase
(C lobe)
SH3
N
SH2 Kinase
(N lobe)
G60R
D61Y A72T
E76K
C.    Oncogenic v-Src mutant B.     Oncogenic SHP2 mutants
C
N-SH2
CONSTITUTIVELY ACTIVE PTK CONSTITUTIVELY ACTIVE PTP
 9 
 
Phosphatidylinositide 3-Kinase (PI3K) Structure and Function 
Class I Phosphatidylinositide 3-Kinases (PI3Ks) are lipid kinases, which 
phosphorylate the 3 position of plasma membrane-associated lipid, phosphatidylinositol 
(4,5) bisphosphate (PIP2), to generate PIP3, which serves to recruit Plekstrin Homology 
(PH)-domain-containing signaling kinases to the plasma membrane, especially PDK1, 
and its downstream effector, the serine-threonine kinase AKT (also known as Protein 
Kinase B, PKB), which it phosphorylates at Threonine 308 (Figure 1.3) (Alessi, James et 
al. 1997; Corvera and Czech 1998; Cantley 2002; Zhao and Vogt 2008).  Activated AKT, 
by phosphorylating several downstream effectors, regulates multiple cellular processes, 
including protein synthesis (via mTOR), proliferation, survival, and motility (Zhao and 
Vogt 2008).  Through a complex positive feedback loop, AKT is further activated by 
mTOR-mediated phosphorylation of Serine 473 (Figure 1.3) (Sarbassov, Guertin et al. 
2005).   
There are two subclasses of Class I PI3K.  The Class IA PI3Ks are heterodimers, 
consisting of a p110 catalytic subunit and a regulatory subunit. The three catalytic 
subunits include p110α (encoded by PIK3CA), p110β (encoded by PIK3CB), and p110δ 
(encoded by PIK3CD) (Zhao and Vogt 2008). These three catalytic subunits can bind to 
any Class IA regulatory subunit, including p85α, and its splice variants p55α and p50α 
(encoded by PIK3R1), p85β (encoded by PIK3R2), and p55γ (encoded by PIK3R3) via an 
interaction between the adapter binding domain (ABD) of the catalytic subunit and the 
inter-SH2 (iSH2) domain of the regulatory subunit (Figure 1.4) (Walker, Perisic et al. 
1999; Zhao and Vogt 2008). Class IB PI3K consists only of p110γ (encoded by 
PIK3CG), and its unique regulatory subunits, p84/87 and p101(Zhao and Vogt 2008). 
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The catalytic subunits p110α and p110β are expressed ubiquitously, while p110δ and 
p110γ are found predominantly in hematopoietic cells (Zhao and Vogt 2008).   
 
 
Figure 1.3: Schematic diagram of PI3K-Akt signaling cascade 
Diagram showing the PI3K-Akt-mTOR signaling cascade, including Ras, a direct 
activator of PI3K activity, the major downstream effectors of PI3K, PDK1 and Akt, and 
the major downstream effectors of Akt, including FOXO, GSK3β, and mTOR.  Notably, 
full activation of Akt requires phosphorylation at the Threonine 308 site, which is 
mediated by PDK1 and at the Serine 473 site, which is mediated by mTOR, while in the 
mTORC2 complex.  mTOR is also positively regulated by Akt via several mediators not 
shown in this figure (represented by the dotted arrow from Akt to mTOR), creating a 
positive feedback loop that regulates Akt activity.  Also shown is the tumor suppressor 
lipid phosphatase PTEN, which catalyzes the dephosphorylation of PIP3 to generate PIP2, 
thereby antagonizing the activity of PI3K. 
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The Class IA (p85) regulatory subunits help promote PI3K activity through two 
important mechanisms: (1) stabilizing the catalytic subunits, thereby preventing their 
rapid degradation, and (2) recruiting the catalytic subunits to phospho-tyrosine residues 
on activated receptors and adapter molecules via its two SH2 domains (Figure 1.4) (Zhao 
and Vogt 2008; Fruman 2010).  It has also been demonstrated that the regulatory subunits 
also negatively regulate PI3K activity through an inhibitory interaction between its N-
SH2 domain and the helical domain of the p110 catalytic subunit, which is relieved when 
the regulatory subunit N-SH2 domain interacts with a phospho-tyrosine residue (Yu, 
Zhang et al. 1998; Luo and Cantley 2005; Luo, Field et al. 2005; Zhao and Vogt 2008).  
In addition, GTP-bound RAS also promotes PI3K activation via an interaction with the 
RAS-binding domain (RBD) of the catalytic subunit (Figure 1.4) (Rodriguez-Viciana, 
Warne et al. 1994; Rodriguez-Viciana, Warne et al. 1996; Pacold, Suire et al. 2000; 
Chan, Rodeck et al. 2002; Zhao and Vogt 2008). 
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Figure 1.4: Schematic diagram of the functional domains of and the intramolecular 
interactions between a PI3K catalytic subunit and a PI3K regulatory subunit 
 
Structurally, PI3K is a heterodimer, consisting of a regulatory subunit (p85) and a 
catalytic subunit (here, p110α).  The regulatory subunit has two Src Homology-2 (SH2) 
domains, which interacts with phosphorylated tyrosine residues; a Src Homology-3 
(SH3) domain, which interacts with proline-rich domains; a Breakpoint clustered 
Homology (BH) domain; and an inter-SH2 (iSH2), which is the principal interacting 
domain with the catalytic subunit.  The catalytic subunit contains an Adapter-Binding 
Domain (ABD), which mediates the major interaction with the regulatory subunit; a Ras-
Binding Domain (RBD), to which Ras binds, promoting activation of PI3K; a protein-
kinase-C homology-2 (C2) domain, which mediates interactions with lipid membranes; 
and the Kinase domain, which mediates the lipid phosphorylation activity (Zhao and 
Vogt 2008). 
 
 
 
PI3K in Cancer and Leukemia 
Hyperactivation of PI3K signaling is found to be a common feature among a wide 
variety of human malignancies, which is not surprising given the role of PI3K in 
regulating proliferation, growth, and survival (Luo, Manning et al. 2003).  Most often, 
this hyperactivation of PI3K is the result of oncogenic transformation of proteins such as 
receptors or kinases upstream of PI3K or through loss of expression or function of the 
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PI3K-antagonist lipid phosphatase PTEN, which removes the phosphate group at the 3 
position, thereby converting the active lipid moiety PIP3, which is the product of PI3K 
activity, to PI(4,5)P2, the inactive lipid moiety that is also the original substrate of PI3K 
activity (Vivanco and Sawyers 2002; Luo, Manning et al. 2003; Salmena, Carracedo et 
al. 2008).   
On the other hand, cancer-causing mutations in genes encoding the Class I 
catalytic or regulatory subunits are not as common.  Of the four catalytic subunits, only 
p110α (PIK3CA) has been found to have cancer-causing mutations (Samuels, Wang et al. 
2004), and more recently mutations in PIK3R1, which encodes the p85α regulatory 
subunit, have been identified in certain cancers.  Interestingly, overexpression of p110δ 
and p110γ has also been observed in acute myeloid leukemia and chronic myelogenous 
leukemia, respectively (Skorski, Bellacosa et al. 1997; Sujobert, Bardet et al. 2005; 
Hickey and Cotter 2006).   
In recent years, there has been significant progress in identifying the roles of 
individual PI3K catalytic subunits in particular physiologic processes and disease states, 
especially cancer.  This research has been complemented by simultaneous efforts to 
develop newer classes of PI3K inhibitors that target particular catalytic subunits with 
several fold specificity, by taking advantage of subtle structural differences between the 
catalytic subunits (Marone, Cmiljanovic et al. 2008).  The goal of this work is to inhibit 
only the activity of the particular catalytic subunit contributing to the pathogenesis of a 
disease, while sparing the activity of the other catalytic subunits, which may be mediating 
important normal functions, thus reducing the risk for off-target and potentially toxic side 
effects. 
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The Hematopoietic-Specific Class IA PI3K Catalytic Subunit p110δ 
The Class IA PI3K catalytic subunit, p110δ, like the sole Class IB PI3K catalytic 
subunit, p110γ, is expressed predominantly in hematopoietic cells, in contrast to p110α 
and p110β, which are ubiquitously expressed, suggesting that p110δ and p110γ might be 
ideal pharmacologic targets in diseases involving the hematopoietic system such as 
autoimmune disorders and leukemias (Okkenhaug, Bilancio et al. 2002; Rommel 2010; 
Cushing, Metz et al. 2012).  While p110γ is associated with signaling mediated by G-
Protein-Coupled Receptors (GPCRs), p110δ is typically found promoting activation of 
PI3K signaling downstream of Receptor Tyrosine Kinases (RTKs) and cytokine 
receptors, indicating that there are unique functions for each catalytic subunit, though 
there has been much work recently demonstrating their potential cooperation in many 
diseases processes (Cushing, Metz et al. 2012).  For our studies we focused on p110δ 
because we wanted to evaluate the role of PI3K in the context of the GM-CSF receptor, 
which is known to be hyper-responsive to its ligand in the presence of activating Shp2 
mutations, and which is known to associate with p85, the major regulatory subunit of 
Class IA PI3K catalytic subunits, such as p110δ (Itoh, Liu et al. 1998; Chan, Leedy et al. 
2005; Perugini, Brown et al. 2010). 
 A mouse model has been generated bearing a point mutation in the Pik3cd gene, 
which encodes p110δ, so that, as a result, endogenous levels of the kinase-dead mutant 
p110δ D910A are expressed (rather than a knockout model, in which there potentially 
may be compensatory upregulation and recruitment of the remaining Class IA catalytic 
subunits, p110α and p110β) (Okkenhaug, Bilancio et al. 2002).  Although, this 
genetically inactivated Pik3cd gene is constitutively expressed, homozygous mutant mice 
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are born at normal Mendelian ratios and do not exhibit any overt phenotype except some 
impairment of B- and T-cell maturation and function and the development of a mild 
inflammatory bowel disease. The fact that p110δD910A/D910A mice are completely viable 
with only modest health effects suggest that p110δ would be an ideal therapeutic target 
since pharmacologic inhibition of its activity would therefore be expected to have 
minimal side effects (Okkenhaug, Bilancio et al. 2002). 
 Because the effects of genetic inactivation of p110δ were mostly observed in B- 
and T-cells, much of the research on the role of p110δ in health and disease have focused 
on processes involving the lymphoid lineage, such a multiple myeloma, T-cell leukemia, 
and a variety of inflammatory conditions (Herman, Gordon et al. 2010; Ikeda, Hideshima 
et al. 2010; Rommel 2010; Lannutti, Meadows et al. 2011; Castillo, Furman et al. 2012).  
However, p110δ has been found to be overexpressed in Acute Myeloid Leukemia (AML) 
(Sujobert, Bardet et al. 2005), and it has been demonstrated to mediate proliferation and 
migration in macrophages (Papakonstanti, Zwaenepoel et al. 2008), which suggests it 
may also be relevant for JMML, an invasive MPD of monocyte-macrophage lineage 
cells. 
 IC87114 was the first PI3K inhibitor with high specificity for p110δ to be 
developed, but its low potency precluded it from entering clinical trials, though it still 
remains an important research tool (Berndt, Miller et al. 2010).  More recently, GS-1101 
(formerly known as CAL-101), an IC87114-derivative with greatly enhanced potency 
against p110δ has been developed, and has entered clinical trials for lymphoid 
malignancies (Castillo, Furman et al. 2012).   
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 Another interesting aspect of p110δ is its apparent Ras-independence (Denley, 
Kang et al. 2008).  The conserved structure of all Class I PI3K catalytic subunits contains 
a Ras-binding domain (RBD) (Figure 1.4) (Zhao and Vogt 2008), to which Ras can bind 
in order to promote full activation of PI3K signaling.  It has been shown that the common 
oncogenic mutation H1047A in PIK3CA (encoding p110α)—along with other nearby 
mutations in the kinase domain—results in a conformational change similar to that 
induced by the binding of RAS, thereby promoting its constitutive activation (Zhao and 
Vogt 2008).  These kinase domain mutations of p110α have been shown to promote 
RAS-independent PI3K hyperactivation as mutating a conserved lysine residue in the 
RBD (and, thus, abrogating RAS interactions) does not reduce AKT phosphorylation or 
cellular transforming ability (Zhao and Vogt 2008).  Similarly, mutation of the WT p110δ 
RBD still retains its cellular transforming ability even in the absence of additional 
activating mutations, suggesting that p110δ, unlike the other Class I PI3K catalytic 
subunits, can mediate its signaling function independent of RAS interaction (Denley, 
Kang et al. 2008).   
 
Mechanisms of Shp2 Regulation of PI3K Activity 
Functional interactions between Shp2 and PI3K have been investigated previously 
in the context of various physiologic processes and disease states, and the interplay 
between Shp2 function and PI3K activity is not always consistent.  In certain receptor-
mediated signaling pathways such as Kit, PDGF receptor, and IGF receptor, it has been 
found that Shp2 positively regulates PI3K activity, while in the context of other 
receptors, such as EGF Receptor, Shp2 is apparently a negative regulator of PI3K activity 
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(Zhang, Tsiaras et al. 2002; Mattoon, Lamothe et al. 2004; Mali, Ma et al. 2012).  For 
example, it has been reported that hyperactivated PI3K signaling, which results from 
loss-of-function mutations in PTPN11 that significantly lower Shp2’s phosphatase 
activity, contributes to the etiology of the cardiac defects found in LEOPARD syndrome, 
indicating that, at least, in regards to normal cardiac development, Shp2 function 
typically inhibits PI3K activity (Kontaridis, Yang et al. 2008; Edouard, Combier et al. 
2010). 
The GM-CSF receptor, a heterodimeric cytokine receptor, has been shown, 
however, to activate PI3K activity upon ligand binding (Perugini, Brown et al. 2010).  
Furthermore, our laboratory previously reported that murine bone marrow-derived 
macrophage progenitors transduced with Shp2 D61Y or Shp2 E76K have higher GM-
CSF-stimulated activation of Akt compared to cells transduced with empty vector or WT 
Shp2 (Figure 1.5) (Yang, Li et al. 2008).  Furthermore, Shp2 has been shown to 
positively regulate PI3K activity downstream of the IL-3 receptor, which shares its βc 
subunit with the GM-CSF receptor, and, therefore, is presumed to promote and regulate 
signal transduction pathways similarly to the GM-CSF receptor (Mohi, Williams et al. 
2005; Yu, Daino et al. 2006).  Based on these findings, we hypothesized that 
hyperactivation of class IA PI3K induced by activating PTPN11 mutations contributes to 
the etiology of JMML, leading us to pursue studies examining various components of the 
PI3K signaling pathway in activating Shp2-induced leukemogenesis.   
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Figure 1.5: Cells expressing gain-of-function mutant Shp2 D61Y and Shp2 E76K 
have higher levels of GM-CSF-stimulated Akt phosphorylation 
 
WT bone marrow-derived LDMNCs transduced with WT Shp2, gain-of-function mutant 
Shp2 D61Y, gain-of-function mutant Shp2 E76K, or empty vector (Mieg3) were cultured 
into adherent macrophages and stimulated with 10 ng/mL GM-CSF for 0, 60, and 120 
minutes, at which point protein lysates were prepared for western blot analysis (adapted 
from Yang, Li et al. 2008). 
 
 
The mechanisms by which Shp2 regulates PI3K remain to be fully elucidated.  It 
is possible that Shp2 regulates PI3K indirectly through Ras, since it is well known that 
Shp2 promotes activation of Ras, and that PI3K is a direct downstream effector of Ras 
(Neel, Gu et al. 2003).  However, it has been shown that gain-of-function Shp2’s 
phosphatase activity is necessary for promoting full activation of Ras and GM-CSF 
hypersensitivity, but that a point mutation abrogating mutant Shp2’s phosphatase activity 
has no effect on IL-3-stimulated Akt hyper-phosphorylation, though mutations targeting 
Shp2’s SH2 domains do (Mohi, Williams et al. 2005; Yu, Daino et al. 2006).  The 
authors of this study conclude that mutant Shp2 promotes IL-3-stimulated 
hyperactivation of PI3K signaling through its scaffolding function, rather than its 
enzymatic function (Yu, Daino et al. 2006).  It has been shown that Shp2 forms a 
complex with the scaffolding molecules Grb2 and Gab2, and the p85 Class IA PI3K 
regulatory subunit, and it might be by participating in this complex that Shp2 is able to 
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promote PI3K activation (Neel, Gu et al. 2003; Yu, Daino et al. 2006; Chan, Kalaitzidis 
et al. 2008). 
 
Summary and Significance 
Juvenile Myelomonocytic Leukemia (JMML), although very rare, is still 
extremely challenging to treat.  Unlike other more common forms of pediatric leukemia, 
such as Acute Lymphoblastic Leukemia (ALL), in which great progress in treatment has 
been made, JMML remains resistant to standard chemotherapy, and the only curative 
therapy is allogeneic hematopoietic stem cell transplantation (HSCT) (Loh 2011).  Even 
with current HSCT protocols, survival is still around 50% (Locatelli, Nollke et al. 2005; 
Bergstraesser, Hasle et al. 2007; Yoshimi, Mohamed et al. 2007), and thus there is a great 
need for finding more effective targeted therapies.  By better understanding the genetic 
aberrations found in JMML and their molecular consequences, we can identify potential 
therapeutic targets and improve outcomes in this disease. 
Over the past few decades, the work of many researchers have identified a 
common signaling aberration underlying the pathogenesis of JMML: hyperactivated RAS 
signaling, either due to activating mutations in RAS itself, or in the RAS GAP, NF1, 
which is a direct negative regulator of RAS activity.  Most recently, mutations have also 
been found in the E3 ubiquitin ligase, CBL, which promotes hyperactivation of RAS 
activity through mechanisms that remain incompletely defined.  The most commonly 
mutated gene found in JMML, however, is the PTPN11 gene, which encodes the protein 
tyrosine phosphatase, SHP2.  SHP2 has also been shown to positively regulate RAS 
activity, and, like CBL, the mechanism through which this regulation occurs is still being 
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explored.  It will be interesting to see if the remaining 10-15% of JMML cases, for which 
a causative gene mutation has not been identified, will also involve proteins that regulate 
RAS activity. 
Although we have learned that RAS hyperactivation seems to be the common 
pathogenic feature of JMML, it still an open question as to how best to interrupt this RAS 
hyperactivation to achieve a desired therapeutic effect.  Targeting RAS itself, although it 
would be the ideal solution, is complicated.  RAS binds GTP with such high affinity, that 
GTP-competitive inhibitors—analogous to the ATP-competitive inhibitors used to target 
kinases—are unlikely to be successful (Gysin, Salt et al. 2011).  Targeting activating 
post-translational modifications of RAS has also been explored as a potential therapeutic 
strategy.  Specifically, investigators have explored farnesyl-transferase inhibitors (FTIs), 
such as tipifarnib, which block the enzymatic addition of hydrophobic farnesyl groups to 
mature RAS proteins, thereby targeting them to inner leaflet of the plasma membrane 
where they carry out their signal transduction function (Epling-Burnette and Loughran 
2010; Liu, Sabnis et al. 2012).  Although it showed promise as a therapy for JMML in 
vitro (Emanuel, Snyder et al. 2000), this strategy has had limited success in clinical trials 
for multiple cancers as a single agent, however, most likely because other membrane-
targeting post-translational modifications, which are not affected by FTIs, such as 
geranylgeranylation, can circumvent the lack of farnesylation (Epling-Burnette and 
Loughran 2010). 
Thus, if RAS itself cannot be inhibited, and if efforts to block its activation have 
also been unsuccessful, then another potential strategy to target oncogenic RAS activity 
and GM-CSF hypersensitivity in JMML is to inhibit one or more of its downstream 
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effector signaling pathways, such as the RAF-MEK-ERK MAPK pathway and the PI3K-
AKT pathway.  Much of the effort so far in investigating the aberrant signaling, which is 
induced by activating SHP2 mutations or other JMML-associated mutations, and which 
ultimately results in GM-CSF hypersensitivity and leukemogenesis, has focused on the 
MAPK pathway.  Indeed, recent studies using mouse models of Nf1 knockout- and gain-
of-function mutant KRas knockin-induced MPD have shown that treatment with the 
clinical grade MEK inhibitor, PD0325901, can effectively reduce GM-CSF 
hypersensitivity and disease progression (Lyubynska, Gorman et al. 2011; Chang, 
Krisman et al. 2013).  However, as MEK is ubiquitously expressed, pharmacologically 
targeting its activity runs the risk of significant toxic side effects.  Therefore, it is 
appropriate to explore other potential targets, which either carry less such risk, or which 
can be simultaneously inhibited along with MEK, in such a way that lower doses of both 
inhibitors (with presumably reduced risk of side effects) can be used. 
Our laboratory has shown previously, that Akt phosphorylation is also greatly 
enhanced in gain-of-function mutant Shp2-expressing cells following GM-CSF 
stimulation (Figure 1.5), suggesting that PI3K also might be an important player in GM-
CSF hypersensitivity and the pathogenesis of JMML (Yang, Li et al. 2008).  Certainly, 
hyperactivated PI3K is known to be involved in a wide array of human malignancies, 
and, as a result, there has been a significant effort to develop new classes of PI3K 
inhibitors with enhanced potency and specificity (Marone, Cmiljanovic et al. 2008).  
With this in mind, we wanted to investigate the potential role of PI3K in gain-of-function 
mutant Shp2-induced GM-CSF hypersensitivity and MPD development. 
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In the following studies we used genetic and pharmacologic approaches to 
investigate the role of Class IA PI3K in gain-of-function mutation Shp2-induced GM-
CSF hypersensitivity and in vivo MPD development.  We begin by demonstrating that the 
GM-CSF-stimulated Akt hyper-phosphorylation in mutant Shp2-expressing cells that our 
lab had previously reported was in fact due to enhanced PI3K activity (Chapter Three).  
We then show that Class IA PI3K is an important contributor to gain-of-function mutant 
Shp2-induced GM-CSF hypersensitivity, both pharmacologically—using the pan-PI3K 
inhibitor, LY294002—and genetically—by deletion of the Pik3r1 gene, which encodes 
the major Class IA PI3K regulatory subunit, p85α, and its splice variants p55α, and p50α 
(Chapter Three) (Fruman, Snapper et al. 1999; Fruman, Mauvais-Jarvis et al. 2000).  In 
both cases, there were significant reductions in GM-CSF-stimulated hyper-proliferation 
and Akt hyper-phosphorylation in mutant Shp2-expressing cells.  Interestingly, we also 
found significant reductions in mutant Shp2-induced Erk hyper-phosphorylation, 
suggesting that Class IA PI3K signaling is an important positive regulator of mutant 
Shp2-induced hyperactivated MAPK signaling.  To increase the potential translational 
application of our observations, we next wanted to explore the individual contributions of 
the three Class IA PI3K catalytic subunits, p110α, p110β, and p110δ, again using both 
genetic and pharmacologic approaches.  Here we found that treatment with the p110δ-
specific inhibitor, IC87114, or the clinical-grade PI3K inhibitor GDC-0941, which has 
high specificity for p110δ and p110α (Folkes, Ahmadi et al. 2008), both significantly 
reduced GM-CSF-stimulated hyper-proliferation and Akt and Erk hyper-phosphorylation, 
and increased apoptosis in gain-of-function mutant Shp2-expressing cells (Chapter Four).  
Interestingly, we also found that the highly potent p110δ-specific inhibitor, GS-9820 
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(formerly known as CAL-120), was able to reduce GM-CSF-stimulated hyper-
phosphorylation of both Akt and Erk as well as GM-CSF-stimulated hyper-proliferation 
at clinically relevant nanomolar concentrations (Chapter Four).  Finally, by crossing gain-
of-function mutant Shp2 D61Y-inducible knockin mice, which provide an in vivo model 
of mutant Shp2-induced MPD (Chan, Kalaitzidis et al. 2009), with kinase-dead mutant 
p110δ D910A mice and p110α inducible knockout mice (Okkenhaug, Bilancio et al. 
2002; Graupera, Guillermet-Guibert et al. 2008), we found that genetic interruption of 
p110δ, but not p110α, significantly reduced GM-CSF-stimulated hyper-proliferation and 
Akt and Erk hyper-phosphorylation in vitro in cells endogenously expressing gain-of-
function mutant Shp2 D61Y (Chapter Five).  We also found that genetic interruption of 
p110δ, but not p110α, significantly decreased mutant Shp2 D61Y-induced splenomegaly 
in vivo (Chapter Five). 
Thus, based on the results of our studies, we propose a model in which activating 
Shp2 mutations induce hyperactivated PI3K signaling, as well as MAPK signaling, in 
response to GM-CSF (and possibly other cytokine and growth factor) stimulation, which 
together promote a pathologically enhanced proliferative and survival response that 
ultimately results in MPD development (Figure 1.6).  In addition, we hypothesize that a 
crucial mediator of this gain-of-function mutant Shp2-induced PI3K hyperactivation is 
the hematopoietic-specific, Class IA PI3K catalytic subunit p110δ, and therefore, 
pharmacologic inhibition of p110δ activity, represents a potential novel therapeutic 
strategy for the treatment of JMML and other mutant Shp2-induced MPDs.  Furthermore, 
because p110δ’s expression is restricted to hematopoietic cells, it is an ideal target for 
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hematopoietic malignancies like JMML, because there is reduced risk of toxic systemic 
side effects. 
 
 
 
Figure 1.6: Schematic diagram showing hypothesized mutant Shp2-induced 
dysregulated signaling that contributes to GM-CSF hypersensitivity 
 
We hypothesize that mutant Shp2 results in hyperactivation of both the Ras-Erk pathway 
and the PI3K-Akt pathway, which together promote hyper-proliferation in response to 
GM-CSF stimulation, ultimately leading to leukemogenesis. 
 
 
 
Ras
 25 
 
Furthermore, because it has been shown that p110δ can induce oncogenic 
transformation of cells independently of Ras, we propose a model in which gain-of-
function mutant Shp2 can promote hyperactivation of p110δ activity, in a Ras-
independent manner.  To explore this question, we combined FTI treatment (which 
prevents Ras activation) with genetic and pharmacologic interruption of PI3K activity.  
Specifically, we found that Pik3r1
-/-
 cells expressing gain-of-function mutant Shp2 E76K 
were relatively insensitive to treatment with the FTI tipifarnib.  We found that addition of 
the PI3K inhibitor, GDC-0941, resulted in further decreases in mutant Shp2-induced 
GM-CSF hypersensitivity beyond what was achieved with multiple doses of tipifarnib, 
suggesting the existence of non-Ras-dependent PI3K activity in the presence of gain-of-
function mutant Shp2.  Thus, these results suggest that even if successful Ras inhibition 
could be achieved in the context of activating Shp2 mutations, PI3K would still have to 
be targeted at least in part as an independent and parallel pathway.  It also suggests an 
alternative model in which, mutant Shp2 can promote aberrant signaling and MPD 
development via Ras-independent mechanisms, instead of exclusively through promoting 
hyperactivation of Ras, as it is currently presumed (Figure 1.7). 
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Figure 1.7: Comparative models of gain-of-function mutant Shp2-induced 
hyperactivation of PI3K as a Ras-dependent versus Ras-independent process 
 
The current model of gain-of-function mutant Shp2-induced aberrant signaling leading to 
MPD development is presumed to be an entirely Ras-dependent process. In comparison, 
we propose a new model in which gain-of-function mutant Shp2 can promote 
hyperactivation of p110δ-mediated PI3K hyperactivation in at least a partially Ras-
independent manner, suggesting that PI3K must be targeted separately in gain-of-
function mutant Shp2-induced MPD. 
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Significance 
Although JMML is a rare condition, it still portends a very dismal prognosis, 
especially compared to other childhood leukemias like ALL, which generally responds 
favorably to chemotherapy.  JMML, on the other hand is resistant to standard 
chemotherapy, and, thus, the only curative therapy is allogeneic hematopoietic stem cell 
transplantation, which still only has a survival rate around 50%.  Thus, JMML is a 
disorder desperately in need of more effective therapeutic options.   
In these studies, we identify Class IA PI3K signaling, particularly that mediated 
by p110δ, as an important contributor to mutant Shp2-induced GM-CSF hypersensitivity 
and MPD development.  We found p110δ to be an intriguing target for several reasons.  
First, both genetic interruption and pharmacologic inhibition of p110δ activity 
significantly reduced not only mutant Shp2-induced Akt hyper-phosphorylation, but Erk 
hyper-phosphorylation as well.  Thus, rather than observing a compensatory increase in a 
parallel oncogenic signaling pathway upon pharmacological blockade of PI3K, we found, 
instead, that we able to reduce flux through two major oncogenic signaling pathways.  In 
contrast, we found that the MEK inhibitor PD0325901, although very efficiently reducing 
MAPK signaling, had no effect on PI3K signaling.   
Another significant aspect of p110δ is the fact that its expression is largely 
restricted to hematopoietic cells, making it an ideal target for hematologic malignancies.  
Thus, it can be expected that pharmacologically inhibiting p110δ would have minimal 
toxic side effects, since very few if any other cell types in the body would have 
significant p110δ-dependent activities.  To illustrate this potential, it should be noted that 
mice constitutively expressing germline kinase-dead p110δ D910A are viable and fertile 
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with no significant deficits or gross phenotypes, except for some defects in lymphoid 
function (Okkenhaug, Bilancio et al. 2002).   
Finally, p110δ is also an interesting target to investigate in the context of 
oncogenic Shp2 signaling, because it has been reported that p110δ, unlike the other Class 
I PI3K catalytic subunits, can induce oncogenic transformation in a Ras-independent 
manner (Denley, Kang et al. 2008).  Mechanistically, this observation is intriguing 
because it is traditionally thought that gain-of-function mutant Shp2 promotes aberrant 
signaling, GM-CSF hypersensitivity, and, ultimately, leukemogenesis by promoting 
hyperactivation of Ras, which then mediates all downstream dysregulated signaling 
processes.  Thus, this work is significant because it provides evidence that gain-of-
function mutant Shp2 can promote aberrant mitogenic signaling at least in part in a Ras-
independent manner.  As a result, this work has important implications for strategies to 
treat mutant Shp2-induced MPD by directly targeting Ras hyperactivation, because it 
suggests that p110δ-mediated PI3K signaling would also have to be targeted as an 
independent and parallel pathway.   
Together, the results of our research demonstrate Class IA PI3K signaling, and 
particularly PI3K activity mediated by p110δ, as an important component of gain-of-
function mutant Shp2-induced GM-CSF hypersensitivity and a key mediator of the 
aberrant oncogenic signal transduction processes that promote the features of enhanced 
proliferation and survival, which contribute to the pathogenesis of JMML and other 
forms of mutant Shp2-associated MPD.  Thus, we believe this work implicates p110δ as 
potential novel therapeutic target for the treatment of JMML. 
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CHAPTER TWO 
MATERIALS AND METHODS 
A. Materials 
1. Plasmids 
a. pMieg3 
pMieg3: WT Shp2, Shp2 D61Y, Shp2 E76K, Shp2 E76K/R32K, Shp2 E76K/R138K, and 
Shp2 E76K/C463A constructs were expressed using the pMieg3 plasmid.  cDNA from 
murine WT Shp2 and mutated forms of Shp2 generated by site-directed mutagenesis in 
the bicistronic pMieg3 vector, co-expressing enhanced green fluorescent protein (eGFP) 
as a marker.  Shp2 D61Y and Shp2 E76K are gain-of-function mutant forms of Shp2 
commonly found in patients with Juvenile Myelomonocytic Leukemia (Yang, Li et al. 
2008).  Shp2 E76K/R32K, Shp2 E76K/R138K, and Shp2 E76K/C463A are loss-of-
function mutant forms of Shp2 E76K that specifically inactivate the N-SH2, the C-SH2, 
and the phosphatase functional domains of Shp2 E76K, respectively. 
 
2. Primers 
Standard PCR reactions were performed using oligonucleotides synthesized by 
Invitrogen. 
Table 2.1: Genotyping primers 
Gene Forward (5’-3’) Reverse (3’-5’) 
Pik3r1-WT 5’-TCCAAATGAAAAGAACGGC 
ATC-3’ 
5’-TGTACCAAAGTCACTGAAA 
AATCTGTT-3’ 
Pik3r1-Neo 5’-AAGATAATATTGAAGCTGT 
AGGGAAAAA-3’ 
5’-TGTTAAGAAGGGTGAGAAC 
AGAGTACC-3’ 
Shp2 Exon 3 
(Shp2 D6Y) 
5’-CAAGGTGAGTGGGCGTTTC 
ATTTTAAC-3’ 
5’-ACCTTTCAGAGGTAGGGTC 
TGCAC-3’ 
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Table 2.1: Genotyping primers (continued) 
Gene Forward (5’-3’) Reverse (3’-5’) 
p110δ 
D910A 
5’-GCGTAACAGAGAGCAAAG 
TCCC-3’ 
5’-AGGGAACCGCCGTATGAC-
3’ 
p110α flox 5’-GGATGCGGTCTTTATTGTC-
3’ 
5’-TGGCATGCTGCCGAATTG-
3’ 
Mx1-Cre 5’-GCCTGCATTACCGGTCGAT 
GCAACGAGTG-3’ 
5’-CTGGCAATTTCGGCTATAC 
GTAACAGGGTG-3’ 
 
Table 2.2: Site-directed mutagenesis primers 
Gene Forward (5’-3’) Reverse (3’-5’) 
Shp2 R32K 5’-AAGTTTGCCACTTTGGCTA 
AACTGGTTCAGTATTACA-3’ 
5’-TGTAATACTGAACCAGTTT 
AGCCAAAGTGGCAAACTT-3’ 
Shp2 
R138K 
5’-CATGGCAGCTTCCTCGTTA 
AAGAGAGCCAGAGCCACC-3’ 
5’-GGTGGCTCTGGCTCTCTTT 
AACGAGGAAGCTGCCATG-3’ 
Shp2 
C463A 
5’-CGGCCAATCCCAGCGCTGG 
CGTGAACCACGACAGGGC-3’ 
5’-GCCCTGTCGTGGTTCACGC 
CAGCGCTGGGATTGGCCG-3’ 
 
 
3. Mice 
a. C57Bl/6 
C57Bl/6 mice were received from Harlan and were used to isolate wild type bone marrow 
low-density mononuclear cells (LDMNCs). 
b. Pik3r1-/- 
Pik3r1
-/-
 mice were a generous gift from Dr. Lewis C. Cantley (Fruman, Mauvais-Jarvis 
et al. 2000). 
c. LSL-Shp2D61Y/+ 
LSL-Shp2
D61Y/+
 mice were a generous gift from Dr. Benjamin G. Neel.  They were 
crossed with Mx1-Cre mice, p110δD910A/D910A mice, and p110αflox/flox mice (Chan, 
Kalaitzidis et al. 2009). 
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d. Mx1-Cre 
Mx1-Cre mice were a generous gift from Dr. Reuben Kapur. 
e. p110δD910A/D910A 
p110δD910A/D910A mice were a generous gift from Dr. Reuben Kapur (Okkenhaug, 
Bilancio et al. 2002). 
f. p110αflox/flox 
p110αflox/flox mice were a generous gift from Dr. Reuben Kapur (Graupera, Guillermet-
Guibert et al. 2008). 
 
4. Antibodies 
Table 2.3: Primary antibodies 
Primary Antibodies Company Clone 
Total Akt Cell Signaling N/A 
Phospho-Akt (S473) Cell Signaling 587F11 
Phospho-Akt (T308) Cell Signaling 244F9 
Total Erk Cell Signaling N/A 
Phospho-Erk Cell Signaling N/A 
Total Shp2 Santa Cruz C-18 
Phospho-Shp2 (Y580) Cell Signaling N/A 
p85α AbD Serotec U5 
p110α Cell Signaling C73F8 
p110β Santa Cruz S-19 
p110δ BD Biosciences 29 
GAPDH Biodesign International 6C5 
Annexin V-APC BD Pharmigen N/A 
 
Table 2.4: HRP Secondary antibodies 
Secondary Antibody Vendor 
Goat Anti-Rabbit IgG HRP Santa Cruz 
Goat Anti-Mouse IgG HRP Santa Cruz 
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5. Inhibitors 
Table 2.5: Inhibitors 
Inhibitor Vendor/Source Target 
LY294002 Selleck Pan-PI3K 
IC87114 Selleck PI3K p110δ 
GDC-0941 Selleck Pan-PI3K (p110δ and p110α)  
TGX-221 Cayman p110β 
GS-9820 Gift from Gilead Sciences p110δ 
Tipifarnib Selleck Ras (via Farnesyl-Transferase) 
PD0325901 Selleck MEK 
 
 
6. Kits 
Table 2.6: Kits 
Kit Vendor Catalog Number 
Plasmid Maxi-Prep Kit Invitrogen K210007 
SuperSignal West Dura Extended Duration 
Substrate Thermo Scientific 34076 
Mini-prep kit Qiagen 27106 
Profection Mammalian Transfection 
System 
Promega E1200 
Annexin V Apoptosis Kit BD Pharmigen 556547 
QuikChange Site-Directed Mutagenesis Kit Agilent 200518-5 
QIAquick Gel Extraction Kit Qiagen 28704 
QIAquick PCR Purification Kit Qiagen 28104 
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B. Methods 
1. Cell Culture 
a. Primary Murine Bone Marrow-Derived Low-Density Mononculear Cells 
(LDMNCs) 
Primary murine bone marrow-derived LDMNCs were isolated from total bone marrow 
cells by Histopaque ficoll gradient (Sigma-Aldrich), and cultured in IMDM (Invitrogen), 
20% FBS (Hyclone), 2% Penicillin/Streptomycin (Invitrogen), Granulocyte-Colony-
Stimulating Factor (G-CSF), Stem Cell Factor (SCF), and Thrombopoietin (TPO) at 100 
ng/mL concentration each.  LDMNCs were maintained at 37˚C and 5% CO2.  LDMNCs 
are cultured for a maximum of 9-10 days, changing their media every 2-4 days. 
b. Primary Murine Fetal Liver Cell-Derived Hematopoietic Progenitor Cells 
Primary murine fetal liver cell-derived hematopoietic progenitor cells were isolated from 
day 14.5 embryos and cultured in IMDM, 20% FBS, 2% Penicillin/Streptomycin, G-CSF, 
SCF, and TPO at 100 ng/mL concentration each.  They were maintained at 37˚C and 5% 
CO2 and were cultured for a maximum of 9-10 days, changing their media every 2-4 
days. 
c. Adherent Macrophage Progenitor Cells 
Primary murine LDMNCs or fetal liver cell-derived hematopoietic progenitors were 
cultured in IMDM, 20% FBS, 2% Penicillin/Streptomycin, and 50 ng/mL Macrophage-
Colony-Stimulating Factor (M-CSF) for up to 7-10 days 37˚C and 5% CO2 to generate 
adherent macrophage progenitors.  A full media change was required after they become 
adherent at day 5-6, and every 2-3 days thereafter. 
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d. Primary Murine Splenocytes 
Primary murine splenocytes were isolated by Histopaque ficoll gradient from total spleen 
cells. 
e. Eco-Phoenix Packaging Cells 
Eco-Phoenix packaging cells were cultured in DMEM (Invitrogen), 10% FBS, 1% 
Penicillin/Streptomycin, 1% L-glutamine (Invitrogen), and 1% Sodium pyruvate 
(Invitrogen) at 37˚C and 5% CO2.  Cells were split every 2-3 days. 
 
2. Retroviral Supernatant Production 
 
Retroviral supernatants were produced by transfecting the Eco-Phoenix cells with 
retroviral vector plasmids using calcium phosphate transfection (ProFection® 
Mammalian Transfection System, Promega, Madison, WI).  Supernatants, collected at 48, 
72, and 96 hours post-transfection were filtered through 0.45 μm filters and concentrated 
3-6X by ultra-centrifugation.   
 
3. Retroviral Transduction of Primary Murine Cells 
Primary murine bone marrow-derived LDMNCs or fetal liver cell-derived hematopoietic 
progenitors were transduced with 2 mL pMieg3-Shp2, pMieg3-Shp2 D61Y, pMieg3 
E76K, pMieg3-Shp2 E76K/R32K, pMieg3-Shp2 E76K/R138K, pMieg3-Shp2 
E76K/C463A retroviral supernatant, supplemented with 100 ng/mL each G-CSF, SCF, 
and TPO in 6-cm non-tissue culture plates coated with Retronectin ® (Takara) for 24 
hours at 37˚C.  After 24 hours, cells were collected, transduced again with fresh retroviral 
supernatant and growth factors, and incubated overnight at 37˚C.  The following 
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morning, cells were collected and plated back in IMDM, 20% FBS, 2% 
Penicillin/Streptomycin and 100 ng/mL each G-CSF, SCF, and TPO for 24 hours before 
performing Fluorescence-Activated Cell Sorting (FACS). 
 
4. Cell Sorting    
Retrovirally transduced cells were sorted using FACS to collect enhanced green 
fluorescent protein-positive (eGFP+) cells. 
 
 
5. Isolation of Total Cellular Protein Lysates 
For isolation of total cellular protein lysates, cells were washed twice with cold PBS and 
then incubated on ice for 5-10 minutes on ice in a lysis buffer containing 50 mM Hepes, 
150 mM NaCl, 10% Glycerol, 1% Triton X, 1.5 mM MgCl2, 1 mM EGTA, 100 mM NaF, 
and 10 mM NaPPi with sodium orthovanadate, ZnCl2, PMSF, and protease inhibitor 
cocktail (Sigma).  Protein lysates were than centrifuged at 13000 rpm for 15 minutes at 
4˚C and quantified using Bradford reagent. 
 
6. Immunoblot Analysis 
Protein lysates were separated by SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
and transferred to nitrocellulose membrane, which was then incubated overnight in 
primary antibody (see Table 2.3) at 4˚C with shaking.  The following day, the membrane 
was washed and incubated with HRP-conjugated secondary antibody (see Table 2.4), 
developed with Supersignal and exposed to X-Ray film or by using a Biorad Imager 
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7. PI3K Activity Assay 
Protein lysates were added to lipid micelles formed by sonication containing 
Phosphatidylinositol (PI; Avanti Polar Lipids), Phosphatidylinositol-(4,5)-bisphosphate 
(PIP2; Avanti Polar Lipids), and Phosphatidyl-serine (PS; Avanti Polar Lipids).  To this 
mixture, was added [
32
P]-labeled ATP, which was then allowed to incubate at 37˚C for 5 
minutes, so that the [
32
P]-labeled γ-phosphate of ATP could be incorporated into PIP2 by 
PI3K activity to form PIP3.  The lipids from this reaction were then spotted on a plate an 
allowed to separate by thin layer chromatography (TLC) overnight.  The following 
morning, the TLC plate was exposed to X-ray film to assess the amount of [
32
P]-labeled 
PIP3 generated by the PI3K activity of the protein lysates. 
 
8. [3H]-Thymidine Incorporation Assay 
Cells were starved for 4-6 hours in IMDM containing 0.2% Bovine Serum Albumin 
(BSA) (Roche) and then plated in 96-well plate (200 μL IMDM with 10% FBS and 2% 
Penicillin/Streptomycin/well) for [
3
H]-Thymidine incorporation assays (1-5 x 10
4
 
cells/well) either at baseline (no growth factor) or in the presence of 0.01 ng/mL, 0.1 
ng/mL, and 1 ng/mL Granulocyte Macrophage-Colony-Stimulating Factor (GM-CSF), 
with or without indicated inhibitors and incubated overnight at 37˚C.  The following 
morning, cells were pulsed with 1 μCi [3H]-Thymidine and incubated for 5-6 hours at 
37˚C.  [3H]-Thymidine incorporation was measured using an automated 96-well cell 
harvester and scintillation counter (Brandel, Gaithersburg, MD). 
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9. Apoptosis Assay 
Cells were then collected and counted.  5 x 10
4
 cells were plated into 12-well non-tissue 
culture plates in 0.5 mL IMDM with 10% FBS and 2% Penicillin/Streptomycin and 0 
ng/mL GM-CSF or 10 ng/mL GM-CSF with 1 μM IC87114 or 0.5 μM GDC-0941 or no 
inhibitor and incubated at 37˚C for 48 hours.  The cells were then collected into 
individual 5-mL polystyrene tubes, washed with PBS and resuspended in 100 μL 1X 
buffer (BD Pharmingen FITC-Apoptosis Detection Kit I #556547 with APC-Annexin V 
#51-65874X (556420)) supplemented with 5 µL propidium iodide (BD#51-
66211E(556463)) and 5 µL Annexin V-APC.  Cells were incubated in the dark at room 
temperature for 30 minutes.  Finally, 200-400 µL of 10X Annexin V Binding Buffer  
(BD# 51-66121E) was added and FACS analysis performed using an Accuri C6 Flow 
Cytometer.   
 
10. Methylcellulose Colony-Forming Assays 
Bone Marrow Low-Density Mononuclear Cells (1.0 x 10
5
) were plated in duplicate in 1 
mL progenitor assays containing 1% methylcellulose (ES-Cult® M3120, Stem Cell 
Technologies), 30% FBS, 2% penicillin/streptomycin, 1% glutamine, and 80 µM β-
mercaptoethanol in the absence or presence of increasing concentrations of GM-CSF 
(0.1-10 µM).  Methylcellulose assays were incubated at 37˚C for 7-10 days before total 
number of colonies were counted. 
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11. Statistical Analysis 
Statistics for Figure 3.4A were performed using Prentice’s rank sum test for replicated 
block data (Prentice 1979) and reported as mean +/- standard error of the mean (SEM).  
Statistics for all other experiments were performed using unpaired, two-tailed student’s 
test, and figures show mean +/- standard deviation (s.d.) or mean +/- standard error of the 
mean (SEM), as indicated in the figure. 
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CHAPTER THREE 
GENETIC DISRUPTION OF p85α, p55α, AND p50α REDUCES GAIN-OF-
FUNCTION MUTANT SHP2-INDUCED GM-CSF HYPERSENSITIVITY 
Introduction 
Our laboratory has previously shown that Akt is hyper-phosphorylated following 
GM-CSF stimulation in murine bone marrow low-density mononuclear cell (LDMNC)-
derived macrophage progenitors expressing gain-of-function mutant Shp2 (Figure 1.5) 
(Yang, Li et al. 2008). However, the role of mutant SHP2 in promoting hyperactivation 
of PI3K remains to be demonstrated, as does the potential contribution of PI3K signaling 
to gain-of-function mutant SHP2-induced GM-CSF hypersensitivity—a hallmark of 
Juvenile Myelomonocytic Leukemia (JMML)—and, as a result, to the pathogenesis of 
mutant SHP2-associated myeloproliferative disease (MPD).  Hyperactivation of PI3K 
signaling is frequently observed in most cancers, and consequently, much work in recent 
years has been dedicated to developing new classes of PI3K inhibitors with higher 
potency and specificity and assessing their suitability as a potential targeted therapy for a 
variety of human neoplasms and other diseases (Luo, Manning et al. 2003; Marone, 
Cmiljanovic et al. 2008). 
Gain-of-function mutations in SHP2 are known to cause hyperactivation of RAS, 
which is thought to promote hyperactivation of growth and survival-promoting signals 
that contribute to the initiation and progression of MPDs such as JMML.  The causative 
role of RAS hyperactivation in leukemogenesis is further evidenced by the fact that 
commonly encountered mutations in JMML, other than activating PTPN11 mutations, 
include gain-of-function mutations in RAS itself, and loss of function mutations in the 
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negative regulator of RAS, NF1.  Although RAS is known to regulate several signaling 
pathways that promote proliferation, growth, and survival, much of the attention has 
focused on SHP2’s effects on the RAF-MEK-ERK pathway.  However, it has been 
demonstrated that RAS can directly bind and activate PI3K (Rodriguez-Viciana, Warne 
et al. 1994; Rodriguez-Viciana, Warne et al. 1996; Chan, Rodeck et al. 2002), suggesting 
that PI3K may also play a role mutant SHP2-induced hyper-proliferation in response to 
GM-CSF stimulation, as well as mutant SHP2-induced MPD development. 
Structurally, Class IA PI3K is a lipid kinase heterodimer, composed of one 
regulatory subunit, and one of three catalytic subunits, p110α, p110β, or p110δ.  The 
regulatory subunit serves to stabilize the expression of the catalytic subunits by 
preventing their rapid degradation, and to recruit the catalytic subunits to specific 
phospho-tyrosine residues on activated receptors and scaffolding molecules, thus 
facilitating activation of PI3K signaling (Zhao and Vogt 2008).  Genetically ablating 
Class IA PI3K signaling by targeting the catalytic subunits would be technically 
challenging, as it would require genetic interruption of all three genes encoding the Class 
IA catalytic subunits.  Instead, we chose the approach of using an available mouse model, 
in which the Pik3r1 gene, encoding the main Class IA PI3K regulatory subunit, p85α and 
its splice variants p55α and p50α, has been genetically disrupted (Fruman, Mauvais-
Jarvis et al. 2000), resulting in dramatically reduced expression of the Class IA catalytic 
subunits and, thus, reduced Class IA PI3K activity. 
By introducing WT Shp2 or gain-of-function mutant Shp2 E76K, a mutation 
commonly found in JMML patients, into Pik3r1
-/-
 hematopoietic progenitor cells, we 
were able to assess the effects of the loss of p85α, p55α, and p50α on gain-of-function 
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mutant Shp2-induced hyper-proliferation and hyperactivation of PI3K signaling in 
response to GM-CSF stimulation. 
 
Results 
Murine Bone Marrow Low-Density Mononuclear Cell-Derived Macrophages 
expressing gain-of-function mutant Shp2 E76K have increased PI3K activity 
Previously, our lab has shown the bone marrow LDMNC-derived macrophage 
progenitors expressing activating Shp2 mutants have higher levels of Akt 
phosphorylation following GM-CSF stimulation than WT Shp2-expressing cells (Yang, 
Li et al. 2008).  We hypothesized that this increase in Akt activation was a result of gain-
of-function mutant Shp2-induced hyperactivation of PI3K, which we measured using an 
in vitro kinase assay. 
Bone marrow-derived LDMNCs from WT mice were isolated by Histopaque 
ficoll gradient, and plasmids containing WT Shp2 or Shp2 E76K were introduced by 
fibronectin-assisted retroviral transduction in the presence of 100 ng/mL each, 
Granulocyte-Colony-Stimulating Factor (G-CSF), Stem Cell Factor (SCF), and 
Thrombopoietin (TPO).  The retroviral vectors expressed each Shp2 cDNA in tandem 
with enhanced Green Fluorescent Protein (eGFP), allowing successfully transduced cells 
to be selected by Fluorescence-Activated Cell Sorting (FACS).  The transduced 
progenitor cells were then cultured into adherent macrophages, and following 7-10 days 
in culture, the adherent macrophages were starved overnight in IMDM, and the following 
morning were stimulated for 60 minutes with either 0 ng/mL GM-CSF or 10 ng/mL GM-
CSF, followed by lysis to collect total cellular protein.  The protein lysates were then 
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used for an in vitro PI3K activity assay.  We found that both at baseline, and following a 
60-minute stimulation with 10 ng/mL GM-CSF, Shp2 E76K-expressing cells had higher 
levels of PI3K activity, indicated by the darker spots on the X-ray film, which correlates 
with the amount [
32
P]-labeled phosphate incorporated into the phosphatidyl-(4,5)-
bisphosphate to produce PIP3, the active second messenger product of PI3K (Figure 3.1) 
(Goodwin, Yang et al. 2012).  Indeed, WT Shp2-expressing cells had an increase in PIP3 
production, following GM-CSF stimulation, but it was markedly lower than that seen in 
the Shp2 E76K-expressing cells, indicating that GM-CSF stimulation promotes activation 
of PI3K, which is significantly enhanced in the presence of an activating Shp2 mutation. 
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Figure 3.1: Gain-of-function mutant Shp2 E76K-expressing cells demonstrate 
increased PI3K activity 
 
PI3K activity assay showing increased Phosphatidylinositide-(3,4,5)-triphosphate (PIP3) 
production both at baseline and following a 60-minute stimulation with 10 ng/mL GM-
CSF in adherent macrophages expressing Shp2 E76K compared to those expressing WT 
Shp2, indicating increased basal and GM-CSF-stimulated PI3K activity in the presence of 
activating mutant Shp2 E76K (Goodwin, Yang et al. 2012). 
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Pharmacologic inhibition of PI3K using the pan-PI3K inhibitor, LY294002, reduces 
gain-of-function mutant Shp2-induced hyper-proliferation in response to GM-CSF 
stimulation 
Having demonstrated that PI3K is hyperactivated in the presence of gain-of-
function Shp2 mutations, we next wanted to determine whether the substantially 
increased PI3K activity in response to GM-CSF stimulation contributed to the classic 
phenotype of GM-CSF hypersensitivity—or enhanced proliferation response following 
GM-CSF stimulation—that is observed in hematopoietic progenitors expressing gain-of-
function mutant Shp2.  To do this, we performed to [
3
H]-Thymidine incorporation assays 
to measure GM-CSF-stimulated proliferation of Shp2 E76K-expressing cells in the 
presence of LY294002, a commonly used pan-PI3K inhibitor.  Proliferation of WT Shp2 
and Shp2 E76K-transduced cells were assessed in the presence of 0 ng/mL GM-CSF or 1 
ng/mL GM-CSF with 0 μM, 5 μM, or 15 μM LY294002 (Figure 3.2A).  Alternatively, 
cells were plated in the presence or absence of 5 μM LY294002 with increases 
concentrations of GM-CSF (Figures 3.2B).  As previously described, hematopoietic 
progenitors expressing gain-of-function mutant Shp2 E76K demonstrate enhanced 
proliferation both in the absence of growth factors, and in the presence of increasing 
concentrations of GM-CSF.  We found that treatment with LY294002 caused a 
concentration-dependent decrease in the proliferation of Shp2 E76K-expressing cells 
stimulated with 1 ng/mL GM-CSF (Figure 3.2A) (Goodwin, Yang et al. 2012).  
Similarly, we found that treatment with 5 μM LY294002 significantly reduced the hyper-
proliferative response in Shp2 E76K-expressing cells induced by the increasing 
concentrations of GM-CSF (Figure 3.2B) (Goodwin, Yang et al. 2012).  These data 
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suggest that cells expressing activating Shp2 mutations not only promote hyperactivation 
of PI3K in response to GM-CSF stimulation, but that this hyperactivated PI3K signaling 
contributes to the hyper-proliferative phenotype. 
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Figure 3.2: Pharmacologic inhibition of PI3K with LY294002 reduces gain-of-
function mutant Shp2 E76K-induced GM-CSF hypersensitivity 
 
(A) [
3
H]-Thymidine incorporation assay measuring 1 ng/mL GM-CSF-stimulated 
proliferation in WT Shp2- and gain-of-function mutant Shp2 E76K-transduced cells in 
the presence of increasing concentrations of the PI3K inhibitor, LY204002 (0, 5, and 15 
μM). Data are representative of two independent experiments; n= 4-6 samples; *p < 
0.005 comparing WT Shp2-expressing cells in the absence to the presence of LY294002 
at 5 μM and 15 μM; **p < 0.001 comparing Shp2 E76K-expresing cells in the absence to 
the presence of LY294002 at 5 μM and 15 μM; statistics performed using unpaired, two-
tailed student’s t-test.  (B) [3H]-Thymidine incorporation assay measuring proliferation in 
response to increasing concentrations of GM-CSF (0-1 ng/mL GM-CSF) in the presence 
or absence of 5 μM LY294002; n = 3 samples; *p < 0.05 and **p = 0.06 comparing Shp2 
E76K-expressing cells in the presence (purple line) or absence (red line) of LY294002; 
statistics performed using unpaired, two-tailed student’s t-test (Goodwin, Yang et al. 
2012). 
A
B
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Genetic disruption of the Pik3r1-encoded Class IA PI3K regulatory subunits, p85α, 
p55α, and p50α, results in reduced gain-of-function mutant Shp2-induced GM-CSF 
hypersensitivity 
 While LY294002 inhibition of proliferation provides useful insight toward the 
relevance of PI3K in gain-of-function Shp2-mediated GM-CSF hypersensitivity, 
interpretation of these data is limited as LY294002 is able to inhibit all classes of PI3K 
(IA, IB, II, and III) as well as to inhibit the function of PI3K-related protein kinases 
(Knight 2010).  To further explore the hypothesis that gain-of-function mutant Shp2-
induced GM-CSF hypersensitivity is at least in part mediated by hyperactivated Class IA 
PI3K signaling, we next used a genetic approach.  We used an existing mouse model in 
which the Pik3r1 gene, which encodes the major Class IA regulatory subunit, p85α, 
along with its splice variants, p55α and p50α, has been constitutively disrupted.  Based 
on our previous results (Figure 3.2), we hypothesized the genetic disruption of the 
Pik3r1-encoded regulatory subunits would result in significantly reduced PI3K signaling 
and Akt hyperactivation.  Because of the cross-talk between the PI3K and MAPK 
signaling pathways, we also predicted a reduction in GM-CSF-stimulated Erk 
hyperactivation.  By diminishing these two pro-growth signaling pathways, we 
hypothesized that genetic disruption of p85α and its splice variants would result in 
reduced gain-of-function mutant Shp2-induced hyper-proliferation in response to GM-
CSF stimulation (Figure 3.3).   
Because mice with homozygous deletion of the Pik3r1 gene typically die around 
embryonic day 15, timed matings between heterozygous males and females were 
performed in which hematopoietic progenitor cells were isolated from fetal livers of 
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homozygous Pik3r1
-/-
 embryos and from WT littermates.  Plasmids containing WT Shp2 
and gain-of-function mutant Shp2 E76K were introduced into these hematopoietic 
progenitors by Fibronectin-assisted retroviral transduction.  Positively transduced cells 
were then used for [
3
H]-Thymidine incorporation to measure proliferation in response to 
GM-CSF stimulation or cultured into adherent macrophages for biochemical analyses. 
 
 
Figure 3.3: Schematic representation of hypothesized role of Class IA PI3K in gain-
of-function mutant Shp2-induced GM-CSF hypersensitivity 
 
We hypothesize that Class IA PI3K signaling is a major contributor to gain-of-function 
mutant Shp2-induced GM-CSF hypersensitivity, such that genetic disruption of the 
Pik3r1 gene, which encodes the major Class IA PI3K regulatory subunits p85α, p55α, 
and p50α, will result in reduced GM-CSF-stimulated PI3K-Akt signaling, Erk activation, 
and resulting GM-CSF hyper-proliferation. 
Ras
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We found that genetic disruption of the Pik3r1-encoded regulatory subunits 
resulted in a significant, but partial, reduction in mutant Shp2 E76K-induced hyper-
proliferation in response to increasing concentrations of GM-CSF stimulation.  A 
complete correction in proliferation similar to that of WT Shp2-expressing cells was not 
achieved, indicating that the hyperactivated PI3K and/or MAPK signaling pathways were 
only partially decreased by the loss of p85α and its splice variants (Figure 3.4A) 
(Goodwin, Yang et al. 2012).   
Biochemical analyses of the WT and Pik3r1
-/-
 cells expressing either WT Shp2 or 
Shp2 E76K revealed that WT cells expressing Shp2 E76K had higher levels of phospho-
Akt (both Serine 473 and Threonine 308) and phospho-Erk than those cells expressing 
WT Shp2, both at baseline and following a 60-minute stimulation with 10 ng/mL GM-
CSF, consistent with previous findings (Figure 3.4B, compare lanes 1 and 2 and lanes 5 
and 6) (Goodwin, Yang et al. 2012).  Interestingly, we found that genetic disruption of 
Pik3r1 substantially reduced mutant Shp2-induced Akt hyper-phosphorylation at both 
Serine 473 and Threonine 308, both at baseline and following GM-CSF stimulation 
(Figure 3.4B, compare lanes 2 and 4 and lanes 6 and 8).  Furthermore, Erk hyper-
phosphorylation was also substantially reduced in Pik3r1
-/-
 cells expressing Shp2 E76K 
(Figure 3.4B, compare lanes 2 and 4 and lanes 6 and 8).  This suggests that PI3K plays a 
positive regulatory role in Erk activation, and that the gain-of-function Shp2-mediated 
hyperactivation of Erk is in part due to or reinforced by hyperactivated PI3K signaling.  
When targeting one signaling pathway, it is important to consider the effects on other 
signaling pathways, which may become disinhibited or hyperactivated when another 
pathway is interrupted.  In this case, it is an interesting observation that genetic disruption 
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of the Class IA signaling pathway results in similar decrease in Erk activation, rather than 
a compensatory hyperactivation.   
These biochemical findings correlate with the proliferation data above (Figure 
3.4A), and together they suggest that the Pik3r1-encoded regulatory subunits are 
necessary for full hyperactivation of PI3K in cells expressing mutant Shp2, and that intact 
Class IA PI3K signaling is required for mutant Shp2-induced GM-CSF hypersensitivity.  
We observed, however, that in the absence of p85α and its splice variants, that Akt hyper-
phosphorylation, although substantially reduced, was not completely abrogated, 
indicating that these mutant Shp2 E76K-expressing cells retained some residual PI3K 
activity inducible by GM-CSF stimulation that was higher in Pik3r1
-/-
 cells expressing 
Shp2 E76K compared to those expressing WT Shp2 (Figure 3.4B, compare lanes 7 and 
8).  We therefore wished to confirm the presence of this residual PI3K activity and to 
investigate the mechanisms by which it might be maintained. 
 
 
 
 
 
 
 
 
 
 
 51 
 
 
Figure 3.4: Genetic disruption of the PI3K regulatory subunits, p85α, p55α, and 
p50α results in significant reduction of mutant Shp2 E76K-induced GM-CSF 
hypersensitivity 
 
(A) [
3
H]-Thymidine incorporation assay measuring proliferation in response to increasing 
concentrations of GM-CSF (0-1 ng/mL) in WT and Pik3r1
-/-
 fetal liver cell-derived 
hematopoietic progenitors transduced with either WT Shp2 or gain-of-function mutant 
Shp2 E76K; 3 independent experiments combined with n=3 replicates per each 
experiment, *p < 0.01 for Pik3r1
+/+
; Shp2 E76K (red) vs. Pik3r1
-/-
; Shp2 E76K (purple) 
at each concentration of GM-CSF; statistics performed using Prentice’s rank sum test for 
replicated block data (Prentice 1979) .  (B) Western blot analyses demonstrating reduced 
Akt (Serine 473 and Threonine 308) hyper-phosphorylation and Erk hyper-
phosphorylation in Pik3r1
-/-
 cells expressing Shp2 E76K compared to WT cells 
expressing Shp2 E76K (compare lanes 4 and 2 and lanes 8 and 6).  Representative of 
three independent experiments (Goodwin, Yang et al. 2012). 
A
B
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Pik3r1
-/-
 cells expressing gain-of-function mutant Shp2 E76K retain residual GM-
CSF-stimulated PI3K activity 
 In order to demonstrate that hematopoietic cells expressing gain-of-function 
mutant Shp2 E76K retained some PI3K activity that was inducible by GM-CSF 
stimulation in the absence of the p85α and its splice variants, p55α and p50α, we cultured 
WT and Pik3r1
-/-
 adherent macrophages transduced with either WT Shp2 and Shp2 
E76K, which were then starved overnight in IMDM without serum or growth factors, and 
then stimulated 16-18 hours later for 60 minutes with 10 ng/mL GM-CSF in the presence 
of either 5 μM of the pan-PI3K inhibitor, LY294002, or DMSO as a control.  Again, we 
found that following stimulation with GM-CSF, Shp2 E76K-induced hyper-
phosphorylation of Akt and Erk were substantially reduced in the absence of the Pik3r1 
regulatory subunits (Figure 3.5, compare lanes 3 and 7).  Additionally, treatment of 
Pik3r1
-/-
 cells expressing Shp2 E76K with LY294002 further reduced Akt 
phosphorylation (Figure 3.5, compare lanes 7 and 8), indicating that in the absence of 
p85α and its splice variants, there was residual PI3K activity that was inducible by GM-
CSF stimulation, and which could be inhibited pharmacologically.  We also observed 
that, while treatment with LY294002 resulted in a reduction of Shp2 E76K-induced Erk 
hyper-phosphorylation in those cells with the Pik3r1 gene intact (Figure 3.5, compare 
lanes 3 and 4), this same inhibitor caused an increase in Erk phosphorylation in Pik3r1
-/-
 
cells expressing Shp2 E76K (Figure 3.5, compare lanes 7 and 8), indicating the 
complicated nature of the cross-talk between these two pathways. 
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Figure 3.5: Treatment of Pik3r1
-/-
 cells expressing gain-of-function mutant Shp2 
E76K with the pan-PI3K inhibitor, LY294002, inhibits residual PI3K activity 
 
Western blot analysis of adherent macrophages cultured from WT and Pik3r1
-/-
 fetal liver 
cell-derived hematopoietic progenitors, demonstrating that there is residual PI3K activity 
in the cells in the absence of the Pik3r1-encoded regulatory subunits, which can be 
inhibited pharmacologically with the pan-PI3K inhibitor, LY294002, as evidenced by the 
near complete abrogation of Akt phosphorylation in Pik3r1
-/-
 cells expressing mutant 
Shp2 E76K in the presence of LY294002 (compare lanes 7 and 8).  Note, however, that 
there is an increase in Erk phosphorylation in the Pik3r1
-/-
 cells expressing Shp2 E76K 
upon treatment with LY294002 (compare lanes 7 and 8) Representative of two 
independent experiments. 
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Genetic disruption of Pik3r1-encoded Class IA PI3K regulatory subunits, p85α, p55α, 
and p50α, results in significantly reduced expression of Class IA catalytic subunits, 
with preferential stabilization of p110δ in the presence of gain-of-function mutant 
Shp2 E76K 
 To begin exploring possible mechanisms for the residual PI3K activity observed 
in Pik3r1
-/-
 cells expressing Shp2 E76K, we assessed the protein expression levels of the 
three Class IA catalytic subunits, p110α, p110β, and p110δ, because it has been reported 
that the stability of these catalytic subunits is substantially decreased in the absence of 
p85α and its splice variants, and their expression levels are reduced as result of rapid 
degradation.  
 WT and Pik3r1
-/-
 cells transduced with either WT Shp2 or Shp2 E76K were 
cultured into adherent macrophages, starved and stimulated before total cellular protein 
lysates were collected as described above.  Western blots analyses revealed that in the 
presence of the Pik3r1-encoded regulatory subunits, there was no difference in the 
expression of p110α, p110β, or p110δ between the WT Shp2- or Shp2 E76K-expressing 
cells, either at baseline or following stimulation (Figure 3.6A, compare lanes 1and 2, and 
lanes 5 and 6) (Goodwin, Yang et al. 2012), indicating that the increased PI3K activity 
caused by Shp2 E76K expression is not due to increased protein expression of one or 
more Class IA catalytic subunits.  In the absence of p85α and its splice variants, 
expression of p110α and p110δ is markedly reduced, while expression of p110β is almost 
completely abrogated (Figure 3.6A).  The residual p110α and p110δ expression might 
result from stabilizing interactions with the remaining regulatory subunits p85β and p55γ.  
We noticed, however, that Pik3r1
-/-
 cells expressing Shp2 E76K had slightly higher levels 
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of p110δ compared to Pik3r1-/- cells expressing WT Shp2 (Figure 3.6A, compare lanes 3 
and 4 and lanes 7 and 8).  We confirmed this observation with four additional 
experiments, and, using densitometric analysis, we found that the expression levels of 
p110δ were approximately two-fold higher in the Shp2 E76K-expressing cells compared 
to the WT Shp2-expressing cells (Figure 3.6B) (Goodwin, Yang et al. 2012).  This 
observation suggests that the catalytic subunit p110δ is being preferentially stabilized in 
Shp2 E76K cells lacking p85α and its splice variants, and we hypothesize that this may 
result from enhanced or compensatory stabilizing interactions with the regulatory subunit 
p85β.  Attempts to assess the interaction between p110δ and p85β by co-
immunoprecipitation were unsuccessful due to a lack of commercially available p85β 
antibodies of sufficient quality.  These results suggest that the residual GM-CSF-
stimulated PI3K activity and incomplete reduction in Shp2 E76K-induced hyper-
proliferation following GM-CSF simulation may be due to retained expression of some of 
catalytic subunits, especially p110δ.  These findings also suggest that p110δ may be the 
principal mediator of mutant Shp2-induced PI3K hyperactivation in response to GM-CSF 
stimulation, and therefore p110δ may be a potential therapeutic target for the treatment of 
activating mutant Shp2-associated MPD. 
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Figure 3.6: Expression of Class IA PI3K catalytic subunits is substantially decreased 
in the absence of Pik3r1-encoded regulatory subunits, but the catalytic subunit 
p110δ is preferentially stabilized in Pik3r1-/- cells expressing gain-of-function mutant 
Shp2 E76K 
 
(A) Western blot analysis of adherent macrophages cultured from WT and Pik3r1
-/-
 fetal 
liver cell derived-hematopoietic progenitors transduced with WT Shp2 or gain-of-
function mutant Shp2 E76K, showing dramatically reduced expression of the Class IA 
PI3K catalytic subunits, p110α, p110β, and p110δ in the absence of the Pik3r1-encoded 
regulatory subunits.  Unlike the other catalytic subunits, p110δ is expressed at slightly 
higher levels in Pik3r1
-/-
 cells expressing Shp2 E76K compared to Pik3r1
-/-
 cells 
expressing WT Shp2 (compares lanes 3 and 4 and lanes 7 and 8). (B) Four additional 
immunoblots showing relatively increased p110δ protein levels in Pik3r1-/- expressing 
Shp2 E76K compared to those expressing WT Shp2 and quantitation using densitometry 
normalized to total Akt expression; n = 5; *p = 0.02; statistics performed using unpaired, 
two-tailed student’s t-test (Goodwin, Yang et al. 2012). 
A
B
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Cells expressing Shp2 E76K in the absence of p85α, p55α, and p50α are relatively 
resistant to treatment with the Ras inhibitor, tipifarnib 
 Because one of consequences of gain-of-function Shp2 mutations is Ras 
hyperactivation, we wished to explore whether the mutant Shp2-induced hyperactivation 
of PI3K was entirely Ras-dependent or at least partially Ras-independent.  This question 
is of clinical relevance, since a demonstration that the mutant Shp2-induced PI3K 
hyperactivation was entirely dependent on Ras would suggest that a therapeutic approach 
of solely targeting Ras hyperactivation would theoretically be sufficient for the treatment 
of mutant Shp2-associated MPD, while a demonstration that mutant Shp2 can 
hyperactivate PI3K independently of Ras would suggest that PI3K would need to be 
targeted in addition to the Ras-MAPK pathway.  To address this question, we used the 
farnesyl-transferase inhibitor (FTI), tipifarnib, which prevents the farnesylation of Ras 
and, as a consequence, prevents its targeting to the inner leaflet of the plasma membrane 
where it conducts its signal transducing activities.   
 WT and Pik3r1
-/-
 macrophages transduced with Shp2 E76K were pretreated for 48 
hours with 10 μM of tipifarnib or vehicle control, before overnight starvation in IMDM 
and a 60-minute stimulation with 10 ng/mL GM-CSF in the continued presence or 
absence of tipifarnib.  Western blot analyses of these cells revealed that treatment of WT 
cells expressing Shp2 E76K with tipifarnib caused a modest decrease in GM-CSF-
stimulated hyperactivation of Akt and Erk (Figure 3.7A, compare lanes 1 and 2) 
(Goodwin, Yang et al. 2012).  As already observed, Pik3r1
-/-
 cells expressing Shp2 E76K 
have significantly lower levels of phosphorylated Akt and Erk following GM-CSF 
stimulation (Figure 3.7A, compare lanes 1 and 3); however treatment with tipifarnib does 
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not bring a further reduction in Akt and Erk activation (Figure 3.7A, compare lanes 3 and 
4), suggesting that the residual PI3K activity that remains in the absence of the Pik3r1-
encoded regulatory subunits is largely Ras-independent.  These biochemical results 
correlate with the proliferation data, in which, as previously observed, genetic disruption 
of Pik3r1 results in partial correction of the Shp2 E76K-induced hyper-proliferative 
response following GM-CSF stimulation, but treatment with 1 μM tipifarnib caused a 
50% decrease in GM-CSF-stimulated proliferation in Shp2 E76K-transduced WT cells, 
while only causing a 30% decrease in proliferation in Shp2 E76K-transduced Pik3r1
-/-
 
cells (Figure 3.7B) (Goodwin, Yang et al. 2012).  This suggests that Pik3r1
-/-
 cells 
expressing Shp2 E76K are less sensitive to Ras inhibition, and that therefore, the residual 
GM-CSF-stimulated PI3K activity in the absence of p85α and its splice variants is, at 
least in part, induced by gain-of-function mutant Shp2 in a Ras-independent manner.  
This finding is particularly significant given the relatively increased expression of p110δ 
observed in Pik3r1
-/-
 cells expressing Shp2 E76K, since it has been reported that p110δ, 
in contrast to the other PI3K catalytic subunits, can induce oncogenic transformation in a 
Ras-independent manner (Denley, Kang et al. 2008). 
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Figure 3.7: Pik3r1
-/-
 cells expressing gain-of-function mutant Shp2 E76K are 
relatively resistant to Ras inhibition mediated by the farnesyl-transferase inhibitor 
tipifarnib 
 
(A) Western blot analyses of adherent macrophages cultured from WT and Pik3r1
-/-
 fetal 
liver cell-derived hematopoietic progenitors transduced with gain-of-function mutant 
Shp2 E76K stimulated for 60 minutes with 10 ng/mL GM-CSF in the presence or 
absence of 10 μM tipifarnib, a farnesyl-transferase inhibitor which blocks activation of 
Ras.  (B)  [
3
H]-Thymidine incorporation assay measuring 1 ng/mL GM-CSF-stimulated 
proliferation of WT and Pik3r1
-/-
 fetal liver cell-derived hematopoietic progenitors 
transduced with gain-of-function mutant Shp2 E76K in the presence of increasing doses 
of tipifarnib (0, 1, or 5 μM); representative of 2 independent experiments; n = 8; *p < 
0.02 comparing Pik3r1
+/+
 Shp2 E76K vs. Pik3r1
-/-
 Shp2 E76K cells in response to1 
ng/mL GM-CSF in the absence of tipifarnib; ^p < 0.001 comparing Pik3r1
+/+
 Shp2 E76K 
cells in absence to the presence of tipifanib at 1 μM and 5 μM; #p < 0.005 comparing 
Pik3r1
-/-
 Shp2 E76K cells in the absence to the presence of tipifarnib at 1 μM and 5 μM; 
statistics performed using unpaired, two-tailed student’s t-test (Goodwin, Yang et al. 
2012). 
A
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Conclusions 
 Gain-of-function mutations in PTPN11 are the most common genetic aberrations 
in JMML patients.  It is already well known that these gain-of-function mutations, as well 
as the other identified mutated genes in JMML, promote hyperactivation of the RAS-
MAPK pathway, which helps promote the observed hypersensitivity to GM-CSF 
stimulation that is thought to be an important underlying mechanism of the pathogenesis 
of JMML (Chan and Feng 2007; Mohi and Neel 2007).  Until now, the contribution of 
PI3K—a known effector of RAS—to GM-CSF hypersensitivity and leukemogenesis has 
not been thoroughly examined.  In these studies, we confirm that PI3K is hyperactivated 
in the presence of activating Shp2 mutations, and, using the pan-PI3K inhibitor 
LY294002, we show that hyperactivated PI3K contributes to mutant Shp2-induced GM-
CSF hypersensitivity. 
In addition, we initiated genetic studies to investigate the role of Class IA PI3K in 
mutant Shp2-induced GM-CSF hypersensitivity, using a genetic mouse model in which 
the main Class IA PI3K regulatory subunit, p85α, and its splice variants, p55α and p50α, 
encoded by the Pik3r1 gene, is constitutively knocked out (Fruman, Mauvais-Jarvis et al. 
2000).  Using this mouse model, we found that genetic interruption of the Pik3r1gene 
reduces mutant Shp2 E76K-induced hyper-proliferation in response to GM-CSF 
stimulation as well as hyper-phosphorylation of Akt, a major downstream effector of 
PI3K activity.  In addition we found that Pik3r1
-/-
 cells expressing Shp2 E76K also had a 
significant reduction in the hyper-phosphorylation of Erk, indicating that PI3K is a 
positive regulator of Erk activity.  Thus, mutant Shp2-induced hyperactivation of PI3K 
may be promoting GM-CSF hypersensitivity not only through Akt or other common 
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effectors of PI3K, but it may also be doing so through the augmentation of the Raf-MEK-
Erk pathway that is already directly hyperactivated by enhanced Ras signaling.   
Although mutant Shp2-induced PI3K hyperactivation and resulting GM-CSF 
hypersensitivity were reduced by genetic disruption of Pik3r1, we found there to be 
residual PI3K activity that could be pharmacologically inhibited.  This residual GM-CSF-
stimulated PI3K activity is likely due to the retained expression—though at greatly 
reduced levels—of two of the Class IA PI3K catalytic subunits, p110α and p110δ, the 
latter of which we observed to be expressed at higher levels in Pik3r1
-/-
 cells expressing 
Shp2 E76K compared to those cells expressing WT Shp2.  This unexpected finding 
suggests that p110δ may serve as the principal mediator of mutant Shp2-induced PI3K 
hyperactivation, and it may also explain why the residual PI3K activity in the absence of 
p85α and its splice variants is relatively resistant to Ras inhibition, since it has been 
previously reported that the transforming capabilities of p110δ is Ras-indpendent, unlike 
the other Class IA catalytic subunits (Denley, Kang et al. 2008).  Importantly, these data 
suggest that PI3K hyperactivity, particularly that mediated by p110δ, may represent a 
potential therapeutic target for gain-of-function mutant Shp2-induced MPD, and that this 
PI3K hyperactivation must be targeted independently of Ras. 
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CHAPTER FOUR 
PHARMACOLOGIC INHIBITION OF PI3K WITH CATALYTIC SUBUNIT-
SPECIFIC INHIBITORS REDUCES GAIN-OF-FUNCTION MUTANT SHP2-
INDUCED GM-CSF HYPERSENSITIVITY 
Introduction 
 Having demonstrated the role of Class IA PI3K signaling in gain-of-function 
mutant SHP2-induced GM-CSF hypersensitivity, a hallmark of Juvenile Myelomonocytic 
Leukemia (JMML) which is thought to contribute to the pathogenesis of the disease, we 
next wanted to explore newer classes of catalytic subunit-specific inhibitors, many of 
which have already entered clinical trials for a variety of malignant and non-malignant 
human diseases.  In recent years, there has been increasing focus on investigating the role 
of individual PI3K catalytic subunits in particular physiologic processes and, especially, 
specific disease states with the hope of targeting the activity of the one or two catalytic 
subunits involved in the pathogenesis of that disease rather than indiscriminately 
inhibiting all PI3K activity (Marone, Cmiljanovic et al. 2008).  This focus would reduce 
the risk of unintended side effects which may occur, given the relatively universal 
importance of PI3K signaling in normal human physiology.  Likewise, we wanted to 
determine whether a particular Class IA catalytic subunit was the principal mediator of 
mutant Shp2-induced PI3K hyperactivation in response to GM-CSF stimulation, so that 
we might be able to take advantage of newly developed catalytic subunit-specific 
inhibitors for more efficient targeting of this pathway. 
 We were particularly interested in focusing on the role of p110δ for a number of 
reasons.  Based on our previous studies using murine cells bearing genetic disruption of 
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the Pik3r1 gene, which encodes the major Class IA PI3K regulatory subunit, p85α and its 
splice variants, p55α and p50α, we found that p110δ expression, though greatly reduced 
like the other catalytic subunits, was relatively higher in Shp2 E76K-expressing Pik3r1
-/-
 
cells compared to the WT Shp2-expressing cells (Figure 3.6).  We postulated that this 
preferential stabilization of p110δ in the presence of the activating Shp2 mutation might 
account for the residual PI3K activity that remained in the absence of the Pik3r1-encoded 
regulatory subunits and it might also explain the relative insensitivity to Ras inhibition in 
the Pik3r1
-/-
 cells expressing Shp2 E76K, given previous studies that suggest that p110δ 
can induce oncogenic transformation independent of Ras (Denley, Kang et al. 2008).  
Therefore, based on these observations, we hypothesized that p110δ might be the 
principal mediator of GM-CSF-stimulated PI3K hyperactivation in the presence of 
activating Shp2 mutations.  Finally, we were also interested in p110δ because its 
expression is mostly confined to hematopoietic cells, unlike the other two Class IA 
catalytic subunits, p110α and p110β, which are ubiquitously expressed (Okkenhaug, 
Bilancio et al. 2002).  This would make p110δ an ideal target for hematologic 
malignancies, thereby reducing the risk of systemic side effects that may occur from 
inhibiting PI3K activity more globally with a less specific inhibitor. 
 At the same, we also wanted to explore the role of p110α, because it is frequently 
associated with human malignancies, being the only Class IA PI3K catalytic subunit 
found to have somatic mutations in human cancer (Zhao and Vogt 2008).  In our studies 
using the Pik3r1
-/-
, we noted that p110α expression, though substantially reduced, was 
also not completely abolished by the loss of p85α and its splice variants.  Unlike p110δ, 
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however, there was no difference in p110α expression between Pik3r1-/- cells expressing 
mutant Shp2 E76K and those expressing WT Shp2. 
 For these in vitro studies, we initially used two commercially available inhibitors, 
IC87114, a p110δ-specific inhibitor, and GDC-0941, a clinical-grade pan-PI3K inhibitor 
with highest specificity for p110δ and p110α (Table 4.1).  Additionally, we also made use 
of the p110β-specific inhibitor, TGX-221 (Table 4.1).  Finally, in collaboration with 
Gilead Sciences, we initiated studies with the highly potent and specific p110δ inhibitor, 
GS-9820 (formerly known as CAL-120).  GS-9820 is structurally similar to the inhibitor, 
GS-1101 (formerly known as CAL-101), which is in clinical trials for lymphoid 
malignancies, but the former has a much better pharmacodynamic profile in mice, and 
therefore is often used in mouse studies (BJ Lannutti, Gilead Sciences, Inc, Seattle, WA, 
personal communication). 
 In addition to performing these studies using WT murine bone marrow-derived 
low-density mononuclear cells (LDMNCs) transduced with WT Shp2 and gain-of-
function mutant Shp2 E76K, we also used bone marrow LDMNCs from LSL-Shp2
D61Y/+
; 
Mx1-Cre+ mice.  These mice express endogenous levels of gain-of-function mutant Shp2 
D61Y, a commonly found mutation in JMML patients (Chan, Kalaitzidis et al. 2009).  
This expression is inducible primarily in hematopoietic cells upon activation of the Cre 
recombinase under the Mx1 promoter following a polyI:polyC-stimulated γ-interferon 
response.  Using these cells has the advantage of providing a more physiologically 
relevant model, since the gain-of-function mutation Shp2 D61Y is expressed at 
endogenous levels, unlike in the transduction model where the mutated Shp2 is 
significantly overexpressed. 
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 We hypothesized that treatment of cells expressing gain-of-function Shp2 
mutations with the IC87114 (p110δ-specific), GDC-041 (p110α- and p110δ-specific), or 
the clinical-grade p110δ-specific inhibitor, GS-9820, would reduce mutant Shp2-induced 
hyper-proliferation as well as Akt and Erk hyperactivation following GM-CSF 
stimulation.  We also hypothesized that these inhibitors would also increase apoptosis in 
mutant Shp2-expressing cells.  Together, we believe these studies will demonstrate the 
potentially utility of PI3K catalytic subunit-specific inhibitors, particularly those with 
high specificity for p110δ, in the treatment of mutant Shp2-induced myeloproliferative 
disease. 
 
Table 4.1: PI3K catalytic subunit-specific inhibitors 
 
Table showing four PI3K inhibitors, along with their IC50 concentrations for each of the 
four Class I PI3K catalytic subunits.  Lowest IC50 concentrations for particular catalytic 
subunits are shown in bold for each inhibitor to emphasize the principal specificity for 
each inhibitor. 
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Results 
Inhibition of PI3K with catalytic subunit-specific inhibitors, IC87114, GDC-0941 and 
TGX-221, reduces GM-CSF-stimulated hyper-proliferation in cells with exogenously 
overexpressed gain-of-function mutant Shp2 E76K 
 WT bone marrow LDMNCs were transduced with WT Shp2 and gain-of-function 
mutant Shp2 E76K, and their GM-CSF-stimulated proliferation was measured in the 
presence of increasing concentrations of the PI3Kcatalytic subunit-specific inhibitors, 
IC87114, GDC-0941, and TGX-221.  IC87114 is specific for p110δ, while TGX-221 is 
specific for p110β, and GDC-0941 is a clinical-grade pan-PI3K inhibitor with highest 
specificity for p110δ and p110α.  We hypothesized that p110δ is the principal mediator of 
gain-of-function mutant Shp2-induced PI3K hyperactivation, which contributes to the 
enhanced proliferative response following GM-CSF stimulation, and that therefore the 
inhibitors with highest specificity for p110δ would be most effective in reducing GM-
CSF stimulated proliferation in these cells. 
 We found that all three inhibitors, IC87114 (Figure 4.1A), GDC-0941 (Figure 
4.1B), and TGX-221 (Figure 4.1C) caused a concentration-dependent decrease in GM-
CSF-stimulated hyper-proliferation in cells transduced with mutant Shp2 E76K.  
Treatment with IC87114 efficiently inhibited GM-CSF-stimulated proliferation in the 5-
25 μM range (Figure 4.1A) (Goodwin, Yang et al. 2012).  This relatively high 
concentration is most likely due to the fact that IC87114, though highly specific for 
p110δ is not very potent (Table 4.1).  TGX-221 demonstrated efficient inhibition of GM-
CSF-stimulated proliferation in the 1-5 μM range (Figure 4.1C), but at these 
concentrations, it is possibly losing specificity for p110β and beginning to also have an 
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inhibitory effect on p110δ, for which it also has a relatively low IC50 (Table 4.1).  By far, 
the inhibitor that decreased GM-CSF-stimulated proliferation the most efficiently was 
GDC-0941, which achieved significant reductions in GM-CSF-stimulated proliferation in 
the 0.1-0.5 μM range (Figure 4.1B) (Goodwin, Yang et al. 2012).  The efficacy of GDC-
0941 could be the result of its extremely low IC50 for p110δ, 3 nM (Table 4.1), or 
because it is also a very potent inhibitor of p110α, which would suggest that both p110δ 
and p110α are responsible for mediating gain-of-function mutant Shp2-induced GM-CSF 
hypersensitivity, and that therefore the activity of both p110δ and p110α must be 
interrupted in order to effectively inhibit mutant Shp2-induced PI3K hyperactivation and 
resulting GM-CSF hypersensitivity. 
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Figure 4.1: Catalytic subunit-specific PI3K inhibitors, especially those with high 
specificity for p110δ reduce gain-of-function mutant Shp2 E76K-induced hyper-
proliferation in response to GM-CSF stimulation 
 
[
3
H]-Thymidine incorporation assays measuring GM-CSF-stimulated proliferation in 
bone marrow-derived LDMNCs transduced with WT Shp2 or Shp2 E76K in the presence 
of three different catalytic subunit-specific PI3K inhibitors: (A) IC87114, a specific 
inhibitor for p110δ, (B) GDC-0941, a highly potent inhibitor of p110δ and p110α, and 
(C) TGX-221, a specific inhibitor for p110β (continued on next page). 
 
A
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Figure 4.1: Catalytic subunit-specific PI3K inhibitors, especially those with high 
specificity for p110δ reduce gain-of-function mutant Shp2 E76K-induced hyper-
proliferation in response to GM-CSF stimulation (continued) 
 
 (A) IC87114 inhibits GM-CSF-stimulated hyper-proliferation in mutant Shp2 E76K-
expressing cells in concentration-dependent manner (0-50 μM); representative of 2 
independent experiments; n = 4-5; *p < 0.05 in WT Shp2-expressing cells comparing the 
absence and the presence of IC87114 at 10 μM; **p < 0.001 in WT Shp2-expressing cells 
comparing the absence and the presence of IC87114 at 25 μM and 50 μM; ^p < 0.005 in 
Shp2 E76K-expressing cells comparing the absence and the presence of IC87114 at 5 μM 
and 10 μM; ^^p < 0.001 in Shp2 E76K-expressing cells in the absence and the presence 
of IC87114 at 25 μM and 50 μM.  (B) GDC-0941 inhibits GM-CSF in mutant Shp2 
E76K-expressing cells in a concentration-dependent manner (0-5 μM); representative of 
2 independent experiments; n = 4-5; *p < 0.005 in WT Shp2-expressing cells comparing 
the absence and the presence of GDC-0941 at 0.5 μM; **p < 0.001 in WT Shp2-
expressing cells comparing the absence and the presence of GDC-0941 at 1 μM and 5 
μM; ^p < 0.005 in Shp2 E76K-expressing cells comparing the absence and the presence 
of GDC-0941 at 0.1 μM; ^^p < 0.001 in Shp2 E76K-expressing cells in the absence and 
the presence of GDC-0941 at 0.5 μM, 1 μM, and 5 μM. (C) TGX-221 inhibits GM-CSF 
in mutant Shp2 E76K-expressing cells in a concentration-dependent manner (0-10 μM); 
representative of 2 independent experiments; n = 4-5; *p < 0.01 in WT Shp2-expressing 
cells comparing the absence and the presence of TGX-221 at 5 μM; **p < 0.001 in WT 
Shp2-expressing cells comparing the absence and the presence of TGX-221 at 10 μM; ^p 
< 0.05 in Shp2 E76K-expressing cells comparing the absence and the presence of TGX-
221 at 1 μM; ^^p < 0.001 in Shp2 E76K-expressing cells in the absence and the presence 
of TGX-221 at 5 μM and 10 μM; statistics performed using unpaired, two-tailed student’s 
t-test (Goodwin, Yang et al. 2012). 
C
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PI3K inhibitors with high specificity for p110δ reduce GM-CSF-stimulated Akt and 
Erk hyper-phosphorylation in cells transduced with gain-of-function mutant Shp2 
E76K 
 To confirm that these inhibitors were causing a decrease in GM-CSF-stimulated 
hyper-proliferation by specifically blocking hyperactivated PI3K signaling, we performed 
biochemical analysis of adherent macrophages expressing exogenous WT Shp2 or Shp2 
E76K in the presence of these inhibitors.  We found that at these doses, the inhibitors 
caused a substantial decrease in GM-CSF-stimulated Akt hyper-phosphorylation both at 
Serine 473 and Threonine 308 in mutant Shp2 E76K-expressing cells, which we believed 
to be the result of the inhibitors blocking the activity of PI3K, particularly that mediated 
by p110δ (Figure 4.2, compare lanes 7 and 8 with lane 6) (Goodwin, Yang et al. 2012).  
We also found that these inhibitors reduced GM-CSF-stimulated hyperactivation of Erk, 
which is consistent with our observations in our earlier studies with Pik3r1
-/-
 cells that 
PI3K has a positive regulatory effect on MAPK signaling (Figure 4.2, compare lanes 7 
and 8 with lane 6).  Mirroring our proliferation data above, GDC-0941 appeared to be a 
more potent inhibitor of GM-CSF-stimulated PI3K hyperactivation, as it was able to 
achieve greater reductions in Akt and Erk hyper-phosphorylation at lower doses than 
IC87114 (Figure 4.2 compares lanes 7 and 8), correlating with its ability to reduce GM-
CSF-stimulated proliferation at lower doses.  Based on these results, it appears that the 
inhibitors are causing a reduction in GM-CSF-stimulated hyper-proliferation in cells 
expressing gain-of-function mutant Shp2 E76K by specifically reducing GM-CSF-
stimulated hyperactivation of PI3K, and that GDC-0941 is a more potent inhibitor of this 
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PI3K hyperactivation than IC87114 either because of its lower IC50 for p110δ, or because 
it is also able to inhibit the activity of p110α, or both. 
 
 
Figure 4.2: PI3K inhibitors with high specificity for p110δ reduce GM-CSF-
stimulated hyperactivation of PI3K and MAPK signaling in mutant Shp2 E76K-
expressing cells 
 
Western blot analyses of adherent macrophages cultured from bone marrow-derived 
LDMNCs transduced with WT Shp2 or gain-of-function mutant Shp2 E76K stimulated 
for 60 minutes with the 10 ng/mL GM-CSF in the presence of 5 μM IC87114 or 0.5 μM 
GDC-0941.  Treatment with either inhibitor reduced GM-CSF-stimulated hyper-
phosphorylation of Akt (at both serine 473 and threonine 308), Erk, and Shp2 (at tyrosine 
580) in cells exogenously expressing gain-of-function mutant Shp2 E76K.  Data 
representative of 2 independent experiments (Goodwin, Yang et al. 2012). 
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Pharmacologic inhibition of both Ras and PI3K cooperate to reduce gain-of-function 
mutant Shp2 E76K-induced GM-CSF hypersensitivity 
 To further explore the question of Ras-dependent and Ras-independent 
hyperactivation of PI3K in the presence of gain-of-function mutant Shp2, we measured 
proliferation of Shp2 E76K-transduced cells with a combination of different doses of the 
PI3K inhibitor, GDC-0941 and the farnesyl-transferase inhibitor, tipifarnib, to block Ras 
activation.  Specifically, we treated cells stimulated with 1 ng/mL GM-CSF with either 0 
μM, 1 μM, or 5 μM tipifarnib in the presence of increasing concentrations of GDC-0941 
(0 μM, 0.1 μM, 0.5 μM, and 1 μM).  We found that treating these cells with tipifarnib 
(either 1 μM or 5 μM) caused a significant reduction in GM-CSF-stimulated 
proliferation, and that at each given concentration of tipifarnib, a further decrease in 
proliferation could be achieved with GDC-0941 in the concentration range of 0.5-1 μM 
(Figure 4.3A) (Goodwin, Yang et al. 2012).   
 Inhibition of Erk and Akt phosphorylation as examined by western blot in cells 
treated with these inhibitors correlated with the reduced level of observed proliferation. 
Starved adherent macrophages were stimulated for 60 minutes in the presence of either 0 
μM, 1 μM, 5 μM, or 10 μM tipifarnib, and for each concentration of tipifarnib, cells were 
also treated with increasing concentrations of GDC-0941 (0 μM, 0.1 μM, and 0.5 μM).  
Similar to the proliferation data, for each concentration of tipifarnib, addition of GDC-
0941 resulted in a further reduction in GM-CSF-stimulated hyper-phosphrylation of Akt 
and Erk in a concentration-dependent manner (Figure 4.3B, compare lanes 6 and 7 with 
lane 5, lanes 9 and 10 with lane 8, and lanes 12 and 13 with lane 11) (Goodwin, Yang et 
al. 2012).  We observed, however, that the magnitude of the reduction of GM-CSF-
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stimulated hyper-proliferation achieved with a given dose of tipifarnib did not appear to 
be commensurate with the magnitude of reduction of GM-CSF-stimulated hyper-
phosphorylation of Akt or Erk, so it is difficult to conclude whether the proliferation 
inhibitory effect of tipifarnib is solely the result of blocking Ras activity or a non-specific 
toxicity effect.  For instance, treatment with 1 μM tipifarnib results in a nearly two-fold 
reduction in GM-CSF-stimulated hyper-proliferation in Shp2 E76K-expressing cells, 
while the same concentration resulted in a modest reduction at best in GM-CSF-
stimulated Akt and Erk hyper-phosphorylation (Figure 4.3).  However, it should be noted 
that we frequently observed differences in the magnitude of biochemical and proliferative 
effects of a variety of inhibitors in our studies.  This may be due to the fact that different 
cells are being used for the different assays—myeloid progenitors for [3H]-Thymidine 
incorporation assays and adherent macrophages for biochemistry analyses—or due to the 
fact that the cells are usually treated for different time periods with the inhibitor under 
investigation—approximately 24 hours for [3H]-Thymidine incorporation assays and 
typically one hour for biochemistry analyses.  The latter factor does not, however, apply 
to the differences in the biochemical and functional effects observed with tipifarnib 
treatment, because the cells are treated for approximately 24 hours for both proliferation 
and biochemical assays, since this inhibitor is targeting an activating post-translational 
modification of Ras, rather than directly blocking its activity.  Unfortunately, at this time, 
FTIs represent the only option for pharmacologically targeting Ras activity.  Despite the 
complexities introduced by using an inhibitor like tipifarnib, we believe the general 
conclusions of these results still hold; i.e., tipifarnib is able to produce some reduction in 
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Ras-mediated PI3K hyperactivation, which contributes to a reduction in GM-CSF-
stimulated hyper-proliferation. 
 Thus, with this in mind, we believe that inhibition of mutant Shp2 E76K-induced 
hyperactivation of Ras with tipifarnib is able to cause a reduction in GM-CSF-stimulated 
PI3K hyperactivation and resulting proliferation, but there remains residual PI3K activity 
that can be blocked pharmacologically, suggesting that this PI3K activity is Ras-
independent.  This correlates well with our previous genetic data in which Pik3r1
-/-
 cells 
expressing mutant Shp2 E76K were relatively insensitive to Ras inhibition with tipifarnib 
(Figure 3.7), and together these data suggest that gain-of-function mutant Shp2 E76K 
promotes hyperactivation of Ras-MAPK and PI3K signaling, which work in concert to 
promote GM-CSF hypersensitivity, suggesting that both pathways most likely must be 
targeted to have an efficient therapeutic effect in the treatment of gain-of-function mutant 
Shp2-induced MPD.   
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Figure 4.3: Simultaneous inhibition of Ras and PI3K cooperatively reduce gain-of-
function mutant Shp2 E76K-induced GM-CSF hypersensitivity 
 
(A) [
3
H]-Thymidine incorporation assay measuring 1 ng/mL GM-CSF-stimulated 
proliferation in the presence of combined increasing concentrations of the farnesyl-
transferase inhibitor tipifarnib (0-5 μM) and the PI3K inhibitor GDC-0941 (0-1 μM); 
representative of 3 independent experiments; n = 5-7; *p < 0.001 comparing Shp2 E76K-
expressing cells in the absence vs. the presence of tipifarnib at 1 μM and 5 μM in the 
absence of GDC-0941; ^p < 0.01 comparing Shp2 E76K-expressing cells not treated with 
tipifarnib in the absence vs. the presence of GDC-0941 at 0.5 μM; ^^p < 0.001 comparing 
Shp2 E76K-expressing cells not treated with tipifarnib in the absence vs. the presence of 
GDC-0941 at 1 μM; #p < 0.005 comparing Shp2 E76K-expressing cells treated with 1 
μM tipifarnib in the absence vs. the presence of GDC-0941 at 0.5 μM; ##p < 0.001 
comparing Shp2 E76K-expressing cells treated with 1 μM tipifarnib in the absence vs. 
the presence of GDC-0941 at 1 μM; +p < 0.01 comparing Shp2 E76K-expressing cells 
treated with 5 μM tipifarnib in the absence vs. the presence of GDC-0941 at 0.1 μM; ++p 
< 0.001 comparing Shp2 E76K-expressing cells treated with 5 μM tipifarnib in the 
absence vs. the presence of GDC-0941 at 0.5 μM and 1 μM; statistics performed using 
unpaired, two-tailed student’s t-test (Goodwin, Yang et al. 2012) (Figure continued on 
next page). 
 
 
 
0
10000
20000
30000
40000
50000
60000
70000
[3
H
]-
Th
ym
id
in
e
 I
n
co
rp
o
ra
ti
o
n
 (
c.
p
.m
. +
/-
s.
d
.)
1 ng/mL GM-CSF - + + + + + + + + + + + +
Tipifarnib (μM) 0 0 0 0 0 1 1 1 1 5 5 5 5
GDC-0941 (μM) 0 0 0.1 0.5 1 0 0.1 0.5 1 0 0.1 0.5 1
*
*
^
^^
#
## +
++ ++
p < 0.001A
 76 
 
 
 
 
Figure 4.3: Simultaneous inhibition of Ras and PI3K cooperatively reduce gain-of-
function mutant Shp2 E76K-induced GM-CSF hypersensitivity (continued) 
 
(B)  Western blot analyses of macrophages cultured from WT bone marrow-derived 
LDMNCs exogenously expressing gain-of-function mutant Shp2 E76K stimulated for 60 
minutes with 10 ng/mL GM-CSF in the presence of increasing combined concentrations 
of tipifarnib (0-10 μM) and GDC-0941 (0-0.5 μM).  Representative data from 2 
independent experiments (Goodwin, Yang et al. 2012). 
 
 
 
 
 
 
 
 
 
 
 
Shp2 E76K
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PI3K inhibitors with high specificity for p110δ increase apoptosis in cells transduced 
with gain-of-function mutant Shp2 E76K 
In addition to imparting an enhanced GM-CSF-stimulated proliferative response, 
activating Shp2 mutations also reduce apoptosis, thereby providing the cells that bear 
them a survival advantage as well as a proliferation advantage.  PI3K is well known to 
negatively regulate apoptosis in many cellular contexts, and so, not surprisingly, a 
frequent consequence of the hyperactivated PI3K signaling found in many neoplasms is 
enhanced survival.  We next wished to investigate whether gain-of-function mutant Shp2-
induced hyperactivated PI3K activity likewise contributes to reduced apoptosis, which 
can be reversed pharmacologically with inhibitors with high specificity for p110δ, as was 
found to be the case with GM-CSF-stimulated hyper-proliferation. 
Sorted WT bone marrow-derived LDMNCs transduced with WT Shp2 or mutant 
Shp2 E76K were plated for 48 hours in the absence or presence of 10 ng/mL GM-CSF 
with 1 μM IC87114, 0.5 μM GDC-0941, or no inhibitor at all, before measuring the 
percentage of Annexin V-positive cells by FACS to assess apoptosis levels.  In the 
absence of growth factors, Shp2 E76K-expressing cells had significantly lower Annexin 
V-positive cells (Figure 4.4).  In the presence of GM-CSF, apoptosis was reduced in both 
WT Shp2-expressing and mutant Shp2 E76K-expressing cells.  However, upon treatment 
with PI3K inhibitors with high specificity for p110δ—either 0.5 μM IC87114 or 1 μM 
GDC-0941—there was a significant induction of apoptosis in Shp2 E76K-expressing 
cells, but not in WT Shp2-expressing cells (Figure 4.4), thus implying that cells bearing 
activating Shp2 mutations are more sensitive to PI3K inhibition than WT cells in terms of 
regulating survival.  Therefore, hyperactivated PI3K signaling, particularly that mediated 
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by p110δ, contributes to both the hyper-proliferative and enhanced survival phenotypes, 
which characterize cells expressing gain-of-function Shp2 mutations and likely contribute 
to the pathogenesis of JMML.  Because pharmacologic inhibition of PI3K, especially 
p110δ, is able to reduce gain-of-function mutant Shp2-induced hyper-proliferation and 
enhanced survival, this suggests that p110δ would be an effective therapeutic target for 
the treatment of mutant Shp2-associated MPD. 
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Figure 4.4: PI3K inhibitors with high specificity for p110δ induce apoptosis in Shp2 
E76K-expressing cells 
 
(A) Average percent of Annexin V-positive cells in WT bone marrow LDMNCs 
transduced with either WT Shp2 or gain-of-function mutant Shp2 E76K in the presence 
or absence of 10 ng/mL GM-CSF and treated with 1 μM IC87114 or 0.5 μM GDC-0941 
or no inhibitor.  Combined data from 5 independent experiments; *p < 0.05 comparing 
Shp2 E76K-expressing cells in the absence of inhibitors with Shp2 E76K-expressing 
cells in the presence of either 1 μM IC87114 or 0.5 μM GDC-0941; statistics performed 
using unpaired, two-tailed student’s t-test.  (B) Representative flow analysis data of one 
experiment (Annexin V-positive cells in upper left and right quadrants). 
B
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PI3K inhibitors with high specificity for p110δ significantly reduce GM-CSF 
hypersensitivity in cells expressing endogenous gain-of-function mutant Shp2 D61Y 
 We next wanted to confirm the pharmacologic findings in cells expressing 
endogenous levels of activating mutant Shp2 to ensure that the observed PI3K 
hyperactivation was not the artifact of exogenous overexpression of an oncogene.  
Accordingly, we used cells from LSL-Shp2
D61Y/+
; Mx1-Cre+ mice, which expresses gain-
of-function mutant Shp2 D61Y under its endogenous promoter in hematopoietic cells, 
when induced by Cre recombinase activity following a polyI:polyC-induced γ-interferon 
response.  These mice provide a more physiologically relevant system for investigating 
oncogene-induced aberrant signal transduction in vitro as well as an in vivo model for 
gain-of-function mutant Shp2-induced MPD. 
 For these studies, bone marrow-derived LDMNCs were isolated 8-12 weeks 
following polyI:polyC treatment to allow sufficient time for disease onset, and these cells 
were used for [
3
H]-Thymidine incorporation assays to measure proliferation or cultured 
into adherent macrophages for biochemical analyses.  As with Shp2 E76K-transduced 
cells, we found that gain-of-function mutant Shp2 D61Y-expressing cells demonstrated a 
greater proliferative response following GM-CSF stimulation than WT Shp2-expressing 
cells (LSL-Shp2
D61Y/+
; Mx1-Cre-; Figure 4.5A).  Similarly, treatment of these cells with 
PI3K inhibitors that have high specificity for p110δ, IC87114 and GDC-0941, caused a 
dose-dependent decrease in GM-CSF-stimulated hyper-proliferation (Figure 4.5A).  As 
with the Shp2 E76K-transduced cells, GDC-0941 was able to inhibit proliferation at 
much lower concentrations—in the 0.1-0.5 μM range—compared to IC87114 , which 
achieved significant inhibition in the 10-25 μM range (Figure 4.5A).  Again, it is not 
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clear if this is the consequence of GDC-0941 having a much lower IC50 for p110δ than 
IC87114, or because GDC-0941 is also able to efficiently inhibit p110α (Table 4.1). 
 Western blot analyses of the Shp2 D61Y cells treated with IC87114 and GDC-
0941 supported the observations of the proliferation assays, and recapitulated the results 
from the pharmacologic studies using cells transduced with gain-of-function mutant Shp2 
E76K.  Serum and growth factor-starved adherent macrophages were stimulated for 60 
minutes with 0 ng/mL GM-CSF or 10 ng/mL GM-CSF in the presence of 5 μM IC87114, 
0.5 μM GDC-0941, or no inhibitor at all.  As previously reported, GM-CSF stimulation 
produced substantial Erk and Akt hyperactivation in cells endogenously expressing 
mutant Shp2 D61Y (Figure 4.5B, compare lanes 2 and 6) (Chan, Kalaitzidis et al. 2009).  
Additionally, at these concentrations, both inhibitors were able to achieve a substantial 
reduction in GM-CSF-stimulated hyper-phosphorylation of Akt at both Serine 473 and 
Threonine 308, indicating that endogenous mutant Shp2 D61Y is promoting 
hyperactivation of PI3K in response to GM-CSF stimulation (Figure 4.5B, compare lanes 
7 and 8 with lane 6).  Furthermore, both inhibitors reduce Erk hyperactivation, 
confirming that our previous observation of PI3K positively regulating Erk activity in the 
presence of activating Shp2 mutants, is not an artifact of oncogene overexpression 
(Figure 4.5B, compare lanes 7 and 8 with lane 6).  These results demonstrate that 
endogenously expressed mutant Shp2 D61Y promotes hyperactivation of PI3K similarly 
to exogenously overexpressed mutant Shp2 E76K, which in both cases contributes to 
GM-CSF hypersensitivity that can be substantially reduced with PI3K inhibitors with 
high specificity for p110δ. 
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 Additionally, we wanted to investigate the relationship between Ras and mutant 
Shp2-induced PI3K hyperactivation in the more physiologically relevant context of 
endogenously expressed mutant Shp2 D61Y.  Again, we combined Ras inhibition, using 
the farnesyl-transferase inhibitor, tipifarnib, with PI3K inhibition, using GDC-0941.  
Similar to the exogenous Shp2 E76K-expressing cells, we found that treatment of 
endogenous Shp2 D61Y-expressing cells with 0.5 μM or 1 μM tipifarnib resulted in a 
significant decrease in GM-CSF-stimulated hyper-proliferation (Figure 4.5C).  
Furthermore, we found that addition of GDC-0941 again caused a concentration-
dependent decrease in GM-CSF-stimulated hyper-proliferation beyond what tipifarnib 
was able to achieve alone (Figure 4.5C).  These results confirm our previous observations 
(Figures 3.7 and 4.4) that Ras inhibition alone is insufficient to fully block mutant Shp2-
induced PI3K hyperactivation, suggesting that this PI3K hyperactivation is at least in part 
Ras-independent.   
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Figure 4.5: PI3K inhibitors with high specificity for p110δ significantly reduce GM-
CSF hypersensitivity in cells endogenously expressing gain-of-function mutant Shp2 
D61Y 
 
(A) [
3
H]-Thymidine incorporation assay measuring 1 ng/mL GM-CSF-stimulated 
proliferation of bone marrow-derived LDMNCs endogenously expressing WT Shp2 or 
mutant Shp2 D61Y from Shp2 D61Y inducible knockin mice in the presence of 
increasing concentrations of the PI3K inhibitors GDC-0941 (0 – 1 μM) or IC87114 (0 – 
25 μM). Data representative of 2 independent experiments; n = 4-6; *p < 0.001 
comparing WT Shp2-expressing cells in the absence of inhibitors or the presence of 
GDC-0941 at 0.1 μM, 0.5 μM, or 1 μM; #p < 0.001 comparing WT Shp2-expressing cells 
in the absence of inhibitors or the presence of IC87114 at 5 μM, 10 μM, or 25 μM; ^p < 
0.005 comparing Shp2 D61Y-expressing cells in the absence of inhibitors or the presence 
of GDC-0941 at 0.1 μM; ^^p < 0.001 comparing Shp2 D61Y-expressing cells in the 
absence of inhibitors or the presence of GDC-0941 at 0.5 μM or 1 μM; +p < 0.05 
comparing Shp2 D61Y-expressing cells in the absence of inhibitors or the presence of 
IC87114 at 5 μM; ++p < 0.001 comparing Shp2 D61Y-expressing cells in the absence of 
inhibitors or the presence of IC87114 at 10 μM or 25 μM; statistics performed using 
unpaired, two-tailed student’s t-test (Figure continued on next page). 
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Figure 4.5: PI3K inhibitors with high specificity for p110δ significantly reduce GM-
CSF hypersensitivity in cells endogenously expressing gain-of-function mutant Shp2 
D61Y (continued) 
 
(B) Western blot analyses of adherent macrophages cultured from bone marrow-derived 
LDMNCs endogenously expressing WT Shp2 or Shp2 D61Y from Shp2 D61Y inducible 
knockin mice stimulated for 60 minutes with 10 ng/mL GM-CSF in the presence of 5 μM 
IC87114 or 0.5 μM GDC-0941.  Data representative of 3 independent experiments 
(Figure continued on next page). 
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Figure 4.5: PI3K inhibitors with high specificity for p110δ significantly reduce GM-
CSF hypersensitivity in cells endogenously expressing gain-of-function mutant Shp2 
D61Y (continued) 
 
(C) [
3
H]-Thymidine incorporation assay measuring 1 ng/mL GM-CSF-stimulated 
proliferation of bone marrow-derived LDMNCs endogenously expressing WT Shp2 or 
mutant Shp2 D61Y from Shp2 D61Y inducible knockin mice in the presence of 
increasing combined concentrations of farnesyl-transferase inhibitor, tipifarnib (0 – 1 
μM), and the PI3K inhibitor, GDC-0941 (0 – 0.5 μM); data representative of 2 
independent experiments; n = 3-4; *p < 0.05 comparing WT Shp2-expressing cells not 
treated with GDC-0941 in the absence versus the presence of tipifarnib at 0.5 μM or 1 
μM; ^ p < 0.001 comparing Shp2 D61Y-expressing cells not treated with GDC-0941 in 
the absence versus the presence of tipifarnib at 0.5 μM or 1 μM; #p < 0.05 comparing 
WT Shp2-expressing cells not treated with tipifarnib in the absence versus the presence 
of GDC-0941 at 0.1 μM or 0.5 μM; &p < 0.05 comparing WT Shp2-expressing cells 
treated with 0.5 μM tipifarnib in the absence versus the presence of GDC-0941 at 0.5 
μM; !p < 0.001 comparing WT Shp2-expressing cells treated with 1 μM tipifarnib in the 
absence versus the presence of GDC-0941 at 0.1 μM or 0.5 μM; @p < 0.005 comparing 
Shp2 D61Y-expressing cells not treated with tipifarnib in the absence versus the presence 
of GDC-0941 at 0.1 μM; @@p < 0.001 comparing Shp2 D61Y-expressing cells not 
treated with tipifarnib in the absence versus the presence of GDC-0941 at 0.5 μM; +p < 
0.001 comparing Shp2 D61Y-expressing cells treated with 0.5 μM tipifarnib in the 
absence versus the presence of GDC-0941 at 0.1 μM or 0.5 μM; %p < 0.005 comparing 
Shp2 D61Y-expressing cells treated with 1 μM tipifarnib in the absence versus the 
presence of GDC-0941 at 0.1 μM; %%p < 0.001 comparing Shp2 D61Y-expressing cells 
treated with 1 μM tipifarnib in the absence versus the presence of GDC-0941 at 0.5 μM.  
Statistics performed using unpaired, two-tailed student’s t-test. 
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MEK inhibition reduces gain-of-function mutant Shp2-induced GM-CSF 
hypersensitivity 
 Thus far, we have demonstrated that PI3K inhibitors, particularly those with high 
specificity for p110δ, are very effective at reducing gain-of-function mutant Shp2-
induced hyper-proliferation, most likely by correcting hyperactivated mitogenic signaling 
pathways, including both PI3K and MAPK.  We next wanted to assess the effect of an 
inhibitor that specifically targets the MAPK pathway alone on mutant Shp2-induced GM-
CSF hypersensitivity, using PD0325901, an extremely potent MEK inhibitor.  This 
inhibitor has been shown to be highly effective in reducing GM-CSF hypersensitivity 
induced by gain-of-function mutations in KRas and loss of Nf1 activity, two other 
molecular aberrations encountered in JMML (Lyubynska, Gorman et al. 2011; Chang, 
Krisman et al. 2013). 
 To assess the inhibitory effect of targeting in MEK in bone marrow LDMNCs 
from Shp2 D61Y inducible knockin mice, we measured GM-CSF-stimulated 
proliferation by [
3
H]-Thymidine incorporation assay in the presence of a range of 
concnetrations of PD0325901 (0-10 μM).  We found that PD0325901 was a very potent 
inhibitor of mutant Shp2-induced, GM-CSF-stimulated hyper-proliferation, achieving a 
significant reduction at concentrations as low as 0.1 μM (Figure 4.6A).   
 Western blot analyses of adherent macrophages expressing Shp2 D61Y confirmed 
that PD0325901 inhibits MEK activity very efficiently, as GM-CSF-stimulated Erk 
hyper-phosphorylation was completely abrogated in the presence of just 0.1μM of the 
inhibitor (Figure 4.6B, compare lanes 7 and 8 with lane 6).  However, treatment with 
PD0325901 had no apparent effect on mutant Shp2-induced hyperactivated PI3K 
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signaling, as GM-CSF-stimulated Akt hyper-phosphorylation was not altered by the 
presence of the MEK inhibitor (Figure 4.6B, compare lanes 7 and 8 with lane 6).  These 
results show that a MEK inhibitor like PD0325901 can also significantly reduce mutant 
Shp2-induced hyper-proliferation in response to GM-CSF stimulation, but it does so 
exclusively by targeting the MAPK pathway, leaving the hyperactivated PI3K pathway 
apparently unaffected. 
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Figure 4.6: Pharmacologic inhibition of MEK reduces GM-CSF hypersensitivity in 
gain-of-function mutant Shp2 D61Y-expressing cells 
 
(A) [
3
H]-Thymidine incorporation assay measuring 1 ng/mL GM-CSF-stimulated 
proliferation of bone marrow-derived LDMNCs endogenously expressing WT Shp2 or 
mutant Shp2 D61Y from Shp2 D61Y inducible knockin mice in the presence of 
increasing concentrations of the MEK inhibitor PD0325901 (0 – 10 μM).  Data 
representative of 2 independent experiments; n = 7; *p < 0.001 comparing WT Shp2-
expressing cells in the absence versus the presence of PD0325901 at 0.1 μM, 0.5 μM, 1 
μM, 5 μM, or 10 μM; ^p < 0.001 comparing Shp2 D61Y-expressing cells in the absence 
versus the presence of PD0325901 at 0.1 μM, 0.5 μM, 1 μM, 5 μM, or 10 μM; statistics 
performed using unpaired, two-tailed student’s t-test.  (B) Western blot analyses of 
adherent macrophages cultured from bone marrow-derived LDMNCs endogenously 
expressing WT Shp2 or Shp2 D61Y from Shp2 D61Y inducible knockin mice stimulated 
for 60 minutes with 10 ng/mL GM-CSF in the presence of 0.1 μM or 0.5 μM 
PD0325901. 
A
B
 89 
 
The highly potent p110δ-specific inhibitor, GS-9820, reduces both GM-CSF-stimulated 
hyperactivation of Akt and Erk, as well as GM-CSF-stimulated hyper-proliferation of 
Shp2 D61Y-expressing cells 
 Thus far, our data has suggested that gain-of-function mutant Shp2 induces 
hyperactivation of PI3K signaling and that this increased PI3K activity plays an 
important contributory role to the GM-CSF hypersensitivity phenotype, which is thought 
to be an important underlying mechanism for mutant Shp2-induced leukemogenesis.  
Furthermore, our results suggest that the hematopoietic-specific PI3K catalytic subunit 
p110δ is a crucial mediator of this hyperactivated PI3K activity, and therefore it 
represents a potential therapeutic target for the treatment of mutant Shp2-associated 
MPD.  The p110δ-specific inhibitor that we used for our initial studies, IC87114, is 
adequate for proof-of-concept experiments, but is not sufficiently potent for clinical use.  
Recently, however, a clinical-grade p110δ-specific inhibitor, GS-1101 (formerly known 
as CAL-101), has been developed.  This inhibitor has been investigated for lymphoid 
malignancies, and has entered clinical trials for them as a result, but its potential use for 
myeloid malignancies of any kind has not been studied as far as we know.  We initiated a 
collaboration with Gilead Sciences, which produces the inhibitor, and acquired GS-9820, 
which is structurally similar to GS-1101, but has a better pharmacodynamic profile in 
mice (BJ Lannutti, Gilead Sciences, Inc., Seattle, WA, personal communication).   
 We measured GM-CSF-stimulated proliferation by [
3
H]-Thymidine incorporation 
assay of cells from Shp2 D61Y-inducible knockin mice, and found that pre-treating the 
cells for two hours with GS-9820 over a range of concentrations from 0.1 to 10 μM cause 
a significant concentration-dependent decrease in 1 ng/mL GM-CSF-stimulated hyper-
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proliferation with concentrations as low as 0.1 μM (Figure 4.7A).  Furthermore, the GS-
9820 showed a significant therapeutic index as GM-CSF-stimulated proliferation of WT 
Shp2-expressing cells were not significantly affected excepted at higher concentrations, 
beginning around 5 μM or higher. 
 To determine whether the inhibitor was having the expected biochemical effect, 
we performed western blot analyses of WT Shp2 and Shp2 D61Y-expressing 
macrophages, which had been starved and then stimulated with either 0 ng/mL GM-CSF 
or 10 ng/mL GM-CCSF in the presence of either 0.1 μM GS-9820 or 0.5 μM GS-9820 or 
no inhibitor at all.  We found that in the presence of GS-9820, there was a concentration-
dependent decrease in GM-CSF-stimulated hyper-phosphorylation of Akt at both Serine 
473 and Threonine 308 (Figure 4.7B, compare lanes 7 and 8 with lane 6), indicating that 
it was effectively blocking mutant Shp2-induced PI3K hyperactivity, as the other PI3K 
inhibitors had.  Furthermore, GS-9820, like the other PI3K inhibitors we investigated, 
caused substantial reductions in GM-CSF-stimulated Erk hyperactivation (Figure 4.8B, 
compare lanes 7 and 8 with lane 6).  Thus, GS-9820 had a similar biochemical profile as 
the other PI3K inhibitors, and it achieved reductions in aberrant signaling pathways at 
clinically relevant concentrations (0.1-0.5 μM).  As with previous drug studies the 
magnitude of biochemical effect was not completely commensurate with the functional 
consequences of the inhibitor.  We found that 0.5 μM GS-9820 almost completely 
abrogated Akt phosphorylation at Serine 473, though the same concentration resulted in 
only a 30% decrease in GM-CSF-stimulated proliferation.  Furthermore, noticeable 
reductions in Akt and Erk hyper-phosphorylation were observed in WT Shp2-expressing 
cells at concentrations of 0.1 and 0.5 μM, though no reduction in proliferation were 
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observed in [
3
H]-Thymidine Incorporation assays.  Again, this lack of congruence may 
stem from the fact that slightly different cells are being used for the different assay: 
myeloid progenitor cells for the [
3
H]-Thymidine Incorporation assays and adherent 
macrophages for biochemical analyses.  It may also be due to the fact that the cells are 
treated for different time periods: the cells in the [
3
H]-Thymidine Incorporation assay 
were pre-treated for two hours with the GS-9820, followed by an approximate 24-hour 
incubation with 1 ng/mL GM-CSF and the GS-9820, while the adherent macrophages 
used for biochemical analyses were stimulated for only one hour with 10 ng/mL GM-
CSF and the GS-9820.  Nevertheless, because GS-9820 was able to produce reductions in 
both GM-CSF-stimulated hyperactivated mitogenic signaling and hyper-proliferation at 
low, clinically relevant concentrations, we believe these data both support our hypothesis 
that p110δ is an important mediator of mutant Shp2-induced hyperactivated PI3K 
signaling and resulting GM-CSF-stimulated hyper-proliferation, and that, therefore, 
highly potent inhibitors targeting p110δ, such as GS-9820 (or GS-1101) represent 
potential therapies for mutant Shp2-associated MPD. 
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Figure 4.7: The highly potent p110δ-specific inhibitor GS-9820 reduces gain-of-
function mutant Shp2 D61Y-induced Akt and Erk hyperactivation and resulting 
hyper-proliferation 
 
(A) 
3
H]-Thymidine incorporation assay measuring 1 ng/mL GM-CSF-stimulated 
proliferation of bone marrow-derived LDMNCs endogenously expressing WT Shp2 or 
mutant Shp2 D61Y from Shp2 D61Y inducible knockin mice in the presence of 
increasing concentrations of the highly potent p110δ-specific inhibitor GS-9820 (0-10 
μM).  Representative data of 2 independent experiments; n = 6-7; *p<0.001 comparing 
Shp2 D61Y-expressing cells in the absence versus the presence of GS-9820 at 0.1 μM, 
0.5 μM, 1 μM, 5 μM or 10 μM; #p<0.05 comparing WT Shp2-expressing cells in the 
absence versus the presence of GS-9820 at 5 μM; ##p<0.05 comparing WT Shp2-
expressing cells in the absence versus the presence of GS-9820 at 10 μM; no significant 
difference was found comparing WT Shp2-expressing cells in the absence versus the 
presence of GS-9820 at  0.1 μM, 0.5 μM, or 1 μM; statistics performed using unpaired, 
two-tailed student’s t-test.  (B) Western blot analyses of adherent macrophages cultured 
from bone marrow-derived adherent macrophages endogenously expressing WT Shp2 or 
Shp2 D61Y from Shp2 D61Y inducible knockin mice stimulated for 60 minutes with 10 
ng/mL GM-CSF in the absence or presence of 0.1 μM or 0.5 μM GS-9820. 
A
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Conclusions 
 Our earlier genetic studies with Pik3r1
-/-
 mice suggested that mutant Shp2-
induced hyperactivated Class IA PI3K signaling is an important contributor to the GM-
CSF hypersensitivity that characterizes JMML.  These initial studies also implicated 
p110δ as a crucial mediator of mutant Shp2-induced PI3K hyperactivation, which, 
coupled with its hematopoietic-specific expression profile, makes it a particularly 
attractive therapeutic target to investigate for mutant Shp2-associated MPD.   
 To this end, we first focused on evaluating the effectiveness of two commercially 
available inhibitors with high specificity for the p110δ catalytic subunit: IC87114, which 
is highly specific for p110δ, but not very potent, and GDC-0941, a clinical-grade pan-
PI3K inhibitor with very high specificity for p110α as well as p110δ (Table 4.1).  We 
found that both inhibitors significantly reduced GM-CSF-stimulated hyper-proliferation 
as well as hyperactivation of both the PI3K and MAPK signaling pathways in cells 
transduced with gain-of-function mutant Shp2 E76K.  These results recapitulated the 
observations of our genetics studies, thereby supporting our hypothesis that 
hyperactivated PI3K signaling plays an important role in mutant Shp2-induced GM-CSF 
hypersensitivity and providing more direct evidence that p110δ is a crucial mediator of 
this enhanced PI3K activity.  In addition, we found that both of these inhibitors increased 
apoptosis in Shp2 E76K-expressing cells, indicating that PI3K hyperactivation 
contributes not only to mutant Shp2-induced hyper-proliferation, but also to enhanced 
survival, suggesting that targeting PI3K, especially p110δ, would be therapeutically 
beneficial on both accounts.  Finally, by combining the PI3K inhibitor with the farnesyl-
transferase inhibitor, tipifarnib, which provides a pharmacologic means of blocking 
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mutant Shp2-induced Ras hyperactivation, we found that the two inhibitors work 
cooperatively to reduce GM-CSF hypersensitivity, which suggests that the mutant Shp2-
induced PI3K hyperactivation is at least in part independent of Ras.  Because it has been 
reported that p110δ alone of the Class I PI3K catalytic subunits can induce oncogenic 
transformation in a Ras-independent manner, these results further implicate an important 
role for p110δ. 
 Because both the previous genetic studies and these initial pharmacologic studies 
involved retroviral transduction of an exogenous mutant Shp2 allele, we wanted to 
confirm that the observed PI3K hyperactivity and its contribution to GM-CSF 
hypersensitivity were not merely an artifact of oncogene overexpression.  Therefore, we 
repeated many of the pharmacologic studies using bone marrow-derived LDMNCs from 
Shp2 D61Y inducible knockin mice (LSL-Shp2
D61Y/+
; Mx1-Cre+), which express 
endogenous levels of mutant Shp2 under its native promoter, and found that the inhibitors 
produced similar reductions in GM-CSF-stimulated hyper-proliferation and hyper-
phosphorylation of Akt and Erk.  Thus, the Shp2 D61Y knockin mice provide a more 
physiologically relevant in vitro model for investigating the effects of mutant Shp2 on 
aberrant signal transduction, as well as a potential in vivo model of mutant Shp2-induced 
MPD with which we can explore the role of PI3K in MPD development and progression. 
 In addition to PI3K inhibitors, we also assessed the MEK inhibitor, PD0325901, 
which has shown great promise as a therapy in other mouse models of JMML including 
gain-of-function Kras mutations and loss of Nf1 activity.  We found that this inhibitor 
very efficiently reduced mutant Shp2-induced hyper-proliferation in response to GM-
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CSF stimulation and almost completely abrogated hyperactivated MAPK signaling, but 
without having any apparent effect on PI3K hyperactivation.   
 Finally, we next wanted to assess the therapeutic potential of a clinical-grade 
p110δ-specific inhibitor with much higher potency than IC87114.  We collaborated with 
Gilead Sciences to initiate studies using GS-9820, an inhibitor that is structurally similar 
to GS-1101, but which has better pharmacodynamics in mice.  GS-1101 is in clinical 
trials for lymphoid malignancies, but has never been investigated for myeloid 
malignancies to the best of our knowledge.  Interestingly, we found that pretreating cells 
for two hours with GS-9820 significantly reduced GM-CSF-stimulated hyper-
proliferation in gain-of-function mutant Shp2 D61Y-expressing cells at clinically 
relevant, nanomolar concentrations.  Furthermore, it was able to decrease substantially 
both Akt and Erk hyper-phosphorylation, recapitulating the biochemical effects observed 
in prior studies targeting PI3K genetically and pharmacologically.  The results of these 
studies are particularly noteworthy, since GS-1101 (which is chemically related to GS-
9820) is already in clinical trials for lymphoid malignancies, suggesting that a highly 
potent p110δ-specific inhibitor, such as GS-1101, may have therapeutic benefit for the 
treatment of gain-of-function mutant Shp2-associated MPD. 
 In sum, our studies suggest that p110δ-mediated PI3K hyperactivation plays an 
important role in mutant Shp2-induced GM-CSF hypersensitivity, and because p110δ 
expression is largely restricted to hematopoietic cells, pharmacologically targeting it 
carries a lower risk of systemic side effects.  PI3K inhibitors with high potency for p110δ 
might also be used in combination with inhibitors that specifically target the mutant 
Shp2-induced hyperactivated MAPK pathway, such as the MEK inhibitor, PD0325901.  
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Because MEK is ubiquitously expressed, it can be expected that pharmacologically 
targeting it in JMML patients might produce unwanted toxic side effects.  However, if 
PD0325901 is used in conjunction with a p110δ-specific inhibitor, which by itself can 
reduce Erk hyperactivation, it can be expected that lower doses of PD0325901 might be 
used with reduced risk of side effects.  Furthermore, combining inhibitors also has the 
added advantage of lowering the risk for the development of drug resistance, which is a 
common concern with any monotherapy approach. 
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CHAPTER FIVE 
GENETIC DISRUPTION OF THE PI3K CATALYTIC SUBUNIT p110δ, BUT NOT 
p110α, REDUCES GAIN-OF-FUNCTION MUTANT SHP2-INDUCED GM-CSF 
HYPERSENSITIVITY 
Introduction 
 The results of our previous studies have demonstrated the important role that 
PI3K plays in gain-of-function mutant Shp2-induced GM-CSF hypersensitivity.  Using 
mice bearing genetic disruption of the Pik3r1 gene, which encodes the main Class IA 
PI3K regulatory subunits p85α, p55α, and p50α, we were able to achieve a significant 
correction in GM-CSF-stimulated hyper-proliferation.  This correction, though 
significant, was not complete, which we hypothesized to be the consequence of some 
residual PI3K activity, potentially mediated by the p110α and p110δ catalytic subunits, 
whose expression levels were significantly reduced in the absence of the Pik3r1-encoded 
regulatory subunits, though not completely absent.  Their stabilization is possibly 
mediated through interactions with the remaining Class IA regulatory subunits, p85β or 
p55γ.  We noticed that p110δ levels were significantly higher in the Pik3r1-/- cells 
expressing gain-of-function mutant Shp2 E76K compared to those expressing WT Shp2, 
suggesting that p110δ may play an important role in mediating gain-of-function mutant 
Shp2-induced PI3K hyperactivation.  This hypothesis was further supported by the 
observation that Pik3r1
-/-
 cells expressing Shp2 E76K were relatively insensitive to 
treatment with the farnesyl-transferase inhibitor, tipifarnib (Figure 3.7), which blocks Ras 
activity.  This observation is significant since it has been reported that p110δ, unlike the 
other Class I PI3K catalytic subunits, can transform cells in a Ras-independent manner.   
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 To further investigate the role of p110δ, we used three inhibitors with high 
specificity for p110δ, IC87114, GDC-0941, and GS-9820, and we found that all three 
reduced gain-of-function mutant Shp2-induced GM-CSF hypersensitivity.  These studies 
were motivated by a desire to find the most efficient way of inhibiting hyperactivated 
PI3K signaling in the context of mutant Shp2-associated MPD.  In recent years, much 
work has been dedicated to identifying the specific activities of the different Class I PI3K 
catalytic subunits in normal physiologic processes and, in particular, in a variety of 
malignant and non-malignant disease processes.  This progress has been coupled with 
continued development of newer classes of PI3K inhibitors with increased potency and 
higher specificity for particular catalytic subunits.  The goal of this line of research is to 
target only the PI3K catalytic subunit involved in a particular disease process, while 
sparing the others, and, in so doing, reducing the risk of unwanted side effects, since 
PI3K is important in many normal physiologic processes.  The catalytic subunit p110δ is 
particularly well suited for this line of inquiry since it is expressed predominantly in a 
hematopoietic-specific manner, unlike the other Class IA PI3K catalytic subunits, p110α 
and p110β, which are ubiquitously expressed.  Therefore, p110δ can be targeted in 
hematopoietic disease with reduced risk of potentially toxic systemic side effects.   
 In our pharmacologic studies, we first investigated two commercially available 
inhibitors, IC87114 and GDC-0941.  IC87114 is very specific for p110δ, but its IC50 is 
still much too high to be clinically relevant (Table 4.1), though it is appropriate for proof-
of-concept studies.  GDC-0941, on the other hand, is a clinical-grade inhibitor, and it has 
a very low IC50 for p110δ, but its IC50 is equally low for p110α, which makes it 
impossible to determine if the inhibitory effects that we observed in our studies are due to 
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its highly potent anti-p110δ activity or if it is due to the fact that it is also blocking 
p110α.  To investigate this issue further, we collaborated with Gilead Sciences to assess 
the efficacy of GS-9820, which is structurally similar to the clinical-grade p110δ-specific 
inhibitor, GS-1101, and found that it very efficiently reduced Akt and Erk 
hyperactivation, and significantly decreased GM-CSF-stimulated hyper-proliferation in 
mutant Shp2 D61Y-expressing cells at clinically relevant, nanomolar concentrations.  All 
together, these pharmacologic data suggest that p110δ is the principal mediator of gain-
of-function mutant Shp2-induced PI3K hyperactivation, which is an important 
contributor to the phenomenon of GM-CSF hypersensitivity, and therefore, p110δ 
represents a potential therapeutic target for mutant Shp2-associated MPD. 
 Because it is difficult to demonstrate that small molecule inhibitors are only 
interfering with the activity of their intended target, we also wanted to explore the 
relative importance of Class IA PI3K catalytic subunits in mediating mutant Shp2-
induced PI3K activation using a genetic approach.  We believed this line of inquiry was 
especially important given the relatively similar structures of the Class IA PI3K catalytic 
subunits, despite the fact these inhibitors have been rationally designed to take advantage 
of subtle structural differences to achieve substantial specificity. 
 Therefore, to avoid some of the potential ambiguities raised by the p110δ-specific 
inhibitors investigated in the previous studies, we used a genetic approach to assess the 
role of p110δ in gain-of-function mutant Shp2-induced GM-CSF hypersensitivity in vitro 
and MPD development in vivo.  We took advantage of a mouse model in which the 
Pik3cd, the gene encoding p110δ, has been genetically inactivated, such that endogenous 
levels of kinase-dead p110δ D910A are expressed (Okkenhaug, Bilancio et al. 2002).  
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This model provides a genetic mimic of very specific p110δ pharmacologic inhibition 
and prevents compensatory recruitment of the other Class IA PI3K catalytic subunits, 
which might occur in a model in which p110δ expression is completely knocked out.  
These mice have the Pik3cd gene constitutively inactivated throughout the entire 
germline, and yet these mice breed normally and have no other overt defects.  This is 
significant, because it suggests that efforts to target p110δ pharmacologically should be 
well tolerated in humans, since genetic loss p110δ function is compatible with life and 
relatively normal function. 
 In a similar way, we also wished to examine the function of p110α, to evaluate its 
potential role in gain-of-function mutant Shp2-induced PI3K hyperactivation, since its 
expression was also retained in Pik3r1
-/-
 cells transduced with Shp2 E76K, though, in 
contrast to p110δ, at the same levels as those cells transduced with WT Shp2.  
Furthermore, aberrant p110α activity is frequently encountered in a variety of cancers, 
making it a candidate worthy of further investigation.  For these studies, we used an 
inducible knockout mouse model of p110αflox/flox; Mx1-Cre+ (Graupera, Guillermet-
Guibert et al. 2008), in which the Pik3ca gene can be inducibly disrupted by Cre 
recombinase activity in hematopoietic cells following a polyI:polyC-stimulated γ-
interferon response. 
 For both catalytic subunits—p110δ and p110α—interactions with mutant Shp2 
were investigated in two ways: first, by adding the mutant Shp2 E76K allele by retroviral 
transduction, and second, by crossing the previously described mice—p110δD910A/D910A 
and p110αflox/flox; Mx1-Cre+—with the Shp2 D61Y inducible knockin mice (Shp2D61Y/+; 
Mx1-Cre+) (Chan, Kalaitzidis et al. 2009).  The latter approach has the advantage of 
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allowing us to explore the function of p110δ and p110α in the more physiologically 
relevant context of endogenously expressed gain-of-function mutant Shp2 in vitro as well 
as providing a model for evaluating the role of these two catalytic subunits in MPD 
development in vivo. 
 
Results 
Genetic inactivation of p110δ reduces GM-CSF-stimulated hyper-phosphorylation of 
Akt and Erk, but does not reduce GM-CSF-stimulated hyper-proliferation of cells 
transduced with gain-of-function mutant Shp2 E76K 
 To begin investigating the role of the Class IA PI3K catalytic subunit p110δ in 
gain-of-function mutant Shp2-induced PI3K hyperactivation and GM-CSF 
hypersensitivity using a genetic approach, we transduced WT and p110δD910A/D910A bone 
marrow low-density mononuclear cells (LDMNCs) with WT Shp2 and gain-of-function 
mutant Shp2 E76K.  Based on our previous observations suggesting an important role for 
p110δ, we hypothesized that genetic interruption of p110δ activity would significantly 
decrease GM-CSF-stimulated hyper-proliferation and Akt hyperactivation, in a manner 
similar to genetic disruption of the Pik3r1 gene or pharmacologic inhibition of p110δ 
activity.  Because of the consistently observed positive regulatory role that PI3K has on 
MAPK signaling, we also predicted a significant decrease in Erk hyperactivation (Figure 
5.1).   
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Figure 5.1: Schematic representation of hypothesized role of the Class IA PI3K 
catalytic subunit p110δ in gain-of-function mutant Shp2-induced GM-CSF 
hypersensitivity 
 
We hypothesize that the hematopoietic-specific Class IA PI3K catalytic subunit p110δ is 
the major mediator of gain-of-function mutant Shp2-induced PI3K hyperactivation, 
which contributes to the phenotype of GM-CSF hypersensitivity.  We hypothesize that 
genetic disruption of the Pik3cd gene, which encodes p110δ, will result in reduced GM-
CSF-stimulated PI3K-Akt signaling, Erk activation, and resulting GM-CSF 
hypersensitivity. 
 
 
 
When we measured GM-CSF-stimulated proliferation by [
3
H]-Thymidine 
incorporation, we found, as usual, that WT cells expressing mutant Shp2 E76K had a 
more robust proliferative response to each given dose of GM-CSF stimulation than those 
Ras
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cells expressing WT Shp2 (Figure 5.2A).  We were intrigued, however, to find that 
p110δD910A/D910A (kinase-dead p110δ knockin) cells expressing gain-of-function mutant 
Shp2 E76K had a statistically identical proliferative response to GM-CSF stimulation as 
WT cells expressing Shp2 E76K (Figure 5.2A), indicating that genetic disruption of 
p110δ activity had no apparent effect on GM-CSF-stimulated hyper-proliferation of cells 
transduced with gain-of-function mutant Shp2 E76K. 
 Western blot analyses of WT and p110δD910A/D910A adherent macrophages 
transduced with WT Shp2 or mutant Shp2 E76K revealed that genetic disruption of 
p110δ activity did, however, affect gain-of-function mutant Shp2 E76K-induced 
hyperactivated PI3K and MAPK signaling.  Again, as previously observed, GM-CSF-
stimulated phosphorylation of Erk and Akt (both Serine 473 and Threonine 308) was 
higher in WT cells expressing mutant Shp2 E76K than those expressing WT Shp2 
(Figure 5.2B, compare lanes 5 and 6).  Interestingly, p110δD910A/D910A cells expressing 
Shp2 E76K had modestly, though consistently, lower levels of both Akt and Erk 
phosphorylation than cells expressing Shp2 E76K in the presence of intact p110δ (Figure 
5.2B, compare lanes 6 and 8).  These modest decreases in hyperactivated PI3K and 
MAPK signaling, however, were apparently not sufficient to reduce proliferation, as we 
had observed (Figure 5.2A).  We had predicted more significant reductions in GM-CSF-
stimulated Akt and Erk hyperactivation and, as a result, a measurable decrease in hyper-
proliferation.  The absence of such a result could not be accounted for by a compensatory 
upregulation of p110α, which could sustain mutant Shp2-induced PI3K hyperactivation 
in the absence of functional p110δ, as there was no difference in the expression levels of 
p110α between WT and p110δD910A/D910A cells expressing Shp2 E76K (Figure 5.2B, 
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compare lanes 2 and 4 and lanes 6 and 8).  We also noted that expression levels p110δ 
D910A were similar to WT p110δ.  Because we were able to observe biochemical 
consequences of genetic interruption of p110δ activity that did not translate into a 
functional effect, we suspected that exogenous overexpression of an oncogene, 
specifically, gain-of-function mutant Shp2 E76K, resulted in an overly exacerbated 
hyperactivation of PI3K and MAPK signaling, thereby preventing proper assessment of 
the role of p110δ in gain-of-function mutant Shp2-induced PI3K hyperactivation.  This 
suspicion led us to believe that this question could be more effectively explored in the 
more physiologically relevant context of endogenously expressed mutant Shp2.   
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Figure 5.2: Genetic inactivation of p110δ reduces Akt and Erk hyper-
phosphorylation, but does not affect GM-CSF-stimulated hyper-proliferation in 
cells exogenously overexpressing gain-of-function mutant Shp2 E76K 
 
(A) [
3
H]-Thymidine incorporation assay measuring proliferation of bone marrow-derived 
LDMNCs from WT and kinase-dead mutant p110δ D910A knockin mice transduced with 
either WT Shp2 or gain-of-function mutant Shp2 E76K in response to increasing 
concentrations of GM-CSF (0-1 ng/mL).  Data representative of 2 independent 
experiments; n = 6; no significant (n.s.) differences were found comparing WT cells 
versus p110δ D910A cells transduced with WT Shp2 at any GM-CSF concentration; no 
significant (n.s.) differences were found comparing WT cells versus p110δ D910A cells 
transduced with Shp2 E76K at any GM-CSF concentration; statistics performed using 
unpaired, two-tailed student’s t-test.  (B) Western blot analyses of macrophages cultured 
from bone marrow-derived LDMNCs from WT and kinase-dead mutant p110δ D910A 
knockin mice transduced with WT Shp2 or gain-of-function mutant Shp2 E76K and 
stimulated for 60 minutes with 0 or 10 ng/mL GM-CSF.  Data representative of 2 
independent experiments. 
A
B
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Genetic deletion of p110α has no effect on GM-CSF-stimulated hyper-proliferation or 
Akt and Erk hyperactivation in cells transduced with gain-of-function mutant Shp2 
E76K 
 Using a similar genetic approach to assess the role of the Class IA PI3K catalytic 
subunit p110α in gain-of-function mutant Shp2-induced PI3K hyperactivation and 
resulting GM-CSF hypersensitivity, we introduced, by retroviral transduction, WT Shp2 
and gain-of-function mutant Shp2 E76K into bone marrow LDMNCs lacking p110α 
expression (p110αflox/flox; Mx1-Cre+) as well as into bone marrow LDMNCs from WT 
control littermates (p110αflox/flox; Mx1-Cre-) approximately four weeks after polyI:polyC 
treatment, allowing sufficient time for recombination of the Pik3ca gene to occur.  
Because we hypothesized that p110δ is the crucial mediator of gain-of-function mutant 
Shp2-induced GM-CSF hypersensitivity, we predicted that genetic deletion of p110α 
would not cause a significant decrease in mutant Shp2-induced hyperactivation of PI3K-
Akt signaling or MAPK signaling, and that, therefore, it would not lead to reduced GM-
CSF-stimulated hyper-proliferation (Figure 5.3).  However, because of p110α’s frequent 
association with human cancer, and because of our observation that p110α expression 
was retained, albeit at drastically reduced levels, in Pik3r1
-/-
 cells transduced with mutant 
Shp2 E76K (Figure 3.7), we thought it would be prudent to formerly investigate the role 
of p110α in gain-of-function mutant Shp2-induced GM-CSF hypersensivity, using a 
similar genetic approach that we had employed for p110δ. 
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Figure 5.3: Schematic representation of hypothesized role of the Class IA PI3K 
catalytic subunit p110α in gain-of-function mutant Shp2-induced GM-CSF 
hypersensitivity 
 
We hypothesize that the Class IA PI3K catalytic subunit p110α is not an important 
mediator of gain-of-function mutant Shp2-induced PI3K hyperactivation,  and that, 
therefore, genetic disruption of the Pik3ca gene, which encodes p110α, will have no 
effect on GM-CSF-stimulated PI3K-Akt signaling, Erk activation, or resulting GM-CSF 
hypersensitivity. 
 
 
 
 
Similar to our observations with cells bearing genetic interruption of p110δ 
activity, loss of p110α had no apparent effect on gain-of-function mutant Shp2 E76K-
induced GM-CSF hypersensitivity (Figure 5.4A).  Again, WT cells expressing Shp2 
Ras
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E76K displayed a proliferative response, which was greater for each increasing 
concentration of GM-CSF stimulation than that of WT cells expressing WT Shp2.  No 
difference in GM-CSF-stimulated proliferative response was observed between Shp2 
E76K-expressing cells lacking p110α versus those with intact p110α expression (Figure 
5.4A). 
However, in contrast to our observations of p110δD910A/D910A cells expressing 
Shp2 E76K (Figure 5.2B), western blot analyses demonstrated that GM-CSF-stimulated 
Akt and Erk hyper-phosphorylation was not lower in p110αflox/flox; Mx1-Cre+ cells 
expressing mutant Shp2 E76K compared to WT cells expressing Shp2 E76K (Figure 
5.4B, compare lanes 6 and 8), indicating that mutant Shp2-induced hyperactivated PI3K-
Akt and MAPK signaling remains intact following the loss of p110α expression, unlike 
genetic disruption of p110δ activity.  Western blots also showed that p110α had been 
efficiently deleted in cells from the p110α inducible knockout mice, and that there is no 
apparent compensatory increase in p110δ expression (Figure 5.4B).  Thus it appears that 
genetic disruption of p110α had no appreciable effect on gain-of-function mutant Shp2-
induced aberrant signaling or GM-CSF hypersensitivity.  As noted above, however, the 
fact that gain-of-function mutant Shp2 E76K is exogenously overexpressed in these cells 
is a confounding factor, which may obscure the subtle effects of losing the expression or 
activity of one or another Class IA PI3K catalytic subunit, and which can only be 
remedied by assessing their roles in the context of endogenously expressed gain-of-
function mutant Shp2. 
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Figure 5.4: Genetic deletion of p110α does not reduce GM-CSF-stimulated hyper-
proliferation or Akt and Erk hyper-phosphorylation in cells exogenously 
overexpressing gain-of-function mutant Shp2 E76K 
 
(A) [
3
H]-Thymidine incorporation assay measuring proliferation of bone marrow-derived 
LDMNCs from WT and p110αflox/flox inducible knockout mice transduced with either WT 
Shp2 or gain-of-function mutant Shp2 E76K in response to increasing concentrations of 
GM-CSF (0-1 ng/mL).  Data representative of 2 independent experiments; n = 4; no 
significant (n.s.) differences were found comparing WT cells versus p110α-/- cells 
transduced with WT Shp2 at any GM-CSF concentration; no significant (n.s.) differences 
were found comparing WT cells versus p110α-/- cells transduced with Shp2 E76K at any 
GM-CSF concentration; statistics performed using unpaired, two-tailed student’s t-test.  
(B) Western blot analysis of macrophages cultured from bone marrow-derived LDMNCs 
from WT and p110αflox/flox inducible knockout mice transduced with WT Shp2 or gain-of-
function mutant Shp2 and stimulated for 60 minutes with 0 or 10 ng/mL GM-CSF.  Data 
representative of 2 independent experiments. 
A
B
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Development of mouse models that allow the investigation of the roles of p110δ and 
p110α in endogenously expressed gain-of-function mutant Shp2-induced GM-CSF 
hypersensitivity in vitro and MPD development in vivo 
 Because genetic disruption of p110δ activity in cells with exogenously 
overexpressed mutant Shp2 E76K did not reduce GM-CSF-stimulated hyper-
proliferation, despite causing a modest decrease in GM-CSF-stimulated Akt and Erk 
hyper-phosphorylation, we suspected that the effect of lost p110δ activity on gain-of-
function mutant Shp2-induced PI3K hyperactivation and resulting GM-CSF 
hypersensitivity was not being adequately investigated, and could be better assessed in 
the more physiologically relevant setting of endogenously expressed mutant Shp2.  To 
accomplish this, we crossed the p110δ D910A kinase-dead constitutive knockin mice 
with gain-of-function mutant Shp2 D61Y inducible knockin mice (LSL-Shp2
D61Y/+
; Mx1-
Cre+) to yield mice with genetically interrupted p110δ D910A in the presence of 
endogenously expressed mutant Shp2 D61Y (p110δD910A/D910A; LSL-Shp2D61Y/+; Mx1-
Cre+, “experimental”), which can be compared to mice expressing mutant Shp2 D61Y in 
the presence of intact p110δ activity (p110δ+/+; LSL-Shp2D61Y/+; Cre+, “positive control” 
or “disease control”) and mice expressing WT Shp2 in the presence of intact p110δ 
activity (p110δ+/+; LSL-Shp2D61Y/+; Cre-, “negative control” or “WT control”) (Figure 
5.5A).  Among these different groups of mice, we predicted that the negative control 
(WT) mice would not develop myeloproliferative disease (MPD) in vivo and would not 
exhibit GM-CSF hypersensitivity or hyperactivated PI3K or MAPK signaling in vitro.  In 
addition, we predicted, as has been reported (Chan, Kalaitzidis et al. 2009), that the 
positive control (D61Y) mice would develop MPD in vivo and would exhibit both GM-
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CSF hypersensitivity and hyperactivated PI3K and MAPK signaling in vitro.  Finally, 
because we hypothesize that p110δ is the crucial mediator of gain-of-function mutant 
Shp2-induced GM-CSF hypersensitivity, we predicted that the experimental 
(D61Y/p110δ) mice would either not develop MPD or would present with a milder MPD 
phenotype in vivo, and that they would exhibit either significantly reduced or entirely 
corrected GM-CSF hypersensitivity and hyperactivation of PI3K and MAPK signaling in 
vivo. 
 Similarly, we wanted to assess the role of p110α by crossing p110α inducible 
knockout mice (p110αflox/flox; Mx1-Cre+) with Shp2 D61Y inducible knockin mice.  In so 
doing, we can better determine if p110δ is an indispensable mediator of gain-of-function 
mutant Shp2-induced PI3K hyperactivation and GM-CSF hypersensitivity, or, rather, if 
p110α plays an equally crucial role in this process.  Answering this question is important, 
because it will allow us to define the most effective way of targeting mutant Shp2-
mediated PI3K hyperactivation; therefore, is targeting p110δ alone sufficient to reduce 
GM-CSF hypersensitivity or must p110α and p110δ be co-targeted for effective blockade 
of hyperactivated PI3K signaling? 
 As with the p110δ kinase-dead mice, we crossed p110αflox/flox; Mx1-Cre+ mice 
with LSL-Shp2
D61Y/+
; Mx1-Cre+ mice to generate mice that express endogenous levels of 
gain-of-function mutant Shp2 D61Y in the absence of p110α expression (p110αflox/flox; 
LSL-Shp2
D61Y/+
; Mx1-Cre+, “experimental”), which can likewise be compared to mice 
expressing Shp2 D61Y in the presence of p110α and all other catalytic subunits 
(p110α+/+; LSL-Shp2D61Y/+; Mx1-Cre+, “positive control” or “disease control”) and mice 
expressing WT Shp2 in the presence of normal p110α expression (p110αflox/flox; LSL-
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Shp2
D61Y/+
; Mx1-Cre-, “negative control” or “WT control”) (Figure 5.5B).  Among these 
different groups, we again predicted that negative control (WT) mice would not develop 
MPD in vivo and would not exhibit GM-CSF hypersensitivity or hyperactivated PI3K or 
MAPK signaling in vitro, while we predicted that the positive control (D61Y) mice 
would develop MPD in vivo and exhibit both GM-CSF hypersensitivity and 
hyperactivated PI3K and MAPK signaling in vitro.  However, because we hypothesized 
that p110δ uniquely is the principal mediator of gain-of-function mutant Shp2-induced 
PI3K hyperactivation, and that, p110α’s role in contrast is dispensable, we predicted that 
the p110α experimental mice (p110αflox/flox; LSL-Shp2D61Y/+; Mx1-Cre+) would develop 
features of MPD in vivo similar to the Shp2 D61Y-expressing positive control mice, and 
that, in vitro, their cells would to exhibit GM-CSF hypersensitivity and hyperactivated 
PI3K and MAPK signaling, unimpeded by the loss of p110α.   
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Figure 5.5: Schematic of strategy for developing mouse models that can be used to 
investigate the roles of the PI3K catalytic subunits p110δ and p110α in 
endogenously expressed gain-of-function mutant Shp2-induced GM-CSF 
hypersensitivity in vitro and myeloproliferative disease development in vivo 
 
(A) To investigate the role of p110δ in GM-CSF hypersensitivity induced by 
endogenously expressed gain-of-function mutant Shp2 D61Y in vitro and MPD 
development in vivo, mice expressing kinase-dead mutant p110δ D910A were crossed 
with LSL-Shp2
D61Y/+
; Mx1-Cre+ mice, which can be induced to express endogenous 
levels of gain-of-function mutant Shp2 D61Y in hematopoietic cells upon polyI:polyC 
treatment.  (B) To investigate the role of p110α in GM-CSF hypersensitivity induced by 
endogenously expressed gain-of-function mutant Shp2 D61Y in vitro and MPD 
development in vivo, p110α-inducible knockout mice (p110αflox/flox) mice were crossed 
with LSL-Shp2
D61Y/+
; Mx1-Cre+ mice. 
A
B
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Genetic interruption of p110δ, but not p110α, results in significantly reduced GM-
CSF-stimulated hyper-proliferation induced by endogenously expressed gain-of-
function mutant Shp2 D61Y 
 To investigate the effects of the loss of either p110δ activity or of p110α 
expression on gain-of-function mutant Shp2 D61Y-induced hyper-proliferation in 
response to GM-CSF stimulation, we performed both [
3
H]-Thymidine incorporation 
assays and methylcellulose colony-forming assays using bone marrow-derived low-
density mononuclear cells (LDMNCs) isolated from mice representing the different 
experimental groups described above approximately 8-12 weeks following polyI:polyC 
treatment, allowing sufficient time for disease onset. 
As we have seen before in [
3
H]-Thymidine incorporation assays, cells expressing 
gain-of-function mutant Shp2 D61Y in the presence of intact PI3K signaling exhibited a 
significantly greater proliferative response for each increasing concentration of GM-CSF 
stimulation compared to cells expressing WT Shp2 (Figure 5.6A, compare red line with 
blue line). Interestingly, we found that cells expressing kinase-dead p110δ D910A in the 
presence of mutant Shp2 D61Y showed a significant decrease in GM-CSF-stimulated 
proliferation compared to those cells expressing Shp2 D61Y in the presence of WT 
p110δ, but rather had a GM-CSF-stimulated proliferative response similar to that of WT 
control cells (Figure 5.6A, compare green line with red line and blue line).  This suggests 
that intact p110δ activity is necessary for maintaining gain-of-function mutant Shp2-
induced GM-CSF hypersensitivity.  In contrast, genetic deletion of p110α had no effect 
on GM-CSF-stimulated proliferation in Shp2 D61Y-expressing cells, as there was no 
significant difference in [
3
H]-Thymidine incorporation between cells from p110αflox/flox; 
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LSL-Shp2
D61Y/+
; Mx1-Cre+ (D61Y/p110α) mice and cells from p110α+/+; LSL-
Shp2
D61Y/+
; Mx1-Cre+ (D61Y) mice (compare purple line with red line). 
Similarly, we performed methylcellulose colony-forming assays in which equal 
numbers of cells from each group were plated in methylcellulose in the presence of 
increasing concentrations of GM-CSF (0-10 ng/mL), before colonies were counted 7-10 
days later.  In this assay, we observed the same pattern as with [
3
H]-Thymidine 
incorporation assay.  As previously reported, cells expressing Shp2 D61Y have increased 
colony forming capacity in response to increasing doses of GM-CSF stimulation 
compared to WT Shp2-expressing cells (Figure 5.6B, compare red and blue lines) (Chan, 
Kalaitzidis et al. 2009).  Shp2 D61Y cells expressing kinase-dead p110δ D910A have 
significantly reduced colony-forming capacity for each dose of GM-CSF up to 1 ng/mL 
(Figure 5.6B, compare red and green lines).  However, genetic deletion of p110α did not 
affect mutant Shp2 D61Y-induced enhanced colony formation in response to GM-CSF 
stimulation (Figure 5.6B, compare red and purple lines), similar to the pattern observed in 
the [
3
H]-Thymidine incorporation assay data. 
Thus, together these data demonstrate that genetic interruption of p110δ, but not 
p110α, can significantly reduce GM-CSF-stimulated hyper-proliferation and enhanced 
colony-forming capacity in cells with activating Shp2 mutations.  This provides further 
support that p110δ is the principal mediator of mutant Shp2-induced GM-CSF 
hypersensitivity, with p110α playing either a negligible or a dispensable role, and that, 
therefore, p110δ should be considered a potential therapeutic target for gain-of-function 
mutant Shp2-associated MPD. 
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Figure 5.6: Genetic disruption of p110δ, but not p110α, significantly reduces GM-
CSF-stimulated hyper-proliferation induced by endogenously expressed gain-of-
function mutant Shp2 D61Y 
 
(A) Proliferation in response to increasing concentrations of GM-CSF (0-1 ng/mL) as 
measured by [
3
H]-Thymidine incorporation and reported as average percent maximal 
stimulation of bone marrow-derived LDMNCs from WT mice, Shp2 D61Y inducible 
knockin mice, Shp2 D61Y-inducible knockin mice expressing kinase-dead mutant p110δ 
D910A, and Shp2 D61Y-inducible knockin mice with genetic deletion of p110α; n=5-8 
mice, performed in replicates of 6; *p < 0.05 comparing Shp2 D61Y mice with WT Shp2 
mice at 0.01 ng/mL and 0.1 ng/mL GM-CSF; ^p < 0.05 comparing Shp2 D61Y mice with 
D61Y p110δ-/- mice at 0 ng/mL, 0.01 ng/mL, and 0.1 ng/mL GM-CSF; no significant 
difference was found comparing Shp2 D61Y mice with D61Y p110α-/- mice at any GM-
CSF concentration; statistics performed using unpaired, two-tailed student’s t-test (figure 
continued on next page). 
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Figure 5.6: Genetic disruption of p110δ, but not p110α, significantly reduces GM-
CSF-stimulated hyper-proliferation induced by endogenously expressed gain-of-
function mutant Shp2 D61Y (continued) 
 
(B) Proliferation in response to increasing concentrations of GM-CSF (0-10 ng/mL) as 
measured by methylcellulose colony-forming assay and reported as average percent 
maximal stimulation of bone marrow-derived LDMNCs from WT mice, Shp2 D61Y 
inducible knockin mice, Shp2 D61Y-inducible knockin mice expressing kinase-dead 
mutant p110δ D910A, and Shp2 D61Y-inducible knockin mice with genetic deletion of 
p110α; n=6-8 mice, performed in replicates of 2; *p < 0.05 comparing Shp2 D61Y mice 
with WT Shp2 mice at 0 ng/mL and 0.01 ng/mL GM-CSF; **p < 0.005 comparing Shp2 
D61Y mice with WT Shp2 mice at 0.1 ng/mL GM-CSF; ^p < 0.05 comparing Shp2 
D61Y mice with D61Y p110δ-/- mice at 0 ng/mL, 0.01 ng/mL, and 0.1 ng/mL GM-CSF; 
no significant difference was found comparing Shp2 D61Y mice with D61Y p110α-/- 
mice at any GM-CSF concentration; statistics performed using unpaired, two-tailed 
student’s t-test. 
 
 
 
0
20
40
60
80
100
120
140
0 ng/mL 0.01 ng/mL 0.1 ng/mL 1 ng/mL 10 ng/mL
GM-CSF
P
e
rc
e
n
t 
M
ax
im
al
 B
o
n
e
 M
ar
ro
w
 C
o
lo
n
y 
Fo
rm
at
io
n
 (
+/
-
S.
E.
M
.)
WT Shp2
Shp2 D61Y
D61Y p110δ-/-
D61Y p110α-/-
*
**
^
^
*
^
B
 118 
 
Genetic interruption of p110δ, but not p110α, results in decreased GM-CSF-stimulated 
hyper-phosphorylation of Akt, Erk, and Shp2 
 To evaluate the consequences of genetic interruption of p110δ and p110α on 
mutant Shp2-induced hyperactivated PI3K-Akt and MAPK-Erk signaling pathways, 
western blot analyses were performed on adherent macrophages cultured from bone 
marrow-derived LDMNCs from mice endogenously expressing gain-of-function mutant 
Shp2 D61Y in the presence of genetically inactivated p110δ D910A or genetically 
deleted p110α.  When we transduced cells from p110δD910A/D910A mice with gain-of-
function mutant Shp2 E76K, we observed modest decreases in GM-CSF-stimulated 
hyper-phosphorylation of both Akt and Erk, suggesting that loss of p110δ activity was 
having some effect on mutant Shp2-induced aberrant signaling, though it was not 
sufficient to decrease the hyper-proliferative phenotype.  We hypothesized that in the 
presence of endogenously expressed mutant Shp2 (rather than exogenously 
overexpressed mutant Shp2) the effects on hyperactivated signaling would be more 
pronounced, especially since there was a significant reduction in GM-CSF-stimulated 
hyper-proliferation and colony-forming capacity in the Shp2 D61Y-expressing cells 
lacking p110δ activity. 
 Comparing macrophages derived from two mice expressing Shp2 D61Y in the 
presence of kinase-dead p110δ D910A with macrophages derived from two mice 
expressing Shp2 D61Y in the presence of intact p110δ activity, we observed that mutant 
Shp2-induced PI3K hyperactivation had been significantly reduced, as GM-CSF-
stimulated Akt hyper-phosphorylation at both Serine 473 and Threonine 308 had been 
substantially decreased (Figure 5.7A, compare lanes 5 and 6 with lanes 7 and 8).  
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Furthermore, we also found that Erk hyper-phosphorylation was also greatly reduced in 
keeping with our previous observations that PI3K positively regulates Erk in the context 
mutant Shp2 (Figure 5.7A, compare lanes 5 and 6 with lanes 7 and 8).  Finally, we were 
also surprised to find that Shp2 phosphorylation at Tyrosine 580 was also reduced, 
indicating that gain-of-function mutant Shp2 hyperactivation was also decreased in the 
absence of p110δ activity (Figure 5.7A, compare lanes 5 and 6 with lanes 7 and 8).  
Finally, we observed that there was no evidence of upregulation of the other two Class IA 
PI3K catalytic subunits, p110α and p110β, to compensate for the lost p110δ activity. 
 In contrast, deletion of p110α had no apparent effect on mutant Shp2 D61Y-
induced hyperactivation of PI3K and MAPK signaling pathways downstream of GM-
CSF stimulation.  First, we observed that p110α had been efficiently deleted and that 
there were no compensatory upregulation of the other two Class IA PI3K catalytic 
subunits, p110β and p110δ (Figure 5.7B, compare lanes 7 and 8 with lane 6, and lanes 3 
and 4 with lane 2).  Secondly, unlike genetic interruption of p110δ activity, deletion of 
p110α did not negatively affect mutant Shp2 D61Y-induced PI3K hyperactivity, as the 
levels of Akt phosphorylation at both Serine 473 and Threonine 308 remained as high in 
the cells from mice expressing Shp2 D61Y in the absence of p110α as in the cells from 
mice expressing Shp2 D61Y in the presence of p110α (Figure 5.7B, compare lanes 7 and 
8 with lane 6).  Similarly, mutant Shp2 D61Y-induced hyperactivation of Erk as well as 
Shp2 itself was also unaffected by the deletion of p110α (Figure 5.7B, compare lanes 7 
and 8 with lane 6).   
 Thus, the results of the biochemistry assays correlate with the observations from 
the proliferation assays, in which genetic inactivation of p110δ substantially reduced both 
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Akt and Erk hyper-phosphorylation as well as GM-CSF-stimulated hyper-proliferation 
and enhanced colony-forming capacity, suggesting that intact p110δ activity is necessary 
to maintain gain-of-function mutant Shp2-induced hyperactivation of PI3K-Akt and Erk 
signaling, which in turn promote the phenotype of an enhanced proliferative response 
following GM-CSF stimulation.  The role of p110α, on the other hand, is either negligible 
or dispensable, as genetic deletion of p110α had no effect on mutant Shp2 D61Y-induced 
Akt or Erk hyperactivation, and thus, not surprisingly, caused no reduction in GM-CSF-
stimulated hyper-proliferation or enhanced colony-forming capacity. 
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Figure 5.7: Genetic disruption of p110δ, but not p110α, significantly reduces GM-
CSF-stimulated hyper-phosphorylation of Akt, Erk, and Shp2 in cells endogenously 
expressing gain-of-function mutant Shp2 D61Y 
 
(A) Western blot analyses of macrophages cultured from bone marrow-derived LDMNCs 
from two Shp2 D61Y inducible-knockin mice expressing WT p110δ and two Shp2 
D61Y-inducible knockin mice expressing kinase-dead mutant p110δ D910A stimulated 
for 60 minutes with 0 or 10 ng/mL GM-CSF.  (B) Western blot analysis of macrophages 
cultured from one WT Shp2-expressing mouse, one Shp2 D61Y inducible knockin mouse 
with intact PI3K signaling, and two Shp2 D61Y inducible knockin mice with deleted 
p110α stimulated for 60 minutes with 0 or 10 ng/mL GM-CSF. 
A
B
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Genetic disruption of p110δ activity, but not p110α expression, results in a significant 
reduction mutant Shp2 D61Y-induced splenomegaly 
 As has been previously reported, LSL-Shp2
D61Y/+
; Mx-Cre+ mice develop 
enlarged spleens (Chan, Kalaitzidis et al. 2009), recapitulating a common clinical feature 
of Juvenile Myelomonocytic Leukemia.  At approximately 8-12 weeks following 
polyI:polyC injections, we measured the spleen weights, animal body weights, and the 
number of ficoll gradient-isolated splenocytes, and we evaluated relative spleen sizes by 
calculating the ratio of spleen weight to body weight (Figure 5.8).  We also determined 
the total number of ficoll gradient-isolated splenocytes and determined the splenocyte 
cellularity by dividing the total number of ficoll gradient-isolated splenocytes by the 
spleen weight (Figure 5.9). 
 As expected, we found that mice expressing gain-of-function mutant Shp2 D61Y 
in the presence of intact PI3K signaling had significantly larger relative spleen sizes 
compared to WT control mice (Figure 5.8A).  Interestingly, we found that Shp2 D61Y-
expressing mice with genetically inactivated p110δ D910A had significantly reduced 
spleen sizes compared to Shp2 D61Y mice (Figure 5.8A), suggesting that loss of p110δ 
activity delayed the onset of or reduced the severity of mutant Shp2-induced MPD 
development.  This is consistent with our previous observations that p110δ is a crucial 
mediator of mutant Shp2-induced PI3K hyperactivation and GM-CSF hypersensitivity, 
which is thought to contribute to the pathogenesis of JMML.  However, in agreement 
with our in vitro data, loss of p110α did not significantly lower average relative spleen, 
though we did observe a lot of variation in spleen size in this group (Figure 5.8A).  
Indeed, if p110α’s role in mutant Shp2-induced GM-CSF hypersensitivity was negligible 
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or dispensable as our in vitro data suggest, then we could expect that loss of p110α would 
probably have a minimal impact on MPD development.  In Figure 5.8B can be seen 
representative spleens showing that spleens from mice expressing Shp2 D61Y in the 
presence of intact PI3K signaling are larger than those of WT control mice.  Here it can 
be seen that spleens from Shp2 D61Y mice with genetically inactivated p110δ are 
smaller, while those from Shp2 D61Y mice with deleted p110α are not appreciably 
different in size from the Shp2 D61Y mice with intact PI3K signaling. 
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Figure 5.8: Genetic disruption of p110δ, but not p110α, reduces gain-of-function 
mutant Shp2 D61Y-induced splenomegaly 
(A) Average relative spleen weight, calculated as the ratio of spleen weight to body 
weight 8-12 weeks following polyI:polyC treatment, which induces expression of Shp2 
D61Y and deletion of p110α.  Relative spleen weights were calculated for WT mice (n = 
6), Shp2 D61Y mice (n = 8), Shp2 D61Y mice expressing kinase-dead mutant p110δ 
D910A (n=9), and Shp2 D61Y mice with genetic deletion of p110α (n=6); *p < 0.05 
comparing average relative spleen weights of Shp2 D61Y mice to WT mice or Shp2 
D61Y p110δD910A mice; no significant difference was found comparing Shp2 D61Y mice 
to Shp2 D61Y p110αfl/fl mice; statistics were performed using unpaired, two-tailed 
student’s t-test.  (B) Photograph showing representative spleens of the various 
experimental groups. 
A
B
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The total number of splenocytes tended to reflect that relative spleen sizes such 
that mice expressing gain-of-function mutant Shp2 D61Y in the setting of intact PI3K 
signaling had a significantly greater total number of ficoll gradient-isolated splenocytes 
compared to WT control mice (Figure 5.9A).  Shp2 D61Y mice expressing kinase-dead 
p110δ D910A had significantly less splenocytes on average than Shp2 D61Y mice, 
correlating with their smaller average overall spleen sizes, while the total number of ficoll 
gradient-isolated splenocytes was not significantly different between Shp2 D61Y mice 
with deleted p110α and Shp2 D61Y mice with intact PI3K signaling (Figure 5.9A).  We 
also calculated splenocyte cellularity as the total number ficoll gradient-isolated 
splenocytes divided by spleen weight to approximate the percentage of immature myeloid 
cells, or infiltrating leukemia cells, occupying the spleen, and we found the same 
essential pattern.  The splenocyte cellularity of the Shp2 D61Y-expressing mice with 
intact PI3K signaling trended to be greater than that of the WT control mice (p = 0.07) 
(Figure 5.9B).  The splenocyte cellularity of the Shp2 D61Y mice with genetically 
inactivated p110δ was significantly lower than that of the Shp2 D61Y mice, while again, 
there was no difference between the Shp2 D61Y mice lacking p110α expression and 
Shp2 D61Y mice with intact PI3K signaling (Figure 5.9B). 
 Together, the spleen data—relative spleen weight, total number of ficoll gradient-
isolated splenocytes, and splenocyte cellularity—can be used to assess MPD 
development in Shp2 D61Y-expressing mice, and it is a clinically relevant metric as 
JMML patients frequently suffer from splenomegaly (Loh 2011).  We found that genetic 
inactivation of p110δ significantly reduced mutant Shp2-induced splenomegaly in vivo, 
while genetic deletion of p110α had no measurable effect, suggesting that p110δ is not 
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only a crucial mediator of GM-CSF hypersensitivity in vitro, but of MPD development in 
vivo, while p110α’s role again appears to be negligible or dispensable.  This provides 
further support that targeting p110δ pharmacologically represents a potentially effective 
therapeutic strategy for the treatment of mutant Shp2-associated MPD. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 127 
 
 
Figure 5.9: Genetic deletion of p110δ, but not p110α, significantly reduces gain-of-
function mutant Shp2 D61Y-induced splenic hyper-cellularity 
(A) Average numbers of ficoll gradient-isolated splenocytes from WT mice (n=5), Shp2 
D61Y inducible knockin mice (n=5), Shp2 D61Y inducible knockin mice expressing 
kinase-dead mutant p110δ D910A (n=4), and Shp2 D61Y inducible mice with genetic 
deletion of p110α (n=5); *p < 0.05 comparing splenocyte numbers of Shp2 D61Y mice 
with those of WT Shp2 mice and Shp2 D61Y p110δD910A mice; no significant (n.s.) 
difference was found comparing splenocyte numbers of Shp2 D61Y mice with that of 
Shp2 D61Y p110αfl/fl mice; statistics performed using unpaired, two-tailed student’s t-
test.  (B) Average splenocyte cellularity for each mouse was calculated by dividing the 
total number of ficoll gradient-isolated splenocytes by the spleen weight for WT mice 
(n=5), Shp2 D61Y inducible knockin mice (n=5), Shp2 D61Y inducible knockin mice 
expressing kinase-dead mutant p110δ D910A (n=4), and Shp2 D61Y inducible mice with 
genetic deletion of p110α (n=5); p = 0.07 comparing splenocyte cellularity of Shp2 D61Y 
mice with that of WT Shp2 mice; p < 0.05 comparing splenocyte cellularity of Shp2 
D61Y mice with that of Shp2 D61Y p110δD910A mice; no significant (n.s.) difference was 
found comparing splenocyte celluarity of Shp2 D61Y mice with that Shp2 D61Y 
p110αfl/fl mice; statistics performed using unpaired, two-tailed student’s t-test. 
A
B
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Conclusions 
 Our previous genetic and pharmacologic studies have demonstrated that 
hyperactivated PI3K, particularly that mediated by the catalytic subunit p110δ, plays a 
crucial role in mutant Shp2-induced GM-CSF hypersensitivity, which is thought to be an 
important contributing factor to the development of Juvenile Myelomonocytic Leukemia.  
Our studies using cells from Pik3r1
-/-
 mice transduced with gain-of-function mutant Shp2 
E76K indicated that activating Shp2 mutations promote hyperactivation of Class IA PI3K 
signaling, which then enhances the activity of one or more downstream effectors that 
cause cells to have an exaggerated proliferative response following GM-CSF stimulation.  
These studies also implicated p110δ as potentially playing an important role in this 
process.   
In an effort to increase the clinical relevance of our work, we then wanted to 
investigate the question of whether just one of the Class IA PI3K catalytic subunits—
p110α, p110β, or p110δ—was primarily responsible for mediating this mutant Shp2-
induced PI3K hyperactivity, which would then allow us to take advantage of the newer 
classes of catalytic subunit-specific PI3K inhibitors.  This pharmacologic strategy makes 
it possible to target only the aberrant PI3K activity directly involved in the leukemia 
process, which we hypothesized to be mediated by a single catalytic subunit (i.e. p110δ), 
while sparing as much as possible the normal PI3K activity involved in other normal 
physiologic processes, which would be mediated primarily by the other catalytic 
subunits, thereby reducing the risk of side effects.  We particularly wanted to focus on 
p110δ, because its expression was preferentially stabilized—though at substantially 
reduced levels—in Pik3r1-/- cells transduced with mutant Shp2 E76K compared to 
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Pik3r1
-/-
 cells transduced with WT Shp2.  Furthermore, p110δ’s hematopoietic-specific 
expression profile, in contrast to the ubiquitously expressed p110α and p110β, makes it a 
particularly attractive target for hematologic malignancies.  However, we also wanted to 
investigate p110α at the same time, because of its frequent association with human 
cancer. 
Accordingly, we initiated studies with three inhibitors that target p110δ: IC87114, 
which is a highly specific, but not very potent, inhibitor of p110δ; GDC-0941, which is 
clinical-grade compound that potently inhibits p110δ, but also inhibits p110α activity 
very efficiently; and GS-9820, a highly potent, clinical grade p110δ-specific inhibitor.  
We found that these inhibitors significantly reduced GM-CSF hypersensitivity and PI3K 
hyperactivation in cells exogenously overexpressing gain-of-function mutant Shp2 E76K, 
as well as in cells from Shp2 D61Y-inducible knockin mice, which provide a more 
physiologically relevant model of endogenously expressed mutant Shp2.  The results of 
these studies provided more evidence that p110δ could be the principal mediator of gain-
of-function mutant Shp2-induced PI3K hyperactivity and an important contributor to 
GM-CSF hypersensitivity. 
To examine the role of p110δ more thoroughly, we used a genetic approach, 
which would circumvent some of the potential ambiguities posed by the use of small 
molecule inhibitors.  We began these studies by transducing cells from mice expressing 
genetically inactivated p110δ D910A and p110α inducible knockout mice with gain-of-
function mutant Shp2 E76K.  In both cases, neither loss of p110δ activity nor loss of 
p110α expression had a significant effect on mutant Shp2 E76K-induced hyper-
proliferation in response to GM-CSF stimulation, suggesting that these two catalytic 
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subunits might be playing redundant roles in mediating mutant Shp2-induced PI3K 
hyperactivation.  However, we did observe that p110δD910A/D910A cells—but not 
p110αflox/flox; Mx1-Cre+ cells—exogenously overexpressing Shp2 E76K showed modest 
decreases in Akt and Erk hyper-phosphorylation, suggesting that loss of p110δ activity 
was negatively impacting mutant Shp2-induced PI3K hyperactivation, but apparently not 
enough to affect the hyper-proliferative phenotype.  We suspected that we might be 
missing the true importance of p110δ in mutant Shp2-induced PI3K hyperactivation, as 
overexpression of an oncogene like Shp2 E76K might artificially distort mitogenic 
signaling beyond what might typically occur in the more physiologically relevant context 
of endogenously expressed gain-of-function mutant Shp2. 
Accordingly, we crossed the PI3K catalytic subunit-targeted transgenic mice form 
the initial studies with Shp2 D61Y-inducible knockin mice to more accurately evaluate 
the consequences of loss of p110δ activity or p110α expression on endogenously 
expressed mutant Shp2 D61Y-induced PI3K hyperactivation and GM-CSF 
hypersensitivity in vitro.  Specifically, we crossed LSL-Shp2
D61Y/+
; Mx1-Cre+ mice with 
p110δD910A/D910A mice or with p110αflox/flox; Mx1-Cre+ mice to generate p110δD910A/D910A; 
LSL-Shp2
D61Y/+
; Mx1-Cre+ mice, which express mutant Shp2 D61Y in the absence of 
p110δ activity, and p110αflox/flox; LSL-Shp2D61Y/+; Cre+, which express mutant Shp2 
D61Y in the absence of p110α expression.  These cells were compared with those of 
Shp2 D61Y-expressing mice with intact PI3K activity and with those of WT control 
mice.   
We found that loss p110δ activity significantly reduced Shp2 D61Y-induced GM-
CSF hypersensitivity, both in terms of GM-CSF-stimulated proliferation as measured by 
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[
3
H]-Thymdine incorporation assays and in terms of GM-CSF-stimulated colony-forming 
capacity.  Loss of p110α expression, in contrast, had no measurable effect on mutant 
Shp2-induced GM-CSF hypersensitivity.  These functional results correlated well with 
our biochemical analyses, in which we found substantial decreases in mutant Shp2 
D61Y-induced hyper-phosphorylation of Akt at both Serine 473 and Threonine 308 as 
well as Erk and Shp2 itself, suggesting that genetic interruption of p110δ significantly 
abrogated mutant Shp2 D61Y-induced hyperactivated PI3K and MAPK signaling.  
Genetic deletion of p110α, on the other hand, had no effect on Akt or Erk hyperactivation 
in Shp2 D61Y-expressing cells, just as it did not impact GM-CSF-stimulated hyper-
proliferation or enhanced colony-forming capacity.  Together, these results implicate 
p110δ as the principal mediator of mutant Shp2-induced PI3K hyperactivation and 
resulting GM-CSF hypersensitivity, while suggesting that p110α’s role is negligible or 
dispensable. 
Additionally, from the mouse models that we have developed, we have evidence 
suggesting that p110δ-mediated PI3K hyperactivation is crucial for mutant Shp2-induced 
MPD development, as mice expressing Shp2 D61Y in the presence of kinase-dead p110δ 
D910A demonstrate substantial improvement in splenomegaly, a common clinical feature 
of JMML, whereas mice expressing Shp2 D61Y in the absence of p110α expression had 
no reduction in relative spleen sizes, total number of ficoll gradient-isolated splenocytes, 
or splenocyte cellularity, in comparison to mice expressing Shp2 D61Y in the presence of 
intact PI3K signaling.  This suggests that p110δ not only plays a crucial role in mutant 
Shp2-induced GM-CSF hypersensitivity, but that its activity is also necessary for the 
development of mutant Shp2-induced leukemogenesis.  Therefore, on the basis of these 
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genetic in vitro and in vivo studies, we believe that p110δ represents a promising 
therapeutic target for the treatment of JMML. 
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CHAPTER SIX 
GAIN-OF-FUNCTION MUTANT SHP2’S FUNCTIONAL DOMAINS ARE 
REQUIRED FOR FULL HYPERACTIVATION OF PI3K 
Introduction 
 In our previous studies, we have shown that gain-of-function mutant Shp2 
promotes GM-CSF-stimulated hyperactivation of PI3K, which is principally mediated by 
the hematopoietic-specific Class IA PI3K catalytic subunit p110δ, and which contributes 
significantly to the phenotype of GM-CSF-stimulated hyper-proliferation.  We also 
wanted to know the mechanisms by which gain-of-function mutant Shp2 promotes 
hyperactivation of PI3K with the hope of identifying additional therapeutic targets for the 
treatment of myeloproliferative disease (MPD) associated with activating Shp2 
mutations.  For instance, gain-of-function mutant Shp2 is thought to induce 
hyperactivated pro-growth and pro-survival signaling primarily, if not exclusively, 
through promoting hyperactivation of Ras.  By using the farnesyl-transferase inhibitor, 
tipifarnib, as a pharmacologic means of interrupting Ras activity, we demonstrated that 
gain-of-function mutant Shp2 can, at least in part, promote hyperactivation of PI3K 
independently of Ras, even though all PI3K catalytic subunits contain Ras-binding 
domains and, accordingly, have been demonstrated to be direct effectors of Ras activity.  
This is particularly significant in light of our observations, that p110δ appears to be the 
principal mediator of mutant Shp2-induced PI3K hyperactivaiton, since it has been 
reported that p110δ, unlike the other Class PI3K catalytic subunits, can oncogenically 
transform cells independent of Ras (Denley, Kang et al. 2008).  This finding suggests that 
gain-of-function mutant Shp2 can promote PI3K hyperactivation independently of Ras, 
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and that, therefore, PI3K most likely must be targeted as an independent and parallel 
pathway in addition to pharmacologically targeting the MAPK pathway for complete 
abrogation of mutant Shp2-induced aberrant mitogenic signaling.   
 One possible strategy to pharmacologically interrupt mutant Shp2-induced 
hyperactivated signaling is to target mutant Shp2 itself.  Shp2 is thought to regulate 
signaling both through its enzymatic function, mediated by it C-terminal phosphatase 
domain, and through its scaffolding function, mediated by its two SH2 domains—N-SH2 
and C-SH2 (Figure 6.1).  Regarding Shp2’s scaffolding function, it has been shown to 
interact with a variety of receptors, including the βc subunit of the GM-CSF receptor at 
Tyrosine 577 and Tyrosine 612 as well as several pertinent signaling molecules, 
including p85α and the Ras GEF Sos, most likely via interactions with other scaffolding 
molecules such as Gab2 and Grb2 (Neel, Gu et al. 2003).  Genetic inactivation of both 
the N-SH2 and C-SH2 domains have been shown to reduce GM-CSF hypersensitivity, 
suggesting that Shp2’s role as a scaffolding molecule might be important for this process.  
On the other hand, the substrates of Shp2’s phosphatase activity, particularly those most 
relevant for promoting human diseases such as hematologic malignancies and Noonan 
Syndrome, have yet to be clearly defined, though it has been shown that this phosphatase 
activity is required for full activation of Ras, and that genetic inactivation of Shp2’s 
phosphatase domain significantly reduces GM-CSF-stimulated hyper-proliferation.  
Interestingly, it has been reported that genetic inactivation of Shp2 E76K’s phosphatase 
domain does not affect PI3K hyperactivation in response to IL-3 stimulation (Yu, Daino 
et al. 2006).  The IL-3 receptor shares the βc subunit with the GM-CSF receptor, and its 
signaling mechanisms are thought to be very similar; additionally, activating Shp2 
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mutations have been shown to impart IL-3 hypersensitivity as well as GM-CSF 
hypersensitivity.  This would suggest that, perhaps, Shp2’s phosphatase activity might 
not be necessary for promoting PI3K hyperactivation in response to GM-CSF 
stimulation, though it has been demonstrated that this phosphatase activity is necessary 
for GM-CSF hypersensitivity (Mohi, Williams et al. 2005).  Investigating this point is of 
particular interest in light of recent work to develop and evaluate the efficacy of a 
compound that inhibits Shp2’s phosphatase activity (Zhang, He et al. 2010).  
Accordingly, we wanted to investigate which of mutant Shp2’s functional domains were 
necessary for promoting full GM-CSF-stimulated hyperactivation of PI3K, in order to 
determine which of Shp2’s function—enzymatic, scaffolding, or both—were required for 
its regulation of PI3K activity. 
 
Results 
Genetic interruption Shp2’s three functional domains—N-SH2, C-SH2, and 
phosphatase—all reduce gain-of-function mutant Shp2 E76K-induced hyper-
proliferation in response to GM-CSF stimulation 
 To investigate whether mutant Shp2 promotes hyperactivation of PI3K through its 
scaffolding function, its phosphatase function, or both, we used site-directed mutagenesis 
to create constructs of mutant Shp2 E76K with an additional loss-of-function mutation 
targeting one of Shp2’s three functional domains: N-SH2, C-SH2, and phosphatase.  
Specifically, we interrupted the two SH2 domains’ ability to bind phosphorylated 
tyrosine residues by mutating a conserved arginine residue to a lysine residue to create 
Shp2 double-mutant constructs that impaired Shp2 E76K’s scaffolding function: Shp2 
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E76K/R32K (interrupting the N-SH2 domain) and Shp2 E76K/R138K (interrupting the 
C-SH2 domain) (Figure 6.1).  To genetically inactivate Shp2 E76K’s phosphatase 
activity, we introduced a mutation in the phosphatase domain, converting a conserved 
cysteine residue to alanine, thus generating the Shp2 E76K phosphatase-dead construct, 
Shp2 E76K/C463A (Figure 6.1).   
 
 
 
 
 
Figure 6.1: Schematic of Shp2 structure with loss-of-function mutations targeting 
gain-of-function mutant Shp2 E76K’s N-SH2, C-SH2, and phosphatase domains 
 
Site-directed mutagenesis was used to introduce loss-of-function point mutations in each 
of Shp2 E76K’s domains—N-SH2 (R32K), C-SH2 (R138K), and phosphatase (PTPase) 
(C463A)—thereby disrupting their function.  In the N-SH2 and C-SH2 domain, 
conserved arginine residues were converted to lysine residues, which prevent effective 
binding to phosphorylated tyrosine residues, thereby abrogating Shp2 E76K’s scaffolding 
function.  In the phosphatase domain, a conserved cysteine residue was converted to an 
alanine residue, thereby abrogating Shp2 E76K’s enzymatic function. 
 
 
 
N-SH2 C-SH2 PTPase
E76K
Shp2
R32K R138K C463A
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 We then transduced WT bone marrow-derived low-density mononuclear cells 
(LDMNCs) with these Shp2 double-mutant constructs as well as with WT Shp2 and 
mutant Shp2 E76K with all three functional domains intact, as controls.  When we 
measured GM-CSF-stimulated proliferation in these cells by [
3
H]-Thymidine 
incorporation, we found, as had been previously reported, that genetic disruption of any 
of the functional domains of gain-of-function mutant Shp2 E76K significantly reduced 
proliferation in response to GM-CSF stimulation (Figure 6.2).  We observed, however, 
that genetic disruption of the phosphatase domain seemed to result in the greatest 
reduction in GM-CSF-stimulated hyper-proliferation, particularly at GM-CSF 
concentrations of 0.1 and 1 ng/mL.  This suggests that mutant Shp2 promotes GM-CSF 
hypersensitivity via both its scaffolding function and its enzymatic function, but perhaps 
its enzymatic function may be more important for mediating the aberrant signaling that 
results in GM-CSF hypersensitivity. 
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Figure 6.2: Genetic disruption of Shp2 E76K’s three functional domains—N-SH2, 
C-SH2, and phosphatase—all significantly reduce GM-CSF-stimulated hyper-
proliferation 
 
[
3
H]-Thymidine incorporation assay measuring proliferation in response to increasing 
concentrations of GM-CSF (0-1 ng/mL) in WT bone marrow-derived LDMNCs 
transduced with WT Shp2, gain-of-function mutant Shp2 E76K with all three functional 
domains intact, Shp2 E76K with genetic interruption of the N-SH2 domain (R32K), Shp2 
E76K with genetic interruption of the C-SH2 domain (R138K), and Shp2 E76K with 
genetic interruption of the phosphatase domain (C463A).  Representative data of two 
independent experiments in replicates of 4-6; *p < 0.001 comparing [
3
H]-Thymidine 
incorporation of Shp2 E76K-expressing cells with WT Shp2-, Shp2 E76K/R32K-, Shp2 
E76K/R138K-, and Shp2 E76K/C463A-expressing cells at 0 ng/mL, 0.01 ng/mL, 0.1 
ng/mL, and 1 ng/mL GM-CSF; statistics performed using unpaired, two-tailed student’s 
t-test. 
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Genetic interruption Shp2’s three functional domains—N-SH2, C-SH2, and 
phosphatase—all reduce gain-of-function mutant Shp2 E76K-induced hyperactivation 
of PI3K and MAPK signaling 
 To investigate the consequences of genetic interruption of Shp2’s three functional 
domains—N-SH2, C-SH2, and phosphatase—on mutant Shp2 E76K-induced 
hyperactivation of PI3K and MAPK signaling, we cultured bone marrow-derived 
LDMNCs transduced with one of the three double mutant Shp2 E76K constructs 
described above as well as with WT Shp2 and mutant Shp2 E76K with intact functional 
domains as controls, into adherent macrophages for biochemistry.  We found that genetic 
interruption of either one of mutant Shp2 E76K’s SH2 domains results in slight 
reductions in Akt hyper-phosphorylation at both Serine 473 and Threonine 308, as well 
as modest reductions in Erk hyper-phosphorylation, indicating that mutant Shp2 E76K’s 
scaffolding function plays a role in promoting hyperactivation of PI3K and MAPK 
signaling (Figure 6.3, compare lanes 3 and 4 with lane 2, and lanes 8 and 9 with lane 7).  
Genetic interruption of the phosphatase domain, however, resulted in substantially greater 
reductions in mutant Shp2 E76K-induced hyper-phosphorylation of Akt at both Serine 
473 and Threonine 308 and of Erk (Figure 6.3, compare lane 5 with lane 2, and lane 10 
with lane 7), which correlates with the more pronounced reductions in GM-CSF-
stimulated hyper-proliferation observed in the cells expressing Shp2 E76K with the 
genetically inactivated phosphatase domain (Figure 6.2).  These results suggest that gain-
of-function mutant Shp2 causes dysregulated PI3K and MAPK signaling through both its 
scaffolding function and its phosphatase function. 
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Figure 6.3: Genetic disruption of Shp2 E76K’s three functional domains—N-SH2, 
C-SH2, and phosphatase—significantly reduce GM-CSF-stimulated hyper-
phosphorylation of Akt, Erk, and Shp2 
 
Western blot analysis of adherent macrophages cultured from WT bone marrow-derived 
LDMNCs transduced with WT Shp2, gain-of-function mutant Shp2 E76K with all three 
functional domains intact, Shp2 E76K with genetic interruption of the N-SH2 domain 
(R32K), Shp2 E76K with genetic interruption of the C-SH2 domain (R138K), and Shp2 
E76K with genetic interruption of the phosphatase domain (C463A) stimulated for 60 
minutes with either 0 ng/mL GM-CSF or 10 ng/mL GM-CSF.  Data representative of two 
independent experiments. 
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Conclusions 
 Previous studies have investigated the mechanisms by which Shp2 regulates 
mitogenic signaling, especially in the context of Shp2 bearing disease-causing mutations 
(Yu, Daino et al. 2006).  These studies have identified two major signal-regulating 
functions of Shp2: a scaffolding function mediated by Shp2’s two SH2 domains, which 
promote interactions between Shp2 and phosphorylated tyrosine residues on other 
scaffolding molecules such as Gab2 and Grb2 and activated receptors such as the GM-
CSF receptor; and its enzymatic function mediated by its C-terminal phosphatase domain, 
though the substrates of this activity still remain to be definitively elucidated.  Previous 
studies have shown that both the scaffolding function and the phosphatase function are 
necessary for promoting gain-of-function mutant Shp2-induced hyper-proliferation in 
response to GM-CSF stimulation.   
We wanted to know more specifically the roles of these functions of Shp2 in 
regulating particular signaling pathways, especially PI3K, since we have demonstrated its 
importance in promoting GM-CSF hypersensitivity in vitro and myeloproliferative 
disease in vivo.  However, previous studies using Ba/F3 cells transduced with activating 
mutant Shp2 constructs bearing genetic disruption of the three functional domains 
suggested that, while the scaffolding function of mutant Shp2 was necessary for 
promoting hyperactivation of PI3K, interruption of the phosphatase domain did not 
reduce Akt hyper-phosphorylation in response to stimulation with IL-3, whose receptor 
shares the βc subunit with the GM-CSF receptor (Yu, Daino et al. 2006).  In other words, 
mutant Shp2-induced PI3K hyperactivation can apparently remain intact in the absence 
of Shp2’s phosphatase function.  This conflicts with a previous study, which reports that 
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Shp2’s phosphatase function is required for promoting GM-CSF hypersensitivity (Mohi, 
Williams et al. 2005) and our observation that PI3K contributes to gain-of-function 
mutant Shp2-induced GM-CSF hypersensitivity.  We hoped to resolve this discrepancy 
by evaluating the roles of mutant Shp2’s functional domains in PI3K hyperactivation and 
GM-CSF hypersensitivity in the more physiologically relevant setting of primary murine 
hematopoietic progenitor cells.  We found in this setting that not only did genetic 
interruption of mutant Shp2’s phosphatase domain reduce Akt hyper-phosphorylation, 
but that it did so more dramatically than the Shp2 E76K constructs with mutations in the 
SH2 domains, which correlated with the more robust reductions in GM-CSF-stimulated 
hyperproliferation observed in cells expressing Shp2 E76K bearing phosphatase-dead 
mutations.  Together, these results show that mutant Shp2 promotes hyperactivation of 
PI3K and resulting GM-CSF hypersesnsitivity via both its scaffolding function and its 
phosphatase functions.   
However, it is difficult to fully compare the consequences of mutating the SH2 
domains with that of the phosphatase mutations, since the cells transduced with Shp2 
E76K bearing loss-of-function domain mutations still retain endogenous WT Shp2 
expression.  It can be expected that the phosphatase-dead Shp2 E76K mutants might 
exhibit a dominant-negative effect on the endogenous WT Shp2, because this construct’s 
SH2 domains are functionally intact and can therefore still interact with potential 
phosphorylated substrates for Shp2 phosphatase activity, thereby blocking access to the 
still-functioning endogenous WT Shp2.  On the other hand, in those cells transduced with 
mutant Shp2 E76K constructs bearing genetic interruption of one of the SH2 domains, 
one could expect that the endogenous WT Shp2 might be able to interact preferentially 
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with its phosphorylated substrates, because its SH2 domains are functionally intact.  In 
other words, the phosphatase-dead Shp2 E76K mutants might interfere more with 
endogenous WT Shp2 activity than the Shp2 E76K mutants bearing genetically 
interrupted SH2 domains, thereby enhancing the apparent effect of the loss of mutant 
Shp2’s phosphatase activity in comparison to the loss of its scaffolding function.  
Regardless of their relative importance, we are still able to conclude that mutant Shp2 
requires both of its SH2 domains as well as its phosphatase function to promote aberrant 
PI3K and MAPK signaling, which contribute to GM-CSF hypersensitivity.  This is 
significant, because it suggests that small molecules that might be able to interrupt either 
one of these functions might represent potential therapeutic strategies for the treatment of 
mutant Shp2-induced MPD. 
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CHAPTER SEVEN 
DISCUSSION 
 Although, Juvenile Myelomonocytic Leukemia (JMML) is rare, it remains 
extremely challenging to treat.  Unlike other pediatric hematologic malignancies such 
ALL, JMML does not respond to standard chemotherapy, and, therefore, the only 
curative therapy at this time is allogeneic hematopoietic stem cell transplantation, which 
has an unacceptably low survival rate of approximately 50% (Loh 2011).  Thus, much 
more effective therapeutic options are needed for this disease.  Hyperactivated RAS 
signaling appears to be a common molecular feature in the pathogenesis of JMML, and 
this can result from gain-of-function mutations in RAS itself, loss-of-function mutations 
in NF1 or CBL, but the most commonly mutated gene in JMML are activating mutations 
in PTPN11, which encodes the protein tyrosine phosphatase Shp2 (Figure 1.1).   
 To date much of the work in JMML research has focused on the hyperactivation 
of the RAF-MEK-ERK (MAPK) pathway in the presence of JMML-causing mutations, 
and likewise, this pathway has been studied extensively as a potential therapeutic target.  
Indeed, the MEK inhibitor PD0325901 has shown great promise in mouse models of 
JMML bearing gain-of-function Kras mutations and genetic deletion of Nf1 (Lyubynska, 
Gorman et al. 2011; Chang, Krisman et al. 2013).  However, the PI3K-AKT pathway is 
also known to be positively regulated by RAS activity, and is frequently found to 
contribute to the pathogenesis of wide array of human malignancies.  Furthermore, Shp2 
is known to form complexes with the Class IA p85 regulatory subunit of PI3K (Yu, 
Daino et al. 2006), suggesting it may directly promote its activation, and our lab has also 
shown that Akt is hyper-phosphorylated in cells expressing gain-of-function mutant Shp2 
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following GM-CSF-stimulation, suggesting that mutant Shp2 promotes PI3K 
hyperactivation, which may contribute to GM-CSF hypersensitivity and leukemogenesis 
(Figure 1.5) (Yang, Li et al. 2008).  Thus, we wanted to know if PI3K signaling might 
also be important mutant SHP2-induced MPD development, and therefore a potential 
therapeutic target for JMML. 
 We began by first confirming that gain-of-function mutant Shp2 can promote 
PI3K hyperactivation in response to GM-CSF stimulation by performing an in vitro PI3K 
activity assay (Figure 3.1).  We also used pharmacologic and genetic approaches to 
demonstrate that mutant Shp2-induced hyperactivtion of PI3K contributes to GM-CSF 
hypersensitivity.  We found that the pan-PI3K inhibitor LY294002 and genetic deletion 
of Pik3r1, which encodes the major Class IA PI3K regulatory subunit p85α and its splice 
variants, p55α and p50α, both reduced GM-CSF-stimulated hyper-proliferation and Akt 
hyper-phosphorylation (Figure 3.2 and 3.4).  We also made the interesting observation 
that mutant Shp2-induced Erk hyper-phosphorylation was also reduced in the absence of 
the Pik3r1-encoded regulatory subunits, an observation that we consistently observed as 
we targeted different components of Class IA PI3K in mutant Shp2-expressing cells 
using both pharmacologic and genetic approaches (Figure 3.4).  The fact that genetic 
deletion of p85α and its splice variants did not result in a complete correction of mutant 
Shp2-induced GM-CSF hypersensitivity led us to suspect that there was residual GM-
CSF-inducible PI3K activity.  We found that this residual PI3K activity was likely 
mediated by p110α and/or p110δ, as there was continued expression of these two PI3K 
catalytic subunits in the absence of the Pik3r1-encoded regulatory subunits, albeit at 
substantially lower levels.  Surprisingly, we found that p110δ’s expression was 
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preferentially stabilized in Pik3r1
-/-
 cells expressing gain-of-function mutant Shp2 E76K, 
suggesting that p110δ might be a critical mediator of mutant Shp2-induced PI3K 
hyperactivation (Figure 3.6).   
 In order to increase the translational potential of these findings we next wanted to 
explore individual contributions of the three Class IA PI3K Catalytic subunits to gain-of-
function mutant Shp2-induced GM-CSF hypersensitivity.  To do this, we first took 
advantage of the newer classes of catalytic subunit-specific PI3K inhibitors that have 
been recently developed (Table 4.1).  We began by focusing on two commercially 
available inhibitors: IC87114, a highly specific, but not very potent p110δ-specific 
inhibitor, and GDC-0941, a clinical-grade pan-PI3K inhibitor that very potently targets 
p110δ and p110α.  We found that both inhibitors reduced GM-CSF-stimulated hyper-
proliferation (Figure 4.1 and Figure 4.5) and Akt and Erk hyper-phosphorylation (Figure 
4.2 and Figure 4.5) in cells expressing gain-of-function mutant Shp2.  We found these 
results to be consistent for cells expressing either exogenously overexpressed mutant 
Shp2 or endogenously expressed mutant Shp2.  In addition to reducing GM-CSF-
stimulated proliferation, we also found that both of these inhibitors selectively increased 
apoptosis in cells expressing mutant Shp2 E76K, suggesting that pharmacologically 
targeting p110δ in mutant Shp2-induced MPD could have the dual beneficial effect of 
both killing leukemia cells and reducing their proliferation.  Next, we collaborated with 
Gilead Sciences to assess the efficacy of the clinical-grade p110δ-specific inhibitor GS-
9820 and found that it efficiently decreased both GM-CSF-stimulated hyper-proliferation 
and GM-CSF-stimulated Akt and Erk hyper-phosphorylation in Shp2 D61Y-expressing 
cells at clinically relevant, nanomolar doses. 
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 Together, this pharmacologic data suggested that p110δ might be an effective 
target for reducing mutant Shp2-induced GM-CSF hypersensitivity, but we believed 
using a genetic approach would provide the most conclusive demonstration of the roles of 
individual catalytic subunits in gain-of-function mutant Shp2-induced GM-CSF 
hypersensitivity and MPD development.  To do this, we used two available mouse 
models: (1) a mouse constitutively expressing kinase-dead p110δ D910A (Okkenhaug, 
Bilancio et al. 2002); and, (2) a p110αflox/flox inducible knockout mouse (Graupera, 
Guillermet-Guibert et al. 2008).  Our initial studies with these mice, which relied on 
exogenously overexpressing gain-of-function mutant Shp2 E76K, were inconclusive, as 
genetic interruption of either p110δ or p110α did not reduce GM-CSF-stimulated hyper-
proliferation, but genetic interruption of p110δ, but not p110α, caused modest reductions 
in GM-CSF-stimulated Akt and Erk hyper-phosphorylation (Figure 5.2 and Figure 5.4).  
To investigate this question in a more physiologically relevant manner, we crossed these 
mice— p110δD910A/D910A and p110αflox/flox—with mice inducibly expressing gain-of-
function mutant Shp2 D61Y under its endogenous promoter: LSL-Shp2
D61Y/+
; Mx1-Cre+ 
(Chan, Kalaitzidis et al. 2009) (Figure 5.5).  We found that genetic interruption of p110δ, 
but not p110α, reduced GM-CSF-stimulated hyper-proliferation and enhanced colony-
forming capacity in Shp2 D61Y-expressing cells (Figure 5.6), and that, likewise, genetic 
disruption of p110δ, but not p110α, reduced GM-CSF-stimulated hyper-phosphorylation 
of Akt, Erk, and Shp2 (Figure 5.7).  Furthermore, mice expressing the presence of kinase-
dead mutant p110δ D910A significantly improved mutant Shp2 D61Y-induced 
splenomegaly, while genetic deletion of p110α had no effect, suggesting that p110δ is a 
crucial mediator of gain-of-function mutant Shp2-induced GM-CSF hypersensitivity in 
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vitro and MPD development in vivo, while the role of p110α in these processes is 
negligible or dispensable.  As a result of these genetic studies, p110δ would appear to be 
a potentially effective target for MPD associated with activating SHP2 mutations. 
 In addition to demonstrating the role of PI3K in gain-of-function mutant Shp2-
induced GM-CSF hypersensitivity, we also wanted to explore the mechanisms by which 
PI3K becomes hyperactivated, as it might reveal additional therapeutic targets. SHP2, 
like all proteins found to be mutated in JMML, are known to regulate RAS activity, 
which serves a signaling node for a number of pathways that regulate proliferation, 
growth, survival, and other important cellular functions.  Two of the most important RAS 
effector signaling pathways are the RAF-MEK-ERK pathway and the PI3K-AKT 
pathway.  Not surprisingly, in the presence of JMML-causing mutations, including gain-
of-function mutations in PTPN11, RAS becomes hyperactivated, as do the downstream 
signaling pathways that it regulates, contributing to the enhanced proliferation and 
survival that gives rise to MPD.  In the case of PI3K, all four Class I PI3K catalytic 
subunits have a conserved RAS-binding domain, through which RAS directly promotes 
activation of PI3K. 
 Our data suggest that p110δ is the principal mediator of gain-of-function mutant 
Shp2-induced PI3K hyperactivation, but it has been reported that p110δ with a mutated 
Ras-binding domain can oncogenically transform cells (Denley, Kang et al. 2008), 
suggesting that p110δ, unlike the other PI3K catalytic subunits, can conduct its signaling 
activity without input from Ras.  Intrigued by this, we wanted to know if gain-of-function 
mutant Shp2 could promote hyperactivation of p110δ in a Ras-independent manner.  This 
would be the first demonstration of gain-of-function mutant Shp2 promoting 
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hyperactivation of an oncogenic signaling pathway independently or Ras, and would 
imply that gain-of-function mutant Shp2 is not necessarily functionally equivalent to 
hyperactivated Ras.  An important implication of this model is that efforts to target 
hyperactivated RAS in the context of activating SHP2 mutations would likely have no 
effect on hyperactivated p110δ-mediated PI3K signaling, which would have to be 
targeted as an independent and parallel pathway (Figure 1.7).   
 To investigate this question, we used a pharmacologic approach to inhibiting Ras 
activity with the farnesyl-transferase inhibitor tipifarnib, which blocks the addition of a 
hydrophobic farnesyl group to mature Ras proteins, thereby preventing their targeting to 
the plasma membrane where they conduct their signaling function (Epling-Burnette and 
Loughran 2010; Liu, Sabnis et al. 2012).  We found that treatment of Pik3r1
-/-
 cells 
expressing gain-of-function mutant Shp2 E76K with tipifarnib only modestly reduced 
GM-CSF-stimulated proliferation and had no effect on Akt phosphorylation, indicating 
that the residual PI3K activity in Shp2 E76K-expressing Pik3r1
-/-
 cells was largely Ras-
independent (Figure 3.7).  This is significant because we postulated that the residual 
PI3K activity in these cells was largely due to the retained expression and preferential 
stabilization of p110δ, which was expressed at significantly higher levels in Pik3r1-/- cells 
transduced with Shp2 E76K than Pik3r1
-/-
 cells transduced with WT Shp2 (Figure 3.6).  
Furthermore, when we added PI3K inhibition with GDC-0941 to mutant Shp2-expressing 
cells treated with tipifarnib, we found that GDC-0941 was able to produce a 
concentration-dependent decrease in GM-CSF-stimulated proliferation and Akt 
phosphorylation beyond the reduction achieved by tipifarnib, indicating the existence of 
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GM-CSF-stimulated Ras-independent PI3K activity in mutant Shp2-expressing cells 
(Figure 4.3 and Figure 4.5).   
 In addition to its role in RAS regulation, SHP2 is thought to have two functions 
by which it can regulate signal transduction processes.  The first of these is its 
phosphatase function, through which it can regulate the activity of signal transduction 
proteins by promoting their dephosphorylation.  The putative substrates of this Shp2 
phosphatase activity remain to be definitively identified, but it has been demonstrated 
that this activity is necessary for full activation of Ras, and that abrogation of this activity 
can significantly impair mutant Shp2-induced GM-CSF hypersensitivity (Neel, Gu et al. 
2003; Mohi, Williams et al. 2005).  Secondly, it is thought that Shp2 can promote signal 
transduction events by acting as a scaffolding molecule, bringing together different 
components of signal transduction machinery by binding their phosphorylated tyrosine 
residues with its two SH2 domains.  Specifically, interactions that are pertinent for our 
studies, have been demonstrated with the GM-CSF receptor, the p85 subunit of PI3K, and 
other scaffolding molecules like Gab2 and Grb2, which then form a complex with the 
Ras GEF Sos, a positive regulator of Ras activity (Yu, Luo et al. 2006; Yu, Daino et al. 
2006; Mohi and Neel 2007). 
 We next wanted to know if gain-of-function mutant Shp2 promotes 
hyperactivation of PI3K via its phosphatase function, its scaffolding function, or both.  
We were particularly interested in this question because of a previous study that showed 
that Shp2 E76K’s phosphatase function was not needed to promote hyperactivation of 
PI3K when stimulated with IL-3 (Yu, Daino et al. 2006), a cytokine which can promote a 
hyper-proliferative response to similar to GM-CSF in mutant Shp2-expressing cells and 
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whose receptor is structurally similar to the GM-CSF receptor.  We found that genetic 
interruption of Shp2 E76K’s SH2 domains as well as its phosphatase domain caused a 
significant decrease in both GM-CSF-stimulated proliferation and Akt hyper-
phosphorylation (Figure 6.2 and Figure 6.3), suggesting that mutant Shp2 promotes 
enhanced PI3K activity through both its scaffolding and its enzymatic function.  
Furthermore, disruption of the phosphatase domain caused a much more significant 
decrease in GM-CSF-stimulated hyper-proliferation and Akt hyperactivation then did 
either of the SH2 domain mutations.  Thus, it appears that Shp2’s phosphatase function is 
critically important for regulating PI3K activity particular in the presence of MPD-
inducing mutations.  This suggests that compounds that can inhibit Shp2’s phosphatase 
activity should significantly reduce PI3K signaling, and thus result in decreased GM-CSF 
hypersensitivity. 
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Overall Conclusions and Significance 
 PTPN11, which encodes the protein tyrosine phosphatase SHP2, is the most 
commonly mutated gene found in Juvenile Myelomonocytic Leukemia (JMML), 
accounting for more than a third of cases.  These mutations, which cause enhanced SHP2 
phosphatase activity, promote dysregulated mitogenic signaling, particularly following 
stimulation of growth factor and cytokine receptors, thereby resulting in a growth factor 
or cytokine hypersensitivity response.  The best characterized of these hypersensitivity 
responses involve the cytokine Granulocyte Macrophage-Colony-Stimulating Factor 
(GM-CSF), which is known to induce significant hyper-proliferation in hematopoietic 
progenitors from patients with JMML.  It is thought that gain-of-function mutant SHP2 
promotes dysregulation of these MPD-inducing mitogenic signaling pathways by causing 
hyperactivation of RAS, a signaling node that regulates several pro-growth and survival 
pathways, most notably the MAPK (RAF-MEK-ERK) and the PI3K-AKT pathways.   
 Until now, much of the focus in JMML research has been on the MAPK pathway 
as the primary mediator of GM-CSF hypersensitivity, and therefore as a potential 
therapeutic target.  Indeed, the MEK inhibitor PD0325901 has shown great efficacy in 
murine JMML models induced by gain-of-function mutant Kras expression or Nf1 
deletion (Lyubynska, Gorman et al. 2011; Chang, Krisman et al. 2013).  Likewise, we 
show that PD0325901 effectively inhibits GM-CSF hypersensivity induced by gain-of-
function mutant Shp2 D61Y, suggesting that it may be a potential therapeutic option for 
JMML patients harboring a variety of mutations.  However, because MEK is ubiquitously 
expressed and is important for multiple normal physiologic processes, pharmacologic 
inhibition of its activity carries significant risk of toxic off-target effects.  Furthermore, 
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targeting a single pathway introduces the risk of developing resistance analogous to 
Imatinib resistance that develops in patients with CML (Reddy and Aggarwal 2012).  
Thus, it is important to identify additional targets in JMML that can reduce the risks of 
off-target side effects and the development of inhibitor resistance. 
 Our studies suggest that PI3K represents one such potential additional target for 
JMML, as they provide the first evidence demonstrating that mutant Shp2-induced 
hyperactivation of the PI3K pathway also contributes significantly to GM-CSF 
hypersensitivity in vitro and development of splenomegaly in vivo.  Interestingly, we 
found that this mutant Shp2-induced hyperactivated PI3K positively regulates or 
reinforces the hyperactivated MAPK signaling as well, since we observed that genetic or 
pharmacologic interruption of PI3K signaling consistently reduced not only Akt 
hyperactivation, as expected, but Erk hyperactivation as well.  Thus, targeting the PI3K 
hyperactivation in the presence of activating Shp2 mutations has the added advantaged of 
reducing oncogenic MAPK signaling as well.  The MEK inhibitor PD0325901 had no 
analogous effect on PI3K signaling, as Akt hyper-phosphorylation remained unchanged. 
Furthermore, our results are significant because they show specificity in the PI3K 
hyperactivity, in that p110δ appears to be the principal mediator of this hyperactivated 
PI3K signaling.  Therefore, by taking advantage of newer classes of catalytic subunit 
inhibitors with high specificity for p110δ, we can expect to block only the PI3K activity 
participating in oncogenic signaling, and not the PI3K signaling mediated by other 
catalytic subunits.  This conclusion is particularly significant because p110δ is expressed 
almost exclusively in hematopoietic cells, making it an ideal target for MPD or other 
diseases of the hematopoietic system.  As a result, because p110δ expression is either 
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absent or negligible in other tissue types, it can be expected that pharmacologic inhibition 
of p110δ will carry greatly reduced risk of toxic side effects.  Thus, targeting p110δ has 
two advantages over targeting MEK: (1) it positively regulates two major mitogenic 
pathways—PI3K and MAPK—contributing to MPD development, while MEK only 
regulates the MAPK pathway; and, (2) p110δ’s expression is hematopoietic-specific, 
while MEK is ubiquitous.   
In summary, we believe these studies implicate p110δ as a potentially effective 
target for gain-of-function mutant Shp2-induced MPD, such as JMML.  The p110δ 
catalytic subunit is a particularly interesting target because of its hematopoietic-specific 
expression profile, its ability to regulate not only PI3K-Akt signaling, but MAPK 
signaling as well, and because of its apparent Ras-independence.  It would be interesting 
to see if other JMML-inducing mutations such as gain-of-function mutations in RAS or 
loss-of-function mutations in NF1 or CBL also promote hyperactivation of p110δ, and 
thus could also be effectively inhibited with p110δ-specific compounds, or if this is a 
feature unique to activating Shp2 mutations.   
To this end, one important potential future direction for this work would include 
more thoroughly investigating the role of PI3K, and in particular specific Class IA 
catalytic subunits in promoting aberrant signaling, GM-CSF hypersensitivity, and 
leukemogenesis in vivo in mouse models of other JMML-associated mutations, including 
gain-of-fucntion Kras inducible knockin mice, and Nf1 inducible knockout mice.  A 
series of in vitro pharmacologic studies, similar to those presented in this dissertation, 
could be performed using these mouse models, to expand the potential utility of PI3K 
inhibitors in the treatment of JMML, regardless of the underlying genetic lesion.  
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Likewise, genetic studies could also be performed by crossing these additional JMML 
mouse models with the kinase-dead p110δ D910A constitutive knockin mouse or the 
p110αflox/flox inducible knockout mouse to achieve this same goal.  Certainly, because 
JMML is such a rare disease, translating this research into clinical trials would be very 
challenging from a patient enrollment standpoint.  This challenge could be eased 
somewhat if it could be demonstrated that hyperactvation of PI3K in general, and p110δ 
in particular, were a common molecular feature of all JMML, and not just JMML 
associated with activating PTPN11 mutations. 
Regardless of the mouse model, it would also be helpful to have in vivo murine 
inhibitor studies of GS-9820 and/or GDC-0941, either alone or in combination with 
PD0325901.  We have made some attempts at such studies, but the results were 
inconclusive (data not shown), largely as a consequence of our mouse model’s prolonged 
disease course and inconsistent phenotype (Chan, Kalaitzidis et al. 2009).  Thus, 
conclusive in vivo inhibitor studies could be more easily accomplished, if a mouse model 
of activating mutant Shp2-induced MPD with a more robust disease phenotype could be 
developed.  We have attempted to address this issue by developing new mouse models, 
but so far with little success.  We attempted to develop a syngeneic mouse model by 
transducing 32D cells with mutant Shp2 E76K, which were then transplanted into 
C3H/Hej mice, but we were unable to achieve engraftment of the transplanted cells, let 
alone the onset of MPD (data not shown).  Currently, we are crossing Shp2 D61Y 
inducible knockin mice with the Vav1-Cre recombinase mouse, which should induce 
expression of the leukemia-causing Shp2 D61Y allele during embryonic development.  
We hope that by turning on the gene in a juvenile stage of development (rather than in 
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adulthood, as with the polyI:polyC injections of the Mx1-Cre-driven model), we can 
better recapitulate this pediatric disease, and achieve a more robust disease phenotype 
that would permit more conclusive in vivo pharmacologic studies. 
Additionally, more work needs to be done in addressing the question of whether 
mutant Shp2 can promote hyperactivation of p110δ independently of Ras.  Admittedly, a 
purely pharmacologic approach is limited, particularly considering the indirect 
mechanism of action of farnesyl-transferase inhibitors, such as tipifarnib.  Certainly, a 
genetic approach would be much more conclusive.  To that end we are currently 
performing studies in which we introduce into bone marrow-derived LDMNCs from 
p110δD910A/D910A; Shp2 D61Y, Mx1-Cre+ by retroviral transduction either WT p110δ or a 
form of p110δ bearing a point mutation in the Ras-binding domain (K223E), such that 
Ras is unable to bind and promote activation of the exogenously expressed p110δ.  A 
similar p110δ construct was used to demonstrate the apparent Ras-independence of 
p110δ-induced oncogenic transformation (Denley, Kang et al. 2008).  As we have seen, 
expression of the kinase-dead p110δ D910A in the presence of gain-of-function mutant 
Shp2 D61Y significantly reduced GM-CSF hyper-proliferation and Akt and Erk hyper-
phosphorylation (Figure 5.6 and Figure 5.7).  We predict that introduction of WT p110δ 
should restore both hyper-proliferation and Akt and Erk hyper-phosphorylation upon 
GM-CSF stimulation.  If mutant Shp2 is able to promote hyperactivation of p110δ 
independently of Ras, than exogenous expression of the Ras-binding domain mutant 
p110δ K223E, should also be to restore GM-CSF-stimulated hyper-proliferation and Akt 
and Erk hyper-phosphorylation.  In addition, we could also address the question of Ras-
independent p110δ hyperactivion using models of pure Ras hyperactivation-induced GM-
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CSF hypersensitivity.  We are working with collaborators to acquire bone marrow cells 
from the gain-of-function mutant Kras inducible knockin mouse and the Nf1 inducible 
knockout mouse, both of which exhibit dysregulated mitogenic signaling as a 
consequence of pure Ras hyperactivation.  We can take advantage of these models to 
explore mechanisms of p110δ activation using a combination of Ras and PI3K inhibitors.  
For instance, we noticed that treatment of mutant Shp2 expressing cells demonstrated 
great sensitivity to the PI3K inhibitor GDC-0941 in presence of a range of concentrations 
of tipifarnib, suggesting that a component of mutant Shp2-induced PI3K hyperactivation 
was Ras-independent (Figure 4.3 and Figure 4.5C).  It would be interesting to see if cells 
bearing either gain-of-function mutations in Kras or loss of Nf1 expression would exhibit 
similar sensitivity to PI3K inhibition in the presence of tipifarnib, since in these cells, 
hyperactivated Ras would provide the only mechanism of promoting PI3K 
hyperactivation. 
Combining the results of our studies with the results of other studies on targeting 
aberrant signaling in JMML, it appears that the best therapeutic option might be a dual 
inhibitor approach combining a MEK inhibitor such as PD0325901 and a p110δ-specific 
inhibitor such GS-1101.  Combining both drugs would presumably allow lower dosages 
of each to be used, particularly the MEK inhibitor, since targeting p110δ will bring a 
concomitant reduction in ERK hyperactivation.  We are currently performing studies 
using combinations of PD0325901 and GS-9820 to confirm this hypothesis.  Clinically, 
this approach would reduce the risk of toxic side effects, and the combined inhibition of 
two important oncogenic signaling pathways would decrease the risk of developing 
resistance to one or the other inhibitor.  In addition, this dual inhibitor approach may also 
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be successfully applied to a wide array of other human malignancies, beyond Juvenile 
Myelomonocytic Leukemia. 
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